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Summary  
Phytotherapeuticals have gained widespread usage in the treatment of symptomatic 
benign prostatic hyperplasia (BPH). Among these phytotherapeutics, the most 
popular and extensively studied are extracts of the dried ripe fruit of Serenoa repens 
(SRE). The commercially available hydroethanolic (96%) SRE, Me180, is already 
used as a medical treatment of symptomatic BPH. However, this extract was so far 
neither investigated in vitro nor in vivo. The other extracts tested herein, derived from 
Vitex agnus-castus (VAC), are so far not described to be used for treatment of 
prostatic diseases or tested on prostate cells. 
In a first part of the present studies, an in vitro screening system was established, 
representative for different prostate disease stages. BPH and prostate cancer (PCA) 
are multifactorial disease processes. Both diseases are age-related proliferative 
disorders of the human prostate and with disturbed homeostasis in both conditions by 
upsetting the balance between prostate cell proliferation and apoptosis. Thus, the 
inhibition of proliferation and the reversion of the imbalance of homoeostasis is a 
desired therapeutic option in both diseases.  
Three different cell lines (BPH-1, LNCaP, PC-3) were chosen, representing different 
disease stages. To evaluate the potential effects of selected plant extracts in 
proliferative prostate diseases, several methodological approaches were used: 
Crystal violet staining and WST-8 (tetrazolium based assay) were conducted to 
establish the effects on cell proliferation and viability. To further elucidate the 
mechanisms of cell death, FACScan analysis was performed to detect effects on cell 
cycle distribution and apoptosis. Apoptosis was further investigated by co-treatment 
of the cells with a pan-caspase inhibitor Z-VAD-fmk and by DNA fragmentation 
assays. In addition, cytotoxicity was determined by measurement of lactate 
dehydrogenase (LDH) in cell supernatants. 
Proliferation of BPH-1 and PC-3 cells was modestly inhibited by Serenoa repens 
extract Me180 in a dose-dependent manner with IC50 values of 100µg/ml, whereas in 
androgen-responsive LNCaP cells, lower IC50 values of 35µg/ml, indicated a 
possible mechanism through androgen-receptors. Me180 exerted similar effects in 
vitro as other SRE’s previously investigated. Additional SRE’s, which varied with 
respect to ripeness conditions of the raw material and the choice of solvents (hexane 
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or ethanol) displayed no crucial differences in potency of growth inhibitory activities. 
Moreover, Me180 exhibited a dose-dependent apoptotic effect in LNCaP cells, with 
additional low cytotoxic effects. A low apoptotic effect was found in BPH-1 cells 
without a cytotoxic effect, whereas PC-3 cells were almost insensitive to the Me180 
treatment. 
In addition, using the same methodology, these preclinical investigations were the 
first to examine the effects of VAC fruit and leaf extracts on prostate cell proliferation. 
The two different VAC’s were found to be effective inhibitors in all three cell lines 
(with IC50 values < 10µg/ml after exposure to fruit extract and < 20µg/ml for leaf 
extract, respectively) inducing apoptosis, and a low cytotoxic effect. Our new results 
suggest that extracts of VAC, by modulating the cell cycle and the apoptotic 
machinery, may possess a potential for development as an agent for prevention 
and/or therapy of benign and malign prostatic hyperplastic diseases. Additional 
studies are however required to further clarify their mechanisms of action and to 
investigate their effects in vivo. 
The in vitro data indicate that the chosen screening model system is suitable for the 
detection of growth inhibitory activities of plant extracts in human prostate cell lines 
and may help to find new phytotherapeuticals for this field of indication. 
 
The objective of the second part was a clinical pilot study to compare the 
therapeutical effects, tolerability and safety of treatment with Serenoa repens extract 
Me180 (SabCaps®) versus tamsulosin (Pradif®) in patients with obstructive BPH. Due 
to stringent exclusion criteria and hence difficulties in patient recruitment, the planned 
patient number of 70 could not be achieved within a reasonable time for the thesis. 
Only 19 patients, aged 50-79 years, with obstructive BPH (mean Qmax < 10ml/s for a 
voiding volume of 150ml or assessed by flow-pressure study) were therefore included 
in the study. Patients were randomised with either 320mg Me180 or Tamsulosin 
0.4mg, given over a scheduled treatment period of 26 weeks in a double-blind 
manner. The primary outcome measures were the change in peak urinary flow rate 
(Qmax) and International Prostate Symptom Score (IPSS) with quality-of-life score 
during the treatment. The secondary outcome measures included average urinary 
flow rate (Qave), post-void residual urine volume and prostate volume, assessed by 
transabdominal ultrasound. In addition, the International Index of Erectile Function 
(IIEF) score was determined and adverse events were recorded. 
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No significant differences were found in baseline parameters between the two 
treatment groups. The treatment over 26 weeks was completed by 18 patients. In the 
tamsulosin group, one patient withdrew from the study because of continuous 
dizziness. There was no significant difference between the two treatments over the 
26 weeks of the study with respect to IPSS, Qmax, Qave, residual urine, prostate 
volume, and IIEF. During this pilot study all participants had some improvements in 
their symptoms of BPH, but there was no significant difference in the beneficial effect 
of either medication over the 26-weeks treatment time. With respect to the overall 
incidence of adverse effects, Me180 was found significantly superior to the 
tamsulosin group (p = 0.013).  
The present data describe for the first time clinical results obtained with Me180. 
Based on this pilot study, future clinical trials with larger patient numbers and longer 
periods of treatment will be needed to assert if Me180 is an efficacious alternative 
medical therapy for men with obstructive BPH. 
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I INTRODUCTION AND AIM OF THIS THESIS 
The popularity of phytotherapy is at an all-time peak. Many patients are searching for 
‘natural’ alternatives or complements to conventional drug therapy. Herbal 
pharmaceuticals are generally promoted as being effective for chronic diseases and 
devoid of adverse effects. However, plant extracts, like any other drugs, may exhibit 
side-effects and interactions with other therapeutics but unfortunately the majority of 
the herbal drugs have not been systematically examined. Phytotherapeuticals should 
be tested in clinical studies with reference (placebo or/ and synthetic) medications 
that are therapeutically equivalent to single compounds. Medical-scientific standards 
in clinical studies (Good Clinical Practice, GCP) with particular indications have to 
prove their efficacy and safety. Moreover, phytotherapeuticals must be of high 
pharmaceutical quality (Good Manufacturing Practice, GMP). Thus, based on this 
knowledge, the rational phytotherapy can be considered as a treatment alternative. 
Benign prostate hyperplasia (BPH) is a non-malignant progressive enlargement of 
the prostate, which can result in bothersome lower urinary tract symptoms (LUTS). 
The frequency of prostate enlargement and associated symptoms increase with age 
(Berry et al 1984). Prostate cancer (PCA) is the most frequently diagnosed cancer in 
men in Western countries and the second leading cause of cancer-related deaths in 
men (Hsing 2000). Although there is no evidence for an association of these two 
proliferative prostatic diseases (Bostwick 1998), both diseases display an age related 
increase in prevalence. With increasing mean life expectancy, the population of men 
being affected by these diseases will expand and the importance of finding effective 
and well tolerated preventive and therapeutic agents rises. 
Phytotherapeuticals have gained widespread usage in the treatment of symptomatic 
BPH. Among these phytotherapeutics, the most popular and extensively studied are 
extracts of the dried ripe fruit of Serenoa repens (Lowe & Fagelman 2002). Despite 
its popularity as a medication, its efficacy and safety for the treatment of symptomatic 
BPH and the possible mechanism of action are still not fully clarified. Although 
numerous in vitro experiments have been conducted to determine their possible 
mechanisms of action, it is uncertain which of the actions demonstrated in vitro might 
be responsible for clinical responses in patients. Only a few randomized clinical trials 
that meet standard criteria of evidence-based medicine but relatively short follow-up 
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times (up to 1 year) were conducted (Carraro et al 1996; Debruyne et al 2002; 
Willetts et al 2003). Thus, the extent of their therapeutic potential remains uncertain. 
Moreover, most of these trials were conducted with the same Serenoa repens 
hexane extract (Permixon®). Most of the plant extracts are unique: (1) because of 
natural variability of different plant sources, the plants are not identical, (2) the 
extraction processes used by the various manufacturers are frequently different, and 
(3) various extraction agents are used for the process, all of which makes 
comparison of the preparations difficult. Therefore, each extract must be studied 
individually and the production of each of these extracts has to be standardised. 
In contrast to established knowledge with Serenoa repens extracts, extracts of Vitex 
agnus-castus are so far not described to be used in prostatic diseases. VAC fruits 
extracts were reported to have a beneficial effect on disorders related to 
hyperprolactinaemia such as cycle disorders, luteal phase defect, mastodynia and 
premenstrual syndrome (Wuttke et al 2003). Recently, a VACF was shown to exhibit 
anti-tumour activities in different human cancer cell lines (Ohyama et al 2003). Its 
effects on human prostate epithelial cells have so far not been investigated. 
 I INTRODUCTION AND AIM OF THIS INVESTIGATIONS 
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Against this background the objectives of the present studies were as follows: 
 
PRECLINICAL INVESTIGATION 
a) Establishment of a representative in vitro cell culture system using three 
different human prostate cell lines indicative of different disease stages. A 
variety of plant extracts were investigated for specific prostate cell functions: 
cell viability, cell proliferation, cell cycle distribution, apoptosis and cytotoxic 
effects.  
b) The commercially available hydroethanolic (96%) Serenoa repens extract Me 
180 is already used as a medical treatment of symptomatic BPH. However, to 
our knowledge, this extract was so far neither investigated in vitro nor in vivo. 
Therefore, this extract was included in the in vitro test model system. 
c) With the aim to investigate the role of the extract quality of Serenoa repens we 
further examined the influence of extracts from different ripening conditions 
and different extraction agents on prostate cell growth. 
d) Vitex agnus-castus fruit extract was examined for the first time on this 
established prostate in vitro test model system. Moreover, the effects of a 
selected fruit extract were compared with a leaf extract. 
 
CLINICAL INVESTIGATIONS 
In a second part, a controlled randomised double-blind pilot study was conducted to 
compare the therapeutical effects and safety of the commercial Serenoa repens 
(Me180, SabCaps®) extract with Tamsulosin (Pradif®) in patients with obstructive 
BPH. As mentioned before, although this extract is already commercially available, it 
has so far not been investigated in patients with BPH. The outcome of the present 
pilot study is intended to form the basis for the design of an extended study with more 
patients to assess the efficacy of the extract over a longer treatment period. 
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II Background 
1 Proliferative prostate diseases 
Benign prostatic hyperplasia (BPH) and prostate cancer (PCA) get manifest in men 
beyond the age of 50. Both diseases display an age related increase in prevalence, 
require androgens for growth and development, and may respond to androgen 
deprivation treatment. In both conditions, there is an imbalance between cell 
proliferation and cell death by apoptosis, resulting in increased cell number (Figure II-
1) (Thompson & Yang 2000). 
 
Figure II- 1 The balance between cell proliferation and cell death 
 
However, BPH and PCA are primarily entities of two different areas of the prostate; 
the transition zone has a high incidence of BPH and a low incidence of carcinoma, 
whereas the peripheral zone has a high incidence of carcinoma and low incidence of 
BPH (De Marzo et al 1999). Thus, there is no evidence that PCA is associated with 
BPH and BPH does not appear to directly progress to carcinoma (Bostwick et al 
1992; Bostwick 1998). 
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1.1 Benign prostatic hyperplasia (BPH) 
Benign prostatic hyperplasia (BPH), as the name implies, is a benign disorder that 
develops predominantly adjacent to the urethra in the transition zone of the prostate. 
BPH presents histologically as a mixture of epithelial (glandular) and stromal (smooth 
muscle and connective tissue) hyperplasia. Despite the well-characterized histology 
associated with BPH, little is known about the underlying aetiology of the disease and 
the precise factors responsible for the pathogenesis of BPH are incompletely known 
(Walden et al 1998). However, the metabolism and action of steroid hormones 
appears to be strongly associated with the proliferation of epithelial and stromal 
prostate cells and thus with the development of BPH.  
The following findings appear to play a crucial role in the development of BPH: 
1. The prostate is androgen-dependent and a source of testosterone is necessary for its 
growth. However, the intraprostatic androgen 5α-dihydrotestosterone (DHT), a 
metabolite of testosterone converted by the 5α-reductase, preferentially binds to the 
androgen receptor. DHT is necessary for prostate growth and appears to play an 
important role in regulation of gene expression (Griffiths et al 1998). 
2. As men get older, the androgen/ estrogen ratio falls due to the rise in estrogen 
production and evidence has been accumulating that estrogens (particularly the 
testosterone/oestrogen ratio) are important regulators, particularly for prostatic 
stromal development (Farnsworth 1999). 
3. Prostate cell proliferation, differentiation and apoptosis are regulated by the integral 
network formed by prostatic epithelial and stromal cells and the extracellular matrix 
for paracrine and autocrine communication by intrinsic factors. Stromal-epithelial 
interactions are mediated by steroid hormones (androgen, oestrogen)  action and 
steroids also regulate the expression of the EGF, IGF and TGF-α families of growth 
factors and receptors (Brown & Lee 2001).  
4. It has been demonstrated that infiltration of the prostate by inflammatory cells is one 
of the aetiologic factors involved in the development of BPH. These inflammatory cell 
types, such as polymorphonuclear neutrophils (PMNs), produce chemotactic 
mediators and contribute to the development of the disease. (Theyer et al 1992) 
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Histological evidence of BPH is found with increasing frequency in elderly men. Berry 
and co-workers reviewed five autopsy series and found that BPH is not seen before 
the fourth decade. Histological BPH is found in 40% of men aged 51-60 and 90% of 
men over 80 (Figure II-2) (Berry et al 1984). 
 
Figure II- 2 Proportion of prostates with histopathological benign prostatic hyperplasia (BPH) 
at autopsy versus age. Mean ± SE. Reprinted from (Berry et al 1984) 
Strictly speaking the terminus ‘benign prostate hyperplasia’ (BPH) describes 
exclusively the histological diagnosis. However, in general BPH is used 
undifferentiated as a synonym for a complex combination of lower urinary tract 
symptoms (LUTS). LUTS are usually, but not exclusively associated with benign 
prostatic hyperplasia (BPH). LUTS can be irritative or obstructive. The former occur 
during the bladder emptying phase and include hesitancy, decreased stream, feeling 
of incomplete emptying, straining to void, intermittency, postvoid dribbling, and 
urinary retention. The latter occur during the storing phase and include daytime 
frequency, nocturia, urgency and urge incontinence associated with involuntary 
detrusor contractions (Barry & Roehrborn 2001). The prevalence of LUTS related to 
BPH depends on the definition used. However, it is obvious that LUTS have a 
significant negative impact on the quality of life of patients. 
The relationship between BPH and LUTS is complex, because not all men with 
histological evidence of BPH will develop LUTS. In addition, LUTS are neither 
specific for BPH, other conditions in the lower urinary tract and elsewhere may be 
causative. As the prostate gland enlarges, it can cause both obstructive and irritative 
symptoms; however, the size of the prostate gland is not predictive of the symptoms 
that patients experience. Volume and form of the prostate can be measured 
 BACKGROUND 
 17 
precisely, but are only of secondary importance for the medical condition. It seems 
undisputable that the severity of the symptoms of BPH does not correlate with the 
volume of the prostate. Significant for the characteristics of the symptoms is the 
direction of increase of the prostate (Barry et al 1993). 
Although LUTS are suggestive of infravesical obstruction, they are not specific to 
BPH and therefore certain diagnostic tests may be necessary to confirm obstruction. 
There is universal agreement that the urethra is a distensible elastic tube with a flow 
controlling zone normally located in the membranous urethra. With the development 
of prostatic obstruction the flow controlling zone moves into the prostatic urethra. The 
enlarging prostate may or may not cause an infravesical obstruction. If obstruction 
develops, it is thought to be partly due to the anatomical presence of the enlarged 
prostate (mechanical or static obstruction) and partly due to the tonus exerted by the 
smooth muscle in the prostate and in the bladder neck (dynamic obstruction). The 
increased urethral resistance prevents the detrusor muscle from rapidly expelling 
urine which again gives rise to a higher driving pressure (Hald et al 1998). 
 
Figure II- 3 Basic features of clinical BPH: obstruction, symptoms and hyperplasia. They 
overlap but are independent variables determining the nature of the clinical situation (Hald 
1989). 
 
Taken together, these three mentioned main aspects, symptomatology, prostate 
enlargement and infravesical obstruction (shown in Figure II-3) determine the clinical 
picture of BPH-patients (Hald et al 1998) and they are variable from one patient to 
another. It is therefore of importance that the condition referred to as clinical BPH be 
defined, especially in clinical trials. Various different symptom questionnaires and 
inclusion criteria complicate the comparison of trials in this indication. Therefore, 
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these basic features of BPH should be clearly defined in clinical trials and inclusion 
and exclusion criteria should be applied according to the current recommendations of 
the International Consultation on BPH. 
1.2 Treatment options for symptomatic BPH 
The main objectives of treatment for LUTS suggestive of BPH, are to provide fast and 
sustained relief of bothersome symptoms, to improve quality of life and to control 
disease progression (Schulman 2003). Current treatment options include ‘watchful 
waiting’, phytotherapeuticals, 5α-reductase inhibitors, α1-blockers, surgical 
intervention. For some decades, transurethral resection of the prostate (TURP) has 
been the gold standard treatment. However, the incidence of complications such as 
blood loss, urinary tract infections, urethral stenosis, incontinence, impotence, and 
the need for re-intervention is clinically significant after prostatic surgery (Kaplan et al 
1995). Moreover, most patients with symptomatic BPH reportedly choose less 
aggressive interventions than invasive surgery, although more active than watchful 
waiting. 
Currently, α-blockers are becoming first-line drug therapy compared with the 5α-
reductase inhibitors and phytotherapy (Chapple 2001). The prostate contains stromal 
tissue with a smooth muscle component. α-blockers inhibit α1-adrenergic receptors 
and have a clinical effect by reducing the sympathetic tone, thereby relaxing smooth 
muscle in the hyperplastic prostate and relieving urinary obstruction. Several 
investigations document significantly more α1- adrenergic receptors in hypertrophic 
prostate tissue than in normal tissue (Yamada et al 1987) and blocking urethral α1- 
adreno-receptors causes the prostate urethra to relax (Chapple 2001). The α1A- 
receptor appears to be the subtype mainly mediating prostatic and bladder smooth 
muscle tone, the dynamic component of bladder outflow obstruction (Walden et al 
1999). Unlike the other common α-blocking agents that are not selective for this 
subtype (doxazosin, alfuzosin and terazosin), tamsulosin possesses high α1A- 
receptor affinity. Common adverse events associated with α1- adrenergic receptor 
blockers are dizziness, asthenia, tachycardia/palpitation, orthostatic hypotension, 
somnolence or abnormal ejaculation. Because of its ‘prostate-selectivity’ tamsulosin 
may improve urinary symptoms and flow with fewer adverse effects (Wilt et al 2003). 
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1.3 Prostate Cancer (PCA) 
Prostate cancer (PCA) is the most frequently diagnosed cancer in men in Western 
countries and the second leading cause of cancer-related deaths in men (Hsing 
2000). It is a very well-known fact that prostate cancer and male sex hormones are 
strongly interrelated. Prostate cancers are well known to progress from hormone 
sensitive to hormone therapy-resistant terminal states. Treatment of advanced 
prostate cancer often involves either surgical gonadectomy or drugs that inhibit 
androgen production and action. Unfortunately, prostate cancer often metastasises to 
lymph nodes, bone, and other distant sites. Metastatic prostate cancer initially 
responds to androgen withdrawal therapy, but tends to become androgen-
independent subsequent to hormonal treatment, so that many patients fail this 
therapy (Shaffer & Scher 2003; So et al 2003). 
One of the goals of current research on PCA is the identification of new agents that 
would prevent and/or slow down the development of this disease. As the incidence of 
prostate cancer has risen in public awareness and in the statistical tables of cancer 
incidence, so aging men have become increasingly more interested in what they can 
do to preserve their health and avoid diseases and prevent their progression. One of 
the reasons to evaluate phytotherapeutic therapies is the possibility that particular 
dietary factors may be responsible for the internationally wide variations that exist in 
the prevalence of and mortality from prostate cancer. In particular, Asian men are at 
significantly lower risk than their North American and Western European counterparts 
(Pisani et al 2002). Asian men who migrate to North America have an increased 
mortality from prostate cancer compared with men in their native countries. This 
implies that environmental factors, rather than genetics alone, may contribute to the 
risk of prostate cancer (Denis et al 1999). 
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2 Selected plant extracts 
Phytotherapeuticals have gained widespread usage in the treatment of symptomatic 
BPH, and there are numerous plant extracts that are widely used in this indication 
(see Table II-1) (Weiss 1999). 
 
Table II- 1 Origin of plant extracts currently used for symptomatic BPH 
Species Common name Part 
Serenoa repens  Saw palmetto (Sägezahnpalme) Fruits 
Hypoxis rooperi  South African star grass (Südafrikanisches Sternengras) Roots 
Pygeum africanum  African plum tree (Afrikanischer Pflaumenbaum) Bark 
Urtica dioica  Stinging nettle (Brennessel) Roots 
Secale cereale  Rye pollen (Roggenpollen) Pollen 
Cucurbita pepo  Pumpkin (Kürbis) Seeds 
 
Most of these plant extracts have not been studied in great detail and there is a lack 
of information on their mode of action. Among these phytotherapeutics, the most 
popular and extensively studied are extracts of the dried ripe fruit of Serenoa repens 
(Lowe & Fagelman 2002). 
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2.1 Serenoa repens 
Key Points about Serenoa repens 
Species name: Serenoa repens (Bartr.) Small  
Syn. : Sabal serrulata (Michaux) Nutt. ex Schultes 
Family: Arecaceae (Palmae) 
Habitat: Serenoa repens is native to the coastal regions of the southern 
states of the United States from South Carolina to Florida, 
Southern California, Southern Europe and North Africa. 
Drug: Sabal fructus 
Partially ripened, dried fruits of Serenoa repens (Bartr.) Small  
Principle 
constituents: 
 
Free and esterified fatty acids 
Long-chain saturated and unsaturated alcohols 
Phytosterols 
Flavonoids 
Polysaccharides 
Indication: Symptomatic treatment of lower urinary tract symptoms (LUTS) 
Secondary to mild and moderate benign prostatic hyperplasia 
Postulated 
mechanisms of 
action: 
5α-reductase inhibition (type1 and 2) 
Anti-androgenic 
Anti-estrogenic 
Anti-proliferative  
Anti-inflammatory 
α1-adrenergic blocking activity 
Dosage: Varies; most studies have used 320mg once daily or 160mg 
twice daily of hexane, hydroethanolic or supercritical CO2 extract
Adverse effects: Mild gastrointestinal distress; infrequent 
Contraindication: No known 
Drug 
interactions: 
No known drug interactions, except from one case report of 
severe intraoperative haemorrhage in a patient who was taking 
Serenoa repens.(Cheema et al 2001) 
Reviewed in (Wilt et al 1998; Boyle et al 2000; Dreikorn 2002) 
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Serenoa repens extracts (SRE) are the most popular phytotherapeutical medication 
used in the treatment of LUTS suggestive of BPH. However, the complete mode of 
action of the extracts is still under investigation. The effects of SRE’s were 
investigated and explained through a multifactorial mechanism including an anti-
androgenic, anti-estrogenic, and growth inhibitory action, and to interfere with 
prolactin receptor signal-transduction, to exhibit anti-inflammatory action and to relax 
prostatic smooth muscle: 
Several SREs were found to inhibit the 5α-reductase in vitro in fibroblasts and in 
homogenates of human BPH tissue (Weisser et al 1996) and in stromal and epithelial 
cells from human BPH, either separated (Delos et al 1995) or co-cultured (Bayne et 
al 1999). SRE has been shown to act as an inhibitor for both isoforms of 5α-
reductase (type 1 and type 2) in a baculovirus-directed insect cell expression system 
(Delos et al 1994; Iehlé et al 1995; Raynaud et al 2002). In all these models, SRE 
was shown to be a non-competitive inhibitor of 5α-reductase, suggesting that the 
mode of action is rather a modulation of the activity by modification of the lipid 
environment of the enzyme than an interaction at its catalytic site (Delos et al 1994; 
Bayne et al 1999). Moreover, there were some conflicting results with regard to the 
competitive binding affinities of SRE to androgen receptors (Sultan et al 1984; 
Ravenna et al 1996; Bayne et al 1999). 
It was shown in an earlier study, that androgen and estrogen receptors became 
localized in the cytoplasm of the prostate cells following treatment with SRE (Di 
Silverio et al 1992). It was suggested that this localization of the receptors may also 
be due to the receptors leaking out of the nucleus into the cytoplasm, a process 
facilitated by the SRE-damaged nuclear membrane. In epithelial and fibroblast cell 
cultures derived from BPH patients, SRE also inhibits 17β-hydroxysteroid 
dehydrogenase, the enzyme responsible for converting androstenedione into 
testosterone (Delos et al 1995).  
Another postulated important action of SRE is the inhibition of the proliferation of 
human prostate cells in vitro induced by basic fibroblast growth factor (bFGF) and 
epidermal growth factor (EGF) (Paubert-Braquet et al 1998). Furthermore, SRE also 
induced a significant reduction in dihydrotestosterone (DHT) and EGF concentrations 
in human BPH following 3-month treatments (Di Silverio et al 1998). In addition, SRE 
was shown to have several other effects and actions in different experimental 
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systems, and these may have an influence on the growth of the prostate. Among the 
effects reported are inhibitory effects on growth factor –induced proliferation of 
human prostate cell cultures (Paubert-Braquet et al 1998), and inhibition of prolactin 
receptor signal transduction in Chinese hamster ovary (CHO) cells (Vacher et al 
1995). The latter effect resulted in reduced K+channel conductance and a reduction 
in the activity of protein kinase C (PKC). It was moreover demonstrated that in 
patients treated with SRE, the extract induces apoptosis in epithelium and in stroma 
(Vacherot et al 2000), and mixed cell death of apoptosis and necrosis in LNCaP cells, 
an androgen-responsive human prostate cell line (Iguchi et al 2001).  Additionally, 
the extract was shown to inhibit urokinase-type plasminogen activator leading to 
suppression of cell invasion in androgen-unresponsive human prostate cancer cells 
(PC-3) (Ishii et al 2001) 
There is also evidence that SRE may act as an anti-inflammatory agent inhibiting 
both phospholipase A2 and the oxidative enzymes responsible for the synthesis of 
the pro-inflammatory eicosanoids (Paubert-Braquet et al 1997), inhibiting both 
cyclooxygenase and lipoxygenase (Wagner et al 1981; Breu et al 1992). In a recent 
pilot study the anti-inflammatory activity of SRE was underlined by histological 
investigations after treatment with the extract (Vela Navarrete et al 2003). 
Numerous clinical trials with SRE have been published. Most are uncontrolled open-
label studies, which provide little useful information for determining the efficacy of 
these phytotherapies. However, two randomised, double-blind studies have shown 
an Serenoa repens hexane extract (Permixon®) to be as effective as the uro-selective 
α1-adrenergic blocker, tamsulosin and the 5α-reductase inhibitor, finasteride, in 
achieving subjective and objective improvements of symptomatic BPH (Carraro et al 
1996; Debruyne et al 2002) after treatment of 6 months and 12 months, respectively. 
A more recent urodynamic trial of 75 patients treated with SRE or placebo showed 
improvement in urodynamic parameters (peak urinary flow, detrusor pressure at 
maximum flow, residual volume, and opening detrusor pressure) after a 9-week-
treatment with extract compared to placebo (Al-Shukri et al 2000). However, in a 
recent double-blind placebo-controlled randomized trial, no significant difference 
between the SRE and placebo was shown over the 12 weeks of the study in the 
symptom score (IPSS) and peak urinary flow rate (Willetts et al 2003). Thus, the 
efficacy of SRE for the treatment of symptomatic BPH needs to be investigated in 
further clinical trials.  
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2.2 Vitex agnus-castus 
Key Points about Vitex agnus-castus (German Commission E Monograph) 
Species name: Vitex agnus-castus L. 
Family: Verbenaceae 
Habitat: Vitex agnus-castus is native to Mediterranean regions, Asia and 
South America. 
Drug: Agni casti fructus 
Ripe, dried fruits of Vitex agnus castus L.  
Principle 
constituents: 
 
Iridoid glycosides (Agnusid, aucubin) 
Aetheric oil 
Diterpenes (rotundifuran, vitexilacton, 6B,7B-DHLD) 
Flavonoids 
Fatty acids (linolic and linoleic acid) 
Sterols controversially discussed 
Indication: Premenstrual complaints, irregularities of the menstrual cycle, 
mastodynia. 
Mechanism of 
action: 
Dopaminergic action 
Inhibition of prolactin secretion action 
Dosage: Aqueous-alcoholic extracts corresponding to 30-40mg of the 
drug 
Adverse effects: Occasional occurrence of itching, urticarial exanthemas 
Contraindication: None known 
Drug 
interactions: 
Interactions are unknown 
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Vitex agnus-castus (VAC) is belonging to the Verbenaceae family, which grows 
naturally and is common in Southern Europe, in the Middle East and in South 
America. Its ripened fruits have a long history of use as a hormone balancing remedy 
and a legendary remedy to help subdue excited libidos among those who would have 
to remain chaste, like monks.  
More recently, Vitex agnus-castus fruit extract (VACF) was reported to have a 
beneficial effect on disorders related to hyperprolactinemia such as premenstrual 
syndrome, cycle disorders, luteal phase defect, and mastodynia (Schellenberg 2001; 
Wuttke et al 2003). Several reports document prolactin-suppressive activities from 
VACF: Prolactin release from cultivated rat pituitary cells was suppressed after 
treatment with VACF (Jarry et al 1994). In a double-blind, placebo-controlled clinical 
trial the extract reduced serum prolactin levels in female patients treated (Wuttke et al 
1997). Prolactin synthesis is regulated by the neurotransmitter dopamine (MacLeod 
1969). Extracts of VACF were shown to exhibit dopamine binding activity to 
recombinant dopamine D2 and dopamine D3 receptor protein (Wuttke 1995; Meier et 
al 2000; Simmen et al 2003). It was therefore proposed that the prolactin suppressive 
action of VACF is due to a dopaminergic action (Wuttke et al 2003). Beyond the 
dopaminergic effect additional pharmacological actions via µ- and k-opioid receptors 
are suggested (Bruggisser et al 1999).  
Furthermore, fruit and leave extracts were shown to exhibit estrogenic activity, 
whereby the leaf extract was shown to be more active than fruit extract (Berger 
1998). Investigations on human recombinant estrogen receptor subtype -α and –β 
revealed a VACF- induced inhibition of both (Liu et al 2001; Wuttke et al 2003). 
Beyond this indication field, a VACF was recently shown to exhibit anti-tumour 
activities in different human cancer cell lines, which included carcinoma cell lines of 
breast, ovarian, gastric, colon, cervix and lung and was compared with “normal” 
human fibroblasts (Ohyama et al 2003). Additionally, in a recent diploma thesis, 
concurrent with the present study, a VACF extract was reported to inhibit the activity 
of recombinant cyclooxygenases COX-1 and COX-2 and 5-lipooxygenase 5-LOX 
activity of differentiated promyelocytic leukemia cells HL-60 cells after stimulation 
with arachidonic acid (Hubacher 2002). 
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Based on this knowledge the rationale for the selection of Vitex agnus-castus extract 
(VAC) as a potential phytotherapeutical drug for proliferative prostate diseases are 
forfold: 
1. VACF induced cell growth inhibitory action in several human cell lines 
A VACF extract was shown to exhibit anti-tumor activities in different 
human cancer cell lines (Ohyama et al 2003), but its effect on human 
prostate epithelial cells has so far not been investigated. 
2. Dopaminergic and prolactin secretion inhibiting action of VAC 
VACF was shown to exert inhibition of prolactin secretion via a 
dopaminergic action (Wuttke et al 2003). Prolactin was reported to 
stimulate the proliferation and the differentiation of prostate cells. It was 
shown that prolactin acts in synergy with androgens either by enhancing 
the testosterone effect or by increasing the number of cytosolic and nuclear 
androgen receptors (reviewed by Reiter et al 1999). Therefore, inhibition of 
prolactin secretion by VACF may exhibit a beneficial effect in both 
proliferative prostatic diseases. 
3. COX-1, COX-2 and 5-LOX inhibiting action in vitro 
A VACF was reported to inhibit the activity of recombinant COX-1 and 
COX-2 and 5-LOX activity of differenciated HL-60 cells after stimulation 
with arachidonic acid (Hubacher 2002). The prostate is often the target of 
acute and chronic inflammatory responses (Donovan & Nicholas 1997). 
These observations may point to a role of inflammatory mediators in the 
pathogenesis of BPH (Eaton 2003). In addition, long-term chronic 
inflammation may contribute to carcinogenesis in many organ systems 
through a postulated mechanism of repetitive tissue damage and 
regeneration in the presence of reactive phagocyte-derived oxygen and 
nitrogen species and cytokines (Ames et al 1995). Moreover, it was shown 
that expression of both COX-1 and particularly COX-2 is increased in 
human PCA (Kirschenbaum et al 2000), indicating that COX-1 and COX-2 
(and/or their prostaglandin products) may play a crucial role in the 
malignant transformation of the prostate. Therefore, COX-1, COX-2 and 5-
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LOX inhibitory properties of VACF may exhibit a beneficial effect in both 
proliferative prostatic diseases. 
 
4. Selective estrogen receptor action 
Estrogen receptor β (ER-β) is preferentially localised in the prostate 
epithelium (Chang & Prins 1999). ER-β knockout mice exhibit prostatic 
hyperplasia and this animal model favours an antiproliferative role of ER-β 
(Weihua et al 2002). In this regard it was proposed that ER-β is a potential 
target for therapeutical intervention in proliferative prostatic disease. It was 
shown by Berger that VACF exhibits estrogen activity (Berger 1998). 
Moreover, Jarry and co-workers reported of a selective action on 
recombinant estrogen β receptor (Jarry et al 2003). Therefore, estrogen β 
activity properties of VACF may exhibit a beneficial effect in both 
proliferative prostatic diseases. 
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1 Introduction 
Benign prostatic hyperplasia (BPH) and prostate cancer (PCA) are multifactorial 
disease processes, the pathogenesis of which is only poorly understood. However, 
the pathogenesis of both, BPH and PCA is likely to be related to uncontrolled growth 
of the prostate gland. Both diseases are age-related proliferative disorders of the 
human prostate with disturbed homeostasis in both conditions by upsetting the 
balance between prostate cell proliferation and apoptosis, leading to BPH and PCA, 
respectively (Figure II-1).Thus, the inhibition of proliferation and the reversion of the 
imbalance of homoeostasis is a desired therapeutic option. To evaluate the potential 
effects of selected plant extracts in these common age-related prostatic disorders in 
elderly men, an in vitro screening system representative for different disease stages 
was established. 
1.1 Overview of the in vitro test system 
Figure III-1 gives an overview of the analysis conducted to assess the in vitro effects 
of selected plant extracts in human prostate cells lines. The chosen assay systems 
are well accepted tools in preclinical drug development and therefore suitable 
methods for the evaluation of effects of plant extracts as an approach of rational 
phytotherapy. 
 
Figure III- 1 Schematic diagram of the in vitro investigations  
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1.2 Target cell selection 
Three different cell lines, representing different disease stages, were chosen to test 
the effects of selected extracts on cell proliferation, induction of apoptosis, and cell 
cycle distribution: BPH-1, an immortalized prostate epithelial cell line established 
from a BPH specimen (Hayward et al 1995) and two prostate cancer cell lines that 
mimic the initial (hormone-sensitive) and advanced (hormone-refractory) stages of 
prostate carcinoma, the androgen-responsive LNCaP (Horoszewicz et al 1980), and 
the androgen-insensitive PC-3 (Kaighn et al 1979). Origins of the three cell lines 
investigated are shown in Table III-1.  
Table III- 1 Prostate Cell Line Origins 
Cell line Source First 
described 
Reference Characteristics Androgen 
receptor protein 
BPH-1 SV40 
immortalised 
benign prostatic 
epithelium 
1995 Hayward et al. non-tumourigenic absent 
LNCaP Lymph node 
metastasis 
1980 Horoszewicz et al. tumourigenic, 
metastatic 
present 
PC-3 Bone metastasis 1978 Kaighn et al. tumourigenic, 
metastatic 
absent 
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1.3 Quantitative measurements of cell growth inhibition 
To investigate the effects on cell growth, the following assay systems were applied:  
• Cell viability  WST-8 tetrazolium assay 
• Cell proliferation Crystal violet assay 
 
Effects of the extracts on viability of cultured cells were measured by a tetrazolium 
based WST-8 salt [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-
disulfophenyl)-2H-tetrazolium, monosodium], which produces a highly water-soluble 
formazan dye upon biochemical reduction in the presence of an electron carrier. 
Proliferation of cells results in an increased mitochondrial reductase system activity, 
which leads to increasing amounts of dark-red formazan. The amount of formazan 
dye generated by the activity of dehydrogenases in cells is directly proportional to the 
number of viable cells. The soluble formazan is released into the cell culture 
supernatant and can be detected in situ. (Ishiyama et al 1997)  
The used WST-8 reagent does not stain cells. Therefore, for measurement of cell 
proliferation additional quantitating of cells by crystal violet staining was used. Flick 
and Gifford (1984) introduced this technique for estimation of cytotoxicity using the 
basic metachromophore, crystal violet. Crystal violet (N-hexamethylpararosaniline) is 
a basic dye which stains cell nuclei (Gillies et al 1986). This method was modified to 
determine cell proliferation directly in a 96-well plate (Kueng et al 1989). The use of 
both assay systems was to distinguish between influences on cell proliferation and 
viability. 
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1.4 Suppression of cell division and/or induction of apoptosis 
At the cellular level, reduction of cell number is controlled by a broad range of 
biochemical activities, either by suppressions in cell division and/or the induction of 
apoptosis.  
Cell division is controlled by specialised checkpoints that induce the progression of 
cells through the cell cycle. Generally, cells do not undergo division unless they 
receive signals to progress in the cell cycle. Signals that direct cells to enter the cell 
cycle are growth factors, cytokines, or other mitogens. They induce cells to divide 
and trigger a large number of signal transduction cascades. Once the cell is 
instructed to divide, it enters the active phase of the cell cycle, which can be divided 
into four stages: 
G1 (gap 1): the period of growth before DNA 
replication 
S (synthesis): as the cell undergoes DNA synthesis 
and replicates its genome 
G2 (gap 2): 
 
the cell prepared to undergo division 
and checks its replication using DNA 
repair enzymes 
M (mitosis): The period of cell-division 
 
Figure III- 2 Cell cycle phases 
Following mitosis, the daughter cells may re-enter the G1 phase, or proceed to a 5th 
phase called G0, where growth and replication stops. Cells in G0 are said to be 
‘quiescent’. G0 cell may eventually re-enter G1 or perhaps die (Alberts 1994).  
Stimulation of or interruption in checkpoint function results in cell cycle arrest and/or 
apoptosis (Hartwell & Kastan 1994). Mutations of control genes can lead to 
mutagenesis. The ability to interfere with this checkpoint functions is characteristic of 
many antiproliferating and antitumourigenic agents, including flavonoids (Knowles et 
al 2000) and nonsteroidal anti-inflammatory agents (Lim et al 1999; Walczak et al 
2001). 
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Two major processes of cell death can be distinguished, apoptosis, a highly 
regulated process, and accidental cell death, generally defined as necrosis. 
(Darzynkiewicz et al 1997) 
 
Figure III- 3 Morphological and biochemical changes during apoptosis and necrosis, reprinted 
from (Darzynkiewicz et al 1997). For more details see text. 
 
In addition, certain chemical compounds and cells are said to be cytotoxic to the cell, 
that is, to cause its death (Table III-2) 
 
Table III- 2 Terminology of cell death 
Apoptosis: programmed cell death, is the physiological process by which unwanted 
or damaged cells are eliminated during development and other normal 
biological processes. 
Necrosis: ‘accidental’ cell death, is the pathological process which occurs when 
cell are exposed to a serious physical or chemical insult. 
Cytotoxicity is the killing property of a chemical compound or a mediator cell 
(cytotoxic T cell). In contrast to necrosis and apoptosis, the term 
cytotoxicity does not indicate a specific cellular death mechanism. 
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Apoptosis, commonly referred too as programmed cell death, is an active process 
which is coordinated by defined biochemical pathways. Apoptosis is the physiological 
mode of cell death that plays a crucial role in tissue homeostasis in multicellular 
organisms, both during development and in the mature organism. The deregulation of 
apoptosis can lead to several diseases, including cancer, autoimmune disorders and 
aging. Too much cell death can lead to impaired development and degenerative 
diseases, whereas too little cell death can lead to diseases such as cancer and 
persistent viral infections.(Darzynkiewicz et al 1997; Muradian & Schachtschabel 
2001; Zhang & Herman 2002) 
 
Figure III- 4 Simplified schematic diagram of extrinsic (death receptor mediated) and intrinsic 
(mitochondrial) pathway of apoptosis. See text for details.  
Apoptosis is mediated by the activation of specific proteases, the caspases, and 
characterized by histological features like phosphatidylserine externalization, DNA 
fragmentation, nuclear condensation, and membrane blebbing. These changes occur 
by two major apoptotic pathways (Figure III-4), one triggered by activation of cell 
surface death receptors, and the other by functional inactivation of the mitochondria 
and their release to the cytosol of pro-apoptotic factors such as cytochrome c. The 
final execution phase of both pathways is mediated by activation of the caspases, a 
family of cysteine proteases. It has been proposed that initiator caspases with long 
prodomains, such as caspase-8 or -9, either directly or indirectly activate effector 
caspases, such as caspase-3 and -7. These effector caspases then cleave and 
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inactivate intracellular factors that are critical for cell survival, such as poly(ADP-
ribose) polymerase (PARP) and lamins, and cause the typical apoptotic morphology 
described above. (Darzynkiewicz et al 1997; Granville et al 1998; Marcelli et al 1999; 
Zhang & Herman 2002)  
When apoptosis occurs in vivo - apoptotic bodies are phagocytised by neighbouring 
cells, without triggering an inflammatory reaction in the tissue. In contrast, necrosis 
leads to swelling of the cell and finally disruption of the cell membrane. Organelles 
like mitochondria and nucleus remain intact throughout the process and the whole 
cell content is released in the surrounding tissue. Therefore the latter is often 
associated with inflammation in the area concerned (Granville et al 1998). Hence, 
induction of apoptosis in benign and malignant hyperplastic cells is the preferred way 
of eliminating them. In addition, an efficient apoptotic process in normal tissues 
prevents malignant transformation by elimination of defective cells and helps to 
correct age-related tissue damage (Zhang & Herman 2002).  
 
To discriminate underlying antiproliferative mechanisms on the cellular level, several 
methodological approaches were performed:  
• Cell cycle arrest and apoptotic ‘prepeak’ by flow cytometry 
• DNA fragmentation in late apoptosis by DNA fragmentation assay 
• Prevention of cell growth inhibition by adding a pan- caspase inhibitor 
• Cell cytotoxicity by lactate dehydrogenase (LDH) measurement 
 
Flow cytometry contributes significantly to cell cycle studies and investigations into 
the effects of pharmacologic agents on proliferating cells. Based on their differences 
in DNA content, cell cycle phases can be discriminated. Cells in G0/G1 phase have 
DNA content set equal to 1 unit of DNA; cells in S phase duplicate DNA, increasing 
its content in proportion to progression through S; and upon entering G2 and later M 
have twice the G0/G1 phase DNA content (2 units). The percentage of apoptotic cells 
can be determined from sub-G0/G1 population, indicating DNA fragmentation. The 
presence of a sub diploid peak is a second hallmark of apoptosis. (Darzynkiewicz et 
al 1997; Lim et al 1999; Darzynkiewicz et al 2001) 
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As shown in Figure III-4 members of the caspase family play a key role in the 
execution of apoptosis (Thornberry & Lazebnik 1998). Z-VAD-FMK is a cell 
permeable pan-caspase inhibitor that irreversibly binds to the catalytic site of 
caspase proteases and inhibits apoptosis (Marcelli et al 1999). The peptide is O-
methylated in the P1 position on aspartic acid providing enhanced stability and 
increased cell permeability. This inhibitor can be used as a general caspase inhibitor. 
Thus, the reversion by the co-treatment with Z-VAD-fmk on extract induced cell 
growth inhibition was investigated.  
Additionally, DNA fragmentation, a hallmark of late apoptosis, was assessed by the 
specific determination of mono- and oligonucleosomes which are released into the 
cytoplasm of cells which die from apoptosis. The assay used is based on a 
quantitative sandwich-enzyme-immunoassay-principle using mouse monoclonal 
antibodies directed against DNA and histones, respectively.  
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in all cells. It is 
rapidly released into the cell culture supernatant upon damage of the plasma 
membrane. Thus in cell culture, the course of drug-induced cytotoxicity can be 
followed quantitatively by measuring the cytosol enzyme LDH by a tetrazolium-based 
kit in the cell supernatant released from damaged cells (Kumi-Diaka 2002). As it is 
released into the cell culture supernatant, LDH participates in a coupled reaction 
converting a yellow tetrazolium salt to red formazan. The amount of enzyme activity 
correlates to the number of damaged cells. 
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2 Material and Methods 
2.1 Cell lines, culture conditions and cell proliferation assays 
Cell cultures 
Human prostate epithelial cell lines BPH-1 (DSMZ ACC 143), LNCaP (ATCC CRL-
1740), and PC-3 (ATCC CRL-1435) were kindly provided by Dr. Bubendorf, Institute 
of Pathology, University Hospital, Basel. Cells were routinely cultured in OptiMEM 1 
(Gibco BRL Life Technologies Cat. No. 31985-047) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Gibco BRL Life Technologies Cat.No. 10270-
106) and 100µg/ml streptomycin and 100 I.U./ml penicillin (Amimed Cat. No. 4-01 
F00-H) (= culture medium). Cells were grown under a humidified 5% CO2 and 95% 
air atmosphere at 37°C. Medium was changed every 2-3 days. All cells used in the 
present study were from 10th through 30th passages. 
Test extracts and compounds 
Table III- 3 Extracts investigated 
Plant Extract Extracting agent Supplier 
Fruit extract Me180 (SabCaps®) 
Lot. No. C002694 
Hydroethanolic (96%) Medichemie AG 
(Ettingen, CH) 
Hexane green nature Fruit extract 
Hexane orange ripe Fruit extract 
Hexane black full ripe Fruit extract 
Hexan 
Ethanol green nature Fruit extract 
Ethanol orange ripe Fruit extract 
Serenoa repens 
Ethanol black full ripe Fruit extract 
Hydroethanolic (96%) 
Vitaplant AG 
(Witterswil, CH) 
Vitex agnus-castus, 
FRUIT extract VACF 08 
Hydroethanolic (60%) Vitaplant AG 
(Witterswil, CH) 
Vitex agnus-castus 
Vitex agnus-castus, 
LEAF extract VAC 03-2 
Hydroethanolic (60%) Vitaplant AG 
(Witterswil, CH) 
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The extracts tested are shown in Table III-3. Me180 containing capsules (SabCaps®) 
were supplied by Medichemie AG, Ettingen, Switzerland. The oily extracts have been 
directly encapsulated into soft gelatine capsules without any additional auxiliaries, so 
that test samples could be taken directly out of the capsules. All others extracts were 
kindly provided by VitaPlant AG, Witterswil, Switzerland. 
Serenoa repens plant material: fruits were collected wild in Florida at three different 
time points in the ripening process (unripe (=green), ripe (=orange), and full ripe 
(=black)). The air-dried, hackled fruits were milled and extracted with ethanol or 
hexane by ultrasound bath for 10 min. The solutions were filtered and evaporated 
under vacuum.  
Solutions of the extracts were freshly prepared for each experiment by dissolution in 
dimethyl-sulfoxide (DMSO) and further diluted to test concentrations, before added to 
the experimental culture medium, giving a final concentration of 0.1% DMSO in each 
treatment group. 
Caspase inhibitor Z-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK, Alexis, Cat. 
No. ALX-260-039) was diluted in DMSO at appropriate concentrations prior to use 
and added to the culture medium. 
All other reagents were of the highest grade available. 
2.2 Colorimetric assays for testing proliferation, viability, apoptosis 
and cytotoxicity 
For cell growth experiments, cells were dispersed from subconfluent cultures by 0.4% 
trypsin in EDTA PBS (Amimed Cat. No. 5-51F) and diluted with culture medium. After 
determination of cell number by counting with a hemocytometer and dilution with 
culture medium, proliferation assays were initiated by seeding into 96-well plates 
(Falcon, 53 3072) at various densities in 150µl culture medium/well (BPH-1 3000 
cells/well, LNCaP 1000 cells/well, PC-3 2000 cells/well) and grown for 24h at 37°C to 
allow cells to attach. After attachment, serum-containing medium and non-attached 
cells were aspirated and replaced by 100µl experimental culture medium (OptiMEM 
with 1% charcoal-stripped (delipidated) bovine calf serum (Sigma Cat. No.1696). 
Cultures were continued for another 24h before 50µl of experimental medium 
containing increasing concentrations of test compounds dissolved in DMSO was 
added and culture continued for additional time intervals (24h, 48h, 72h). Controls 
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received 0.1% DMSO only. In the caspase inhibitor assay, cells were co-incubated 
with 100µM Z-VAD-fmk. 
Cell viability was quantified after indicated treatment times by adding 15µl 
tetrazolium-based WST-8 Cell Counting Kit-8 Reagent (Dojindo CK-04-13, Japan) 
and incubated for a further 60min at 37°C. Then the optical density (O.D.) of the dye 
solution was read with microplate reader (Model 3550; Bio-Rad Laboratories) at 
450nm. Growth inhibition was calculated as the percent inhibition with respect to the 
control (control = 100%). 
Cell number was determined by crystal violet staining as described by Kueng [8]. 
Briefly, if necessary after measurement of cell viability, cultures were terminated by 
fixing cells with 15µl of an 11% solution of glutaraldehyde (Fluka, Cat. No. 49626) 
(final conc. 1%) on a rotary shaker for at least 20min at room temperature. Plates 
were washed thoroughly with tap water and air-dried. Cells were subsequently 
stained with 100µl of a 0.1% solution of crystal violet (Merck, Cat. No. 1408) 
dissolved in 200mM HEPES Ultrol® buffer (pH 6.0) (Calbiochem, Cat. No. 391338). 
After being shaken for 20 minutes at room temperature, excess dye was removed by 
extensive washing with deionised water. The plates were air dried prior to dissolving 
the bound dye in 100µl 10% acetic acid. The optical density (O.D.) of the dye solution 
was measured at 550nm using a Bio-Rad microplate reader against acetic acid as a 
blank and expressed as percent of control (control =100%). 
Cytotoxicity was estimated by measuring the activity of lactate dehydrogenase LDH 
in the cell culture supernatants using a Cytotoxicity Detection Kit (LDH) (Roche, 
No. 1 644 793). Culture medium was removed and centrifuged at 300g for 10 min to 
obtain a cell-free supernatant. 100µl/well of each cell-free supernatant was 
transferred in triplicates to wells in a 96-well microtiter plate and 100µl of LDH assay 
reaction mixture was added to each well. After 10 min incubation, the absorbance of 
the colour generated was read on a Bio-Rad microplate reader at 490 nm with a 
reference wavelength of 595nm. Triton-X100 (1%) was used as positive control. The 
mean O.D. for each treatment was normalized for cell number based on the crystal 
violet test group and expressed as n-fold of control (control = 1).  
Apoptosis was assayed using the Cell Death Detection ELISA plus assay 
(ROCHE, No.1774 425), quantitating histone-associated DNA fragments in the 
cytoplasm of cells. Cells were incubated with or without the indicated concentrations 
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of each of the three extracts for 48h at 37°C before apoptosis was measured 
according to the supplier’s instructions. In brief, supernatants of the cells were 
investigated for cytotoxicity tests (Cytotoxicity Detection Kit (LDH) see above) and 
attached cells were lysed in 200µL of lysis buffer per well, at room temperature for 30 
min. The plates were centrifuged, and 20µL of diluted cell lysates as well as positive 
and negative control lysates (provided with the kit) were added to anti-histone 
antibody-coated assay plates. Thereafter, 80µl of the immunoreagent were added 
per well and the plates were incubated for 2h on a plate shaker (500 rpm at room 
temperature). The plates were washed three times with incubation buffer and air 
dried. All samples were treated with anti-DNA-peroxidase followed by development 
with 100µl of ABTS® substrate. The resultant absorbance (in which increasing units 
of absorption correlates with the increasing levels of apoptosis) was measured 5 min 
later with the microplate reader (405nm). The amounts of histone-DNA fragments 
were computed as a ratio of the control. The resulting values were normalized for cell 
number based on the crystal violet staining and expressed as n-fold. 
2.3 Cell cycle and apoptosis analysis by FACScan 
Culture and treatment of prostate cell lines were performed in 25cm2 flasks (Falcon 
35 3109) at the same density per area as in the microtiterplate assays (BPH-1 150 
000 cells, LNCaP 100 000 cells, and PC-3 125 000 cells, respectively). Media were 
replaced after 24h by 10 ml experimental culture medium for 24h before treatment 
with various concentrations of Serenoa repens extract (10, 30, 50, 100µg/ml) or Vitex 
agnus-castus extract (3, 10, 30µg/ml). Both extracts were dissolved in DMSO and 
added to experimental culture medium. Experimental culture medium containing 
0.1% DMSO served as the control. 
After 48 h, adherent cells were harvested by trypsinization, and floating cells were 
recovered by centrifugation at 300g for 10min. Both adherent and floating cells were 
combined. The cells were washed once with phosphate buffered-saline (PBS) and 
fixed in ice-cold 70% ethanol.  
Fixed cells were stored at 4°C until stained with propidium iodide reagent (containing 
50µg/ml of propidium iodide and 100µg/ml of RNAse).The cells were incubated in the 
dark for 1h at 37°C and kept overnight at 4°C. Cell cycle analysis was performed 
using a Becton Dickinson FACScan cytometer (Becton Dickinson, San Jose, CA). For 
each treatment 8000 events were recorded. The DNA content of 8000 cells stained 
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with propidium iodide was measured with a FACScan instrument equipped with 
FACStation running Cell Quest software (Becton Dickinson). Cell cycle analysis of 
DNA histograms was performed with the Multicycle program for Windows 3.0. 
2.4 Statistical analysis 
Each data set represents the mean of three independent experiments. The 
experiments were performed in triplicate unless otherwise stated. All statistical 
comparisons were made with Microsoft EXCEL, Version 7.0, using the unpaired, 2-
tailed t-test, assuming unequal variance. Data are expressed as mean values ± 
standard deviation. Statistical significance was established at values of p< 0.05. 
Single asterisk indicates p <0.05. Double asterisks indicate p <0.01. The IC 50 values 
were defined as the concentration which inhibited the growth of cells by 50% 
compared with that of control cells and were calculated by Sigma plot for Windows, 
Version 8.0. 
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3 Results  
3.1 In vitro effects of Serenoa repens 
3.1.1 Serenoa repens-induced cell growth inhibition in prostate cell lines 
To determine the effects of Serenoa repens extracts (SRE) on cell growth and 
viability, human prostate epithelial cell lines (BPH-1, LNCaP, and PC-3) were 
incubated with increasing concentrations of different SRE ranging from 10 to 100 
µg/ml. Inhibition of cell proliferation by the extracts was evaluated by crystal violet 
(CV) staining and inhibition of cell viability was studied with a WST-8 assay kit 
measuring the conversion of a tetrazolium compound to its visible formazan product 
by metabolically active cells. 
In an initial study, the effects of exposure time were determined by treating prostate 
cells with a commercially available Serenoa repens extract Me180 for various time 
periods (24-72h). In all three cell lines, cell growth was inhibited in a dose- and time 
dependent manner. Figure III-5 contains data representing BPH-1 cells treated with 
Me180; however, similar results were obtained with all three cell lines. With rising 
treatment times, in all three cell lines, optical density (O.D.) values of stained cells by 
CV were steadily increasing in controls, indicating that proliferation rate of the control 
cells was not reduced after 72h of treatment. For further experiments, a 48h-
treatment time was chosen, because initial growth inhibitory effects were detectable 
after 24h. Therefore, 48h ensured adequate time for studying the molecular 
mechanisms involved in growth inhibition. 
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Figure III- 5 Time- and dose-dependent growth inhibition of BPH-1 cells by Me180. Cell 
proliferation was assessed in the presence of various concentrations of Me180. Cells were 
incubated for 24, 48, and 72 h. Fixed cells were stained by crystal violet staining (CV). The 
optical density (O.D.) of the dissolved dye was determined at 550nm. A: O.D. values are 
expressed as means ± SD (n = 3). B: Values are calculated as % of control (=100%) and 
expressed as means ± SD (n = 3). 
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As shown in Figure III-6, among the three cell lines, cell proliferation was more 
inhibited in LNCaP cells than in BPH-1 and PC-3 cells with an IC50 value of 35ug/ml. 
A significant suppression of LNCaP cell proliferation occurred at 30 µg/ml (p<0.01), 
showing a maximum inhibition at all concentrations from 40-100 µg/ml compared to 
controls. In the applied dose range, BPH-1 and PC-3 cell lines were not affected by 
the treatment of lower than 70µg/ml Me180 for 48h and were only significantly 
reduced at 100µg/ml compared to controls. Statistical analysis comparing the 
difference of the means at various concentrations of extract on the BPH-1 and PC-3 
cell lines, showed no significance (p>0.1). 
Me180 on human prostate epithelial cell lines
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Figure III- 6 Effect of SRE Me180 on cell viability of different prostate cell lines (BPH-1, LNCaP, 
PC-3). Cells were incubated in the presence of various concentrations of Me180 for 48h. Cell 
viability was measured by WST-8. The results are expressed as % of control containing the 
vehicle (0.1%) in the absence of SRE. All data are means ± SD (n=3). Cell viability of LNCaP 
cells were significantly (**, p< 0.01) inhibited after treatment of 30µg/ml of Me180 compared to 
solvent treated control, whereas BPH-1 cells were significantly (**, p< 0.01) inhibited after 
treatment of 90 and 100µg/ml of Me180 compared to vehicle treated control and PC-3 where 
only significantly inhibited at 100µg/ml (**, p< 0.01).  
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In the WST-8 assay, the produced formazan is released into the cell medium by 
viable cells. Since this generated formazan dye is highly water soluble, no washing 
and no solubilisation steps are necessary before O.D. determination. The toxicity of 
WST-8 is so low that after the assay is completed, the same cells can be used for 
further cell proliferation measurements by the CV assay. No significant differences 
were found between these two assay systems, indicating that the treatment did not 
reduce cell viability, and thus confirm the results obtained by the two assay systems 
run in sequence. In an example (Figure III-7), both parameters show similar results. 
 
** **
Effects of Me180 on cell proliferation and cell viability of LNCaP cells
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Figure III- 7 Effects of Me180 on cell proliferation and viability in LNCaP cells for 48h. No 
significant differences were found between the two assay systems, CV and WST-8. Cell growth 
was significantly inhibited by Me180 treatment in concentrations of 30-100µg/ml compared to 
DMSO-treated control (**, p<0.01). Values are calculated as % of control (=100%) and expressed 
as means ± SD (n = 4). 
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3.1.2 Test of different Serenoa repens-qualities (ripeness, extracting 
agent) on prostate cell growth 
Serenoa repens fruits from three different ripeness stages (unripe (green), medium-
ripe (orange), and full ripe (black)) were processed with 2 different extraction 
solvents, ethanol or hexane. 
The extraction with ethanol (96%) led to a precipitate, whereas the extraction with 
hexane gave a homogeneous extract without precipitate. We therefore examined all 
different phases (mixed total extract, supernatant, and precipitate) of ethanol extracts 
on cell growth of the three prostate cell lines. Up to 100µg/ml no statistically 
significant growth inhibition was found with the precipitate in all three cell lines and by 
all ripeness conditions. However, the strongest growth inhibitory effect on prostate 
cells was found by the supernatants (Figure III-8), giving comparable effects with the 
commercial ethanol (96%) extract Me180 (Figure III-7). 
Effect of different extract fractions of ethanolic black fruit SRE on LNCaP cells
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Figure III- 8 Effect of three different extract fractions (precipitation, supernatant, and total 
extract) of the ethanol extract of black ripe fruit of SRE on LNCaP after 48h treatment time in 
various concentrations. Cell proliferation was assessed by CV staining. Values are calculated 
as % of control (=100%) and expressed as means ± SD (n = 3). The supernatants exhibit the 
strongest effect, whereas cell growth was only weakly inhibited by the extract precipitations. 
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No differences were seen among the three ripeness conditions in the hexane extract 
in all three cell lines as shown in Figure III-9A. Cell lines were comparably affected as 
with Me180 treatment, inhibiting cell growth of BPH-1 and PC-3 only weakly at 
highest concentrations and exhibiting stronger effects on LNCaP cells (Figure III-7, 
III-9). Comparing the IC50 values, the hexane extracts exhibited significantly stronger 
(p= 0.03) effects, with IC50 values of 31µg/ml compared to 37µg/ml for the ethanol 
supernatants. 
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Figure III- 9 Effects of increasing concentrations of selected Serenoa repens extracts on LNCaP 
cell proliferation (CV) after 48h of treatment. Values are calculated as % of control (=100%) and 
expressed as means ± SD (n = 3). A: Comparison of supernatants of hexane extract of the three 
different ripeness conditions. B: Comparison of ethanol extracts of the three different ripeness 
conditions. 
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3.1.3 Effects of Me180 on cell cycle distribution in proliferating prostate 
cells  
A fluorescence-activated cell sorter (FACS) method was used to test, if cell growth 
inhibitory effects of SRE are mediated by perturbation of cell cycle progression. 
The method is based on the binding of propidium iodide to double stranded DNA. 
The binding is independent of base specificity and is proportional to the DNA content 
of a cell. It can be used to study the distribution of a given cell population in the 
different phases of the cell cycle and it also provides an indication of the proportion of 
cells undergoing apoptosis, because apoptotic cells can have a DNA content that is 
less than cells in G0/G1 (=pre-peak, B.A.D. background aggregates and debris). 
DNA content is plotted on the horizontal axis of each graph and the number of cells is 
plotted on the vertical axis of each graph.  
In Figures III-10, III-11, III-12, the inset depicts cartoons of the cells in the various 
phases of the cell cycle after treatment for 48h with Serenoa repens extract Me180. 
The percentages of cells in the different phases of the cell cycle in the DNA 
histograms were calculated and are shown below. 
The effects appeared to be specific for each cell line. In BPH-1 cells (Figure III-10) 
only minor changes occurred in cycle distribution. A statistically significant (p< 0.05) 
decrease of cells in S phase (from 14.6% in controls to 7% at 100µg/ml) with a dose-
dependent but non-significant increase of cells in G2/M phase was observed. 
In LNCaP cells, Me180 treatment led to a statistically significant (p<0.05), dose-
dependent increase in the number of cells in the sub G0/G1 (apoptotic) pre-peak with 
1.5% in controls and 11.3% at the highest concentration of 100µg/ml, as shown in 
Figure III-11. Me180 treatment also resulted in an increase of the percentage of cells 
in the S phase. However, no more relevant shifts within the cell cycle phases were 
observed indicating that the extract only marginally affects LNCaP cells in cell cycle 
progression (Figure III-11). 
In PC-3 cells (Figure III-12), treatment with Me180 exerted a dose-dependent shift 
from G0/G1 to S phase, with a statistically significant (p<0.05) decrease of the 
percentage of cells in G0/G1 phase from 60% to 52% and an accordant but non 
significant increase in the S phase from 26% to 33%. 
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Figure III- 10 Cell cycle analysis after exposure of BPH-1 cells to Me180 for 48h.  
A: Representative flow-cytometry histograms of BPH-1 control and Me180 100µg/ml 
B: Percentage of cells in G0/G1, S, or G2/M phase of the cell cycle and B.A.D. (apoptotic pre-
peak). Values are expressed as mean ± SD from three independent experiments. 
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Figure III- 11 Cell cycle analysis after exposure of LNCaP cells to Me180 for 48h.  
A: Representative flow-cytometry histograms of LNCaP control and Me180 50µg/ml 
B: Percentage of cells in G0/G1, S, or G2/M phase of the cell cycle and B.A.D. (apoptotic pre-
peak, arrow). Values are expressed as mean ± SD from three independent experiments. 
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Figure III- 12 Cell cycle analysis after exposure of PC-3 cells to Me180 for 48h.  
A: Representative flow-cytometry histograms of PC-3 control and Me180 100µg/ml 
B: Percentage of cells in G0/G1, S, or G2/M phase of the cell cycle and B.A.D. Values are 
expressed as mean ± SD from three independent experiments. 
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3.1.4 Induction of apoptosis and cytotoxic effects by Serenoa repens 
extract 
Cell cycle studies demonstrated that in all three cell lines only minor effects occurred 
in cell cycle progression after Me180 treatment. To clarify this effect observed with 
respect of apoptosis and cell cytotoxicity, we further applied two different assay 
systems, one to assess the reversion of apoptosis by a pan-caspase-inhibitor (Z-
VAD-fmk) interfering with the apoptotic process, and the other, to assess the 
induction of DNA fragmentation, a hallmark of late apoptosis. 
As shown in Figure III-13, cell growth inhibition in BPH-1 cells was only weakly 
reversed by co-treatment with the caspase inhibitor. As expected, the effect was 
stronger in LNCaP cells as compared to BPH-1 cells. In cell cycle analysis Me180-
treated LNCaP cells revealed a G0/G1 “pre-peak” indicating that apoptotic cell death 
might be involved (Figure III-11). The reversion of Me180-induced cell growth 
inhibition by co-treatment with the pan-caspase inhibitor Z-VAD-fmk (100µM) 
demonstrated that this was due in part to apoptosis (Figure III-13). However, this 
reversion was only statistically significant at low concentrations of 25µg/ml of extract 
(p<0.05). No reversion was found in PC-3 cells. 
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Figure III- 13 Me180-induced cell growth inhibition is partially reversed by co-treatment with the 
pan-caspase inhibitor Z-VAD-fmk 100µM for 48h. Fixed cells were stained by crystal violet. 
Optical density of the dissolved dye was determined at 550nm and calculated as % of control 
(=100%) and expressed as means ± SD of three independent experiments. Reversion of cell 
growth inhibiting effects was statistically significant only in LNCaP cells at 25µg/ml extract (*, 
p<0.05). 
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Based on observed effects, DNA fragmentation, an event of late apoptosis, was 
evaluated as a further indicator of apoptosis after treatment of prostate epithelial cells 
with Me180. Furthermore, lactate dehydrogenase (LDH) in the cell supernatant was 
assessed to evaluate, whether Me180-induced cell growth inhibition was also partly 
due to cytotoxicity.  
Concentrations of 50µg/ml and 100µg/ml Me180 were tested for 48h in all three 
prostate cell lines. As shown in Figure III-14, our results suggest two different modes 
of cell death involved: through an apoptotic pathway leading to enhanced DNA 
fragmentation after the treatment with Me180 and secondly via a cytotoxic effect 
leading to an increase of LDH activity in the cell supernatants of treated cells 
compared to untreated cells.  
BPH-1 cells treated with Me180 displayed a statistical significantly (p<0.01) dose-
dependent increase of DNA fragmentation (2.6-fold for 50µg/ml and 3.8-fold for 
100µg/ml compared to untreated controls), corresponding to previous results 
obtained by reversion with the caspase inhibitor (Figure III-13), but in contrast to the 
cell cycle analysis (Figure III-10), were no apoptotic pre-peak was observed.  
Moreover, corresponding to cell cycle analysis (Figure III-11) and reversion by co-
treatment with the caspase inhibitor (Figure III-13), LNCaP revealed also a dose- 
dependent increase in DNA fragmentation with 3-fold with 50µg/ml and 4.3 fold with 
100µg/ml SRE, respectively, showing further evidence of apoptosis. 
In contrast, in PC-3 cells Me180-treatment did not result in apoptosis as evidenced 
by a lack of DNA fragmentation (Figure III-14). These observations were consistent 
with the lack of the apoptotic pre-peak in cell cycle analysis (Figure III-12) and the 
lack of a reversion of cell growth inhibition by the caspase inhibitor (Figure III-13). 
The PC-3 cells thus appear to be insensitive to Me180-treatment. 
Consistent with these findings, LDH leakage, as a marker of necrosis, increased 
more in LNCaP cells than in PC-3 and in BPH cells. Higher concentration of 
100µg/ml of SRE caused statistically significant increase of LDH in the cell 
supernatant (p<0.01), indicating more severe cellular damage in LNCaP, whereas in 
BPH-1 and PC-3 cells no change in LDH was detected as compared to controls 
(Figure III-14). 
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Figure III- 14 Induction of DNA fragmentation and LDH leakage after exposure of prostate cell 
lines to Serenoa repens extract Me180 for 48h. Values are calculated as n-fold of control (n=1) 
and expressed as means ± SD of three independent experiments. Dose-dependent statistically 
significant (**, p<0.01) increase of DNA fragmentation was only observed in BPH-1 cells, 
whereas a significant (*, p<0.05) increase was also observed in LNCaP cells with 50µg/ml of 
extract. Statistically significant increase of LDH in the cell supernatant was only found in 
LNCaP at the highest concentration of 100µg/ml (**, p<0.01). 
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3.2 Effects of Vitex agnus-castus extracts in prostate cell lines 
3.2.1 Antiproliferative response of cells to extracts of Vitex agnus-castus 
Recently, a Vitex agnus-castus fruit extract (VACF) was shown to exhibit anti-tumour 
activities in different human cancer cell lines (Ohyama et al 2003), but its effects on 
human prostate epithelial cells has so far not been investigated. As for SRE-
treatment, the effects of VACF were first determined by incubating prostate cells with 
various doses ranging from 1 to 30µg/ml, and 3 to 100µg/ml of VACF and Vitex 
agnus-castus leaf extract (VACL), respectively, for various time periods (24-72h). 
Figure III-15 illustrates the dose- and time-dependent effects in BPH-1 cells by 
VACF, as a representative example.  
Cell proliferation and viability was equally affected in all three human prostate cell 
lines (BPH-1, LNCaP, and PC-3) by a significant decrease after VACF-treatment 
compared to controls. The difference between treated and untreated cells was 
already significant (p<0.05) after 24h and this difference became more prominent and 
profound over time. Inhibition of cell growth was significant (p<0.01) at 10 and 30 
µg/ml for all three cell lines after treatment of 48h (Figure III-17).  
Comparing fruit and leaf extracts, VACF (fruit) was the more potent extract, causing 
significant inhibition of cell growth with IC50 values of 7, 8 and 7µg/ml in BPH-1, 
LNCaP, and PC3, respectively. VACL (leaf) treatment also inhibited prostate cell 
growth, but at approximately two-fold higher concentrations, corresponding to IC50 
values of 17, 15 and 20 µg/ml (Figure III-16).  
Similarly to the results with SRE-treatment, comparable data were obtained with 
WST-8 assay and with CV assay, respectively, showing that the amount of the 
formazan produced by viable cells corresponds to the number of attached cells 
stained by CV. A 48h growth inhibition curve of each cell line after treatment with 
VACF comparing the two methods is depicted in Figure III-17. 
The next series of experiments were performed to gain further information on the 
mechanism of Vitex agnus-castus mediated growth inhibition. 
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Figure III- 15 Time- and dose-dependent growth inhibition of proliferation of BPH-1 cells by 
Vitex agnus-castus fruit extract (VACF). Cells were incubated with various concentrations of 
VACF for various time periods (24, 48, and 72 h). Fixed cells were stained by crystal violet. The 
optical density (O.D.) of the dissolved dye was determined at 550nm. A: Optical density (O.D.) 
values are expressed as means ± SD (n = 3). B: Values are calculated as % of control (=100%) 
and expressed as means ± SD (n = 3). 
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Figure III- 16 Growth inhibition of prostate cell lines by VAC- treatment for 48h. Fixed cells were 
stained by crystal violet staining. The optical density (O.D.) of the dissolved dye was 
determined at 550nm. Values are calculated as % of control (=100%) and expressed as means ± 
SD (n = 3). A: Vitex agnus-castus fruit extract, B: Vitex agnus-castus leaf extract. 
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Figure III- 17 Effects of VACF on cell proliferation and viability in prostate cell lines cells for 
48h. No significant differences were assessed between the two assay systems, CV and WST-8. 
Cell growth was significantly inhibited by VACF at 10 and 30 µg/ml in all three cell lines 
compared to untreated controls (**, p<0.01). Values are calculated as % of control (=100%) and 
expressed as means ± SD (n = 4). 
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3.2.2 Effects of VACF on cell cycle distribution in proliferating prostate 
cells  
Cell proliferation assays indicated that VACF significantly reduced the survival of 
human prostate cell lines, leading us to further investigate the molecular mechanisms 
of cell death involved. To determine whether the inhibition of cell growth was due to 
apoptosis and/or cell cycle arrest, cell cycle analysis wascarried out by flow 
cytometry for all cell lines investigated. As mentioned before, propidium iodide 
staining of cellular DNA, followed by FACS analysis, provides a useful method for 
evaluating the cell cycle. In Figures III-18-20 we present cell cycle distribution data 
after treatment with 10µg/ml VACF for 48h. Percentages of cells in the different 
phases of the cell cycle after exposure to VACF in various concentrations (3,10,30 
µg/ml) for 48h are displayed in the figures below. 
VACF treatment clearly altered the pattern of cell cycle distribution in all three 
prostate cell lines: The flow cytometric analysis showed, that solvent treated controls 
of all three cell lines gave little or no events recorded in the sub G0/G1 (apoptotic) 
pre-peak and displayed a distribution of cells in the G0/G1, S and G2/M phases 
typical of proliferating cancer cell lines. The number of cells in the sub G0/G1 pre-
peak increased dose-dependently after 48h of treatment in all three cell lines. In a 
concentration of 30µg/ml VACF, this increase was statistically significant in all three 
cell lines (p<0.01). As mentioned earlier, this additional sub G0/G1 pre-peak is 
characteristic for apoptotic cells and represents a first indicator for DNA 
fragmentation.  
Additionally, in BPH-1 cells treatment with VACF resulted in a dose-dependent 
decrease of cell number in G0/G1 phase compared to untreated controls being 
significant at 30µg/ml (p<0.05), and displayed a concomitant increase in the 
percentage of cells in G2/M phase, statistically significant at 30µg/ml (p<0.01) shown 
in Figure III-18. These effects were less clear after treatment of LNCaP cells (Figure 
III-19). In PC-3 cells, the treatment with VACF revealed a dose-dependent, but non-
significant decrease of the percentage of cells in G0/G1 phase with a corresponding 
dose-dependent but significant (p<0.05) increase of cells in the S phase (Figure III-
20). 
All data showed treatments of 48h of VACF exposure. Similar effects by VACF were 
observed after prolonging treatment time to 72h.  
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Figure III- 18 Cell cycle analysis: BPH-1 cells were exposed to various concentrations of VACF 
for 48h. Histograms show cell cycle distribution of cells treated with or without VACF 10µg/ml 
for 48h. The percentage of cells in each phase was calculated based on the DNA histogram and 
are displayed for increasing concentration of VACF in the figure below. The values represent 
the means ± SD of three independent experiments.  
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Cell cycle analysis VACF on LNCaP
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Figure III- 19 Cell cycle analysis: LNCaP cells were exposed to various concentrations of VACF 
for 48h. Histograms show cell cycle distribution of cells treated with or without VACF 10µg/ml 
for 48h. The percentage of cells in each phase was calculated based on the DNA histogram and 
are displayed for increasing concentration of VACF in the figure below. The values represent 
the means ± SD of three independent experiments.  
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Cell cycle analysis VACF on PC-3
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Figure III- 20 Cell cycle analysis: PC-3 cells were exposed to various concentrations of VACF 
for 48h. Histograms show cell cycle distribution of cells treated with or without VACF 10µg/ml 
for 48h. The percentage of cells in each phase was calculated based on the DNA histogram and 
are displayed for increasing concentration of VACF in the figure below. The values represent 
the means ± SD of three independent experiments.  
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3.2.3 Estimation of induction of apoptosis and cytotoxicity by VACF 
Further assays were performed to investigate the effects of VACF- and VACL -
induced cell death. Most of the morphological changes that are observed during the 
apoptotic process are caused by a set of cysteine proteases in the caspase cascade, 
which are activated especially in apoptotic cells. Therefore, prostate cell lines were 
exposed to VAC together with a broad spectrum caspase inhibitor. As shown in 
Figure III-21 and III-22, the caspase inhibitor Z-VAD-fmk (100µM) reversed the VAC 
growth inhibiting effect in all three cell lines investigated. The modest reversion of 
VACF and VACL induced cell growth inhibition by co-treatment with the pan-caspase 
inhibitor Z-VAD-fmk demonstrated that cell growth inhibition is partially due to 
caspase-mediated apoptosis. However, statistical significance for reversion of VACF-
induced cell growth inhibition was only achieved in BPH-1 cells at concentrations of 
10 and 30 µg/ml and in LNCaP cells at 30µg/ml (p<0.05), and for VACL-induced cell 
growth inhibition at 30µg/ml in BPH-1 (p<0.01) and in PC-3 cells (p<0.05).  
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Figure III- 21 VACF-induced cell growth inhibition is partially reversed by co-treatment with 
pan- caspase inhibitor Z-VAD-fmk (100µM) for 48h. Fixed cells were stained by CV. O.D. of the 
dissolved dye was determined at 550nm and calculated as % of control (=100%) and expressed 
as means ± SD (n = 3). (* = p<0.05) 
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Figure III- 22 VACL-induced cell growth inhibition is partially reversed by co-treatment with 
pan- caspase inhibitor Z-VAD-fmk 100µM for 48h. Fixed cells were stained by CV. O.D. of the 
dissolved dye was determined at 550nm and calculated as % of control (=100%) and expressed 
as means ± SD (n = 3) (*,p<0.05 and **, p<0.01). 
To further investigate the apoptotic effects and to differentiate between apoptosis and 
cytotoxicity, we further used a combined assay system detecting DNA fragmentation 
in the cells (ELISA) and LDH in the cell supernatants of the same cells. The data 
obtained show that VACF and VACL reduce human prostate cell proliferation in 
culture partly by apoptosis. However, in addition, the increased LDH leakage 
indicated that inhibition of proliferation was also partly due to a cytotoxic reaction 
(Figures III-23 and III-24). 
A dose-dependent increase of VACF-induced DNA fragmentation, a hallmark of late 
apoptosis, was found in all three cell lines. In BPH-1 cells fruit and leaf extract 
exhibited a statistically significant enhancement at concentrations of 10 and 30 µg/ml 
by fruit (p<0.01) and leaf extracts (p<0.05). In LNCaP and PC-3 cells, the apoptosis-
inducing activity of both extracts was dose-dependent, being observed at 
concentrations as low as 5µg/ml subsequently increasing with higher concentrations 
of 10µg/ml.  
A similar pattern of cell death was observed by LDH measurement in the cell 
supernatant, as an indicator of cell membrane damage with subsequent release of 
cytosolic LDH. VACF showed a dose-dependent and significant increase of LDH in 
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the cell supernatant of all three cell lines. However, in all three cell lines apoptosis 
reaction was higher than cytotoxic effects compared to controls. Comparable results 
were obtained by investigating VACL (Figure III-24). Released LDH was only 
significantly enhanced in BPH-1 and LNCaP at the highest concentration of 30µg/ml 
VACL (p< 0.01) whereas no increase was shown in PC-3 cells. 
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Figure III- 23 Effects of increasing doses of VACF on prostate cells DNA fragmentation and 
LDH release after 48h of treatment. Values were calculated as n-fold of control (n=1) and 
expressed as means ± SD (n = 3) (*,p<0.05 and **, p<0.01, compared to control). 
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Figure III- 24 Effects of increasing doses of VACL on prostate cells DNA fragmentation and 
LDH release after 48h of treatment. Values were calculated as n-fold of control (n=1) and 
expressed as means ± SD (n = 4) (*,p<0.05 and **, p<0.01, compared to control).  
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3.3 Summary of the in vitro effects of SRE and VAC  
Extracts of Serenoa repens fruits and Vitex agnus-castus fruits and leaves were 
tested for their effects on proliferating human prostate cancer cells. Investigated cell 
lines revealed to be less sensitive to SRE than to VAC treatment (Figure III-25). IC50 
values obtained with all extracts investigated on all three prostate epithelial cell lines 
are summarized in Table III-4. 
Cell growth inhibition profile of Serenoa repens and 
Vitex agnus-castus extract in human prostate cell lines
SRE                            VACF                            VACL
BPH-1 LNCaP PC-3 BPH-1, LNCaP, PC-3, BPH-1. LNCaP. PC-3.
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Figure III- 25 Growth inhibition profile of Serenoa repens and Vitex agnus-castus fruit and leaf 
extract in human prostate cell lines. After treatment with indicated extracts cells were fixed and 
stained with crystal violet. The optical density (O.D.) of the dissolved dye was determined at 
550nm. IC50 values were expressed as % of controls (=100%). 
Comparing the Serenoa repens effects in BPH-1, LNCaP and PC-3 cells, LNCaP 
cells revealed to the most sensitive cell line, showing growth inhibition with a 3-fold 
lower IC50 value than BPH-1 and PC-3. In LNCaP cells, SRE induced a mixed cell 
death phenotype, exhibiting apoptotic effects but also a low cytotoxicity, whereas in 
BPH-1 cells, SRE exhibited apoptotic effects without any cytotoxic effect, and PC-3 
cells revealed to be almost insensitive to SRE treatment (Table III-4). 
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In contrast to SRE, VAC-induced effects appeared to be less specific for each cell 
line. Cell growth of all three cell lines was inhibited with similar IC50 values and 
exhibiting apoptotic effect but also low cytotoxic activity. The investigated fruit extract 
of VAC revealed to be the more potent cell growth inhibitor than the leaf extract with 
approximately two fold lower IC50 values (Figure III-25) 
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Table III- 4 Summary of the in vitro effects of SRE and VAC in human prostate cell lines 
Extracts  
Me180 VACF VACL 
 IC50 values of prostate cell growth either with SRE and VAC for 48h 
BPH-1 ~ 100 µg/ml 7 µg/ml 15 µg/ml 
LNCaP 35µg/ml 8 µg/ml 17 µg/ml 
PC-3 ~ 100 µg/ml 7 µg/ml 20 µg/ml 
 apoptotic pre-peak 
BPH-1 
LNCaP 
PC-3 
- 
+ 
- 
+ 
+ 
+ 
n.d. 
n.d. 
n.d. 
 partial reversion by pan caspase inhibitor 
BPH-1 
LNCaP 
PC-3 
+ 
+ 
- 
+ 
+ 
+ 
+ 
- 
+ 
 DNA fragmentation 
BPH-1 
LNCaP 
PC-3 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
 cytotoxicity (LDH) 
BPH-1 
LNCaP 
PC-3 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
n.d. not determined 
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4 Discussion  
4.1 The in vitro screening model system 
4.1.1 Selected target cells 
Benign prostatic hyperplasia (BPH) and prostate cancer (PCA) are known to be 
independent and intrinsically heterogeneous diseases. Of the hundreds of species of 
mammals, all of which have prostate glands, only humans and dogs have a 
propensity for spontaneously developing BPH and PCA (De Marzo et al 1999). Data 
obtained in rats and mice may not reflect the appropriate situations in men, because 
only the dorsolateral lobe of rodent prostates is ontogenetically comparable to the 
human prostate (Untergasser et al 1999). Thus, to assess the efficacy of potential 
chemopreventive or therapeutic agents by in vitro approaches, a promising strategy 
is to take advantage of cultured cells that broadly represent the spectrum of stages 
these proliferative prostate diseases are likely to exhibit. In this respect, in the 
present study, the panel of three different human prostate epithelial cell lines (BPH-1, 
LNCaP, and PC-3) was used for testing the effects of selected plant extracts. 
BPH-1 cells were established from a BPH-specimen and may best resemble the BPH 
situation in situ. However, for the use in cell culture, the cell line was immortalised by 
SV40-large T antigen. It has been reported that SV40-large T antigen can bind to and 
inactivate p53 (Levine 1997). The tumour suppressor p53 is considered to play an 
important role in the control of the cell cycle, allowing DNA repairing or induction of 
apoptosis. Normal cells respond to DNA damage by increasing their production of 
p53. Mutations in the p53 gene, producing a defective protein, are often found in 
cancer cells (Schumacher et al 2001), but were also reported in BPH-1 tissue 
(Schlechte et al 1998).  
PCA typically belongs to a class of tumours that are initially androgen hormone- 
dependent, but are well known to progress to hormonal therapy-resistant terminal 
stages (Klocker et al 1999). Therefore, LNCaP and PC-3 cells, the two other cell lines 
included in our cell model system, exhibit different growth properties that are best 
reflecting the intrinsic heterogeneity of human PCA. The LNCaP cell line is one of the 
most widely used in vitro model of prostate cancer. LNCaP cells maintain several 
characteristics of the primary human prostatic carcinoma, such as the 
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responsiveness to androgen (Andrews et al 2002b). They produce PSA, expresse 
the wild type p53 and a point mutation in the androgen receptor gene, which is also 
found in prostate cancer (Gaddipati et al 1994). They do not undergo apoptosis after 
androgen withdrawal, but respond to androgenic stimulation by proliferation (Lee et al 
1995). By contrast, PC-3 cells are not responsive to androgens and do not express 
consistent levels of androgen receptor protein and are p53-negative (Mitchel et al 
2000).  
Considering all these characteristic features, our system appears to be a suitable in 
vitro model system for the screening of different plant extract with respect to their 
growth inhibitory activities in human prostate cells. 
4.1.2 Assay systems 
The applied assay systems are well accepted tools in preclinical drug development 
and therefore suitable methods for the evaluation of effects of plant extracts as an 
approach to rational phytotherapy. 
Throughout the study, WST-8, a novel tetrazolium based assay, was used for cell 
viability assessment. This test has the advantage over previously used tetrazolium 
assays by producing a highly water-soluble formazan dye directly in situ (Ishiyama et 
al 1997). It is known from other tetrazolium salts (e.g. MTT) that their reactions are 
sensitive to the concentration of glucose, hydrogen ions, NADH, and NADPH (Vistica 
et al 1991). Since it is not described if the WST-8 is affected by any of these 
molecules, cell proliferation was verified by a second test using crystal violet which 
stains adherent cells. In the crystal violet staining assay the loss of cells due to 
manipulations is minimal, because of cell fixation in situ with 1% glutaraldehyd before 
any washing (Gillies et al 1986). As shown in Figures III-7 and III-17 (comparison of 
WST-8 –CV tested cells) the amount of formazan produced by viable cells is directly 
proportional to the number of living cells stained by crystal violet, indicating that the 
treatment did not reduce cell viability, and thus confirms the results obtained by the 
two assay systems.  
Cell cycle analysis is a suitable method for the overall understanding of the influence 
of investigated drugs on cell cycle processes. However, our investigations revealed 
several problems associated with the cell cycle analysis. Defects in cell cycle control 
are some of the most common features of cancer cells, because they divide under 
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conditions under which their normal counterparts do not. In addition, polyploidy of 
cancer cells may exhibit discrepancies in cell cycle analysis. Furthermore, the 
mixture of constituents in our extracts may lead to several overlapping mechanisms 
preventing a clear dose-dependent single target effect. However, the subG1 “pre-
peak” is a clear indicator for apoptotic fragmentation, which was further confirmed by 
other apoptosis-detection methods. 
Apoptosis, “programmed cell death”, is a complex sequence of mechanisms which 
are functionally active at various time points, meaning that e.g. after short incubation 
times, DNA fragmentation may not be completed. Apoptosis is therefore preferentially 
not only assessed by a single method or at one time point. Hence, we investigated 
the co-treatment with a pan-caspase inhibitor interfering with several targets in the 
execution of apoptosis and further evaluated the extract-induced DNA fragmentation, 
a hallmark of late apoptosis. Since the Cell Death Detection ELISA used here does 
not require pre-labelling of cells, it can detect internucleosomal degradation of 
genomic DNA during apoptosis even in cells that do not proliferate. Unfavourable for 
our study, the test showed high standard deviations, which could possibly result from 
washing steps and small amounts of fragmented probes. However, the measured 
DNA fragmentation was in a comparable range in every fragmentation assay and 
was therefore a suitable method to complement the results from the cell cycle 
analyses and the co-treatment assays with the caspase inhibitor. 
To complete our assay system, we additionally examined if the plant extracts 
displayed cytotoxic effects. The LDH Cytotoxicity Detection Kit is based on the 
measurement of the cytosolic enzyme lactate dehydrogenase (LDH) in the cell 
supernatants after release from damaged cells. The assay system was designed to 
allow simultanous measurements of LDH in the supernatants and DNA fragmentation 
in cellular extracts making a direct comparison of apoptotic and cytotoxic effects 
possible. 
Our screening system revealed to be an appropriate screening system for the 
detection of the inhibitory activity of plant extracts in human prostate cell lines which 
were selected as cellular models of human proliferative prostate diseases. 
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4.2 In vitro investigations with extracts of Serenoa repens 
4.2.1 Serenoa repens-induced cell growth inhibition  
Primarily, the cell growth inhibiting effects of the commercially available Serenoa 
repens extract Me180 was assessed in three different human prostate epithelial cell 
lines representing different stages of prostate epithelium diseases. Proliferation of all 
three cell lines investigated was inhibited in a dose- and time-dependent manner by 
Me180-treatment (Figure III-5 and III-6). In particular, the androgen-responsive 
LNCaP cells were affected more severely by Me180 than the androgen-unresponsive 
PC-3 and BPH-1 cell lines, with respect to both cell growth inhibition and cellular 
damage (Figure III-6 and III-14). Me180 inhibited BPH-1 and PC-3 cell growth only at 
the highest concentrations (70-100µg/ml), while at lower concentrations little effect on 
cell survival was detected. 
These observations are generally in line with results from others, who showed that 
Serenoa repens extracts (SRE’s) were effective in reducing the survival of both 
androgen-dependent and independent human prostate cancer cell lines (Ravenna et 
al 1996; Iguchi et al 2001). Accordingly, both authors reported stronger effects in 
LNCaP cells than in other cell lines (PC-3 and others, unfortunately not specified). In 
the present study the cell growth inhibiting effects on LNCaP were 3-fold higher with 
IC50 values about 35µg/ml compared to 100µg/ml reported by Iguchi et al 2001. The 
discrepancies between these results may be partly due to the prolonged time of 
exposure from 24 to 48h, but could also be due to differences in the cell model 
system used. Investigating different exposure times we found that the Me180 induced 
a time-dependent growth inhibition over 72h (Figure III-5). However, in contrast to 
previous studies, the effects on LNCaP cells, even after 24h exposure time, were 
also more pronounced. A second explanation for these differences could be that we 
replaced the culture medium containing foetal bovine serum (FBS) with medium 
containing 1% charcoal-stripped serum (cFBS) devoid of steroid hormones and other 
factors, which could have a probable effect on cell growth. Ravenna and co-workers, 
who showed corresponding results in both LNCaP and PC-3 cells, reported medium 
change from 10% FBS to 5% cFBS (Ravenna et al 1996). In other reports 
investigating SRE on prostatic cell growth (Goldmann et al 2001; Iguchi et al 2001) 
no medium change was mentioned. Moreover, by evaluating the ideal serum 
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supplementation, we found that addition of 10% FBS medium did partly abrogate the 
growth inhibition effect, indicating that SRE could not overcome the mitogenic effect 
provided by growth factors contained in 10% FBS supplemented cell culture media 
(data not shown). 
The fact that the androgen-responsive LNCaP cells were the most affected by the 
SRE treatment, may indicate that in some way hormone responsiveness makes cells 
more susceptible to the extracts. This provides further evidence, that the expression 
of androgen receptors and/or the responsiveness to androgens may play a crucial 
role in SRE-induced growth inhibition. Previous in vitro and in vivo studies have 
shown that the anti-androgenic effects may be related to an interference of SRE in 
several steps involved in the mechanism of action of androgens within target cells. In 
fact, some in vitro experiments on the rat ventral prostate tissue cultures and in 
cultured genital skin fibroblasts evidenced a significant inhibition of the binding of 5α-
dihydrotestoterone (DHT) at nuclear and cytosolic receptor levels in the presence of 
SRE (Briley et al 1983; Briley et al 1984; Carilla et al 1984). In the same in vitro 
models, the drug caused a marked reduction in testosterone conversion to DHT and 
a partial inhibition of 3α-oxidoreductase activity followed by a decreased formation of 
5α-androstane-3α-17β-diol (Briley et al 1984; Sultan et al 1984). Studies performed 
on baculovirus –directed insect cell expression system showed that SRE displayed 
inhibitory activity of both 5α-reductase isozymes type 1 and 2 (Delos et al 1995; Iehlé 
et al 1995). Estrogen and androgen receptor determination have been performed in 
the cytosol and in nuclear extracts from prostatic tissues of patients with BPH, 
confirming the anti-androgenic properties of SRE and evidenced its antagonist 
activity with nuclear estrogen receptors (Di Silverio et al 1992). Ravenna and co-
workers further showed an SRE induced double agonistic/ weak antagonistic 
androgenic action that seemed to be mediated by the mutated androgen receptor in 
LNCaP cells (Ravenna et al 1996). It was reported further by the same authors that in 
the hormone-independent PC-3 cells, if transfected with the wild-type androgen 
receptor, SRE exerted a clear anti-androgenic responsiveness effect. 
Taken together, all these findings may underline that hormone responsiveness 
makes cells more susceptible to the action of SRE. However, it can not be excluded 
that other factors may be involved. Our further investigations indicated that apoptotic, 
cytotoxic and anti-inflammatory effects must also be involved in determining the cell 
growth inhibition. We will consider these aspects in the next section.  
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4.2.2 Mechanisms of cell death induced by Serenoa repens extract 
To further investigate the antiproliferative effects in more detail and to determine the 
mechanisms involved, cell cycle distribution, apoptotic and cytotoxic effects were 
examined after treatment with Serenoa repens extract Me180. Corresponding to the 
results obtained in cell growth assays, the treatment displayed the strongest dose-
dependent effects in LNCaP cells in all investigations. In flow-cytometric cell cycle 
analysis Me180-treated LNCaP cells showed a dose-dependent increase of G0/G1 
“pre-peak”, indicating an induction of apoptosis by the extract (Figure III-11). This 
observed apoptotic effect was evidenced by a dose-dependent increase of DNA 
fragmentation and a partial reversion of cell growth inhibitory effects of Me180 by co 
treatment with the pan-caspase inhibitor Z-VAD fmk (Figure III-13 and III-14). The 
detection of lactate dehydrogenase (LDH) in the tissue culture supernatant is an 
indicator of the toxicity of the compounds tested. The increase of LDH in the LNCaP 
cell supernatants with rising concentrations of Me180 shows, that at higher 
concentrations additional cytotoxic effects must also be involved in Me180 induced 
cell death, particularly at the highest concentration of 100µg/ml (Figure III-14).  
In BPH-1 cells treated with Me180, the observed dose-dependent increase in DNA 
fragmentation (Figure III-14) and the dose-dependent partial reversion by the co 
treatment with the pan-caspase inhibitor (Figure III-13) was not accompanied by an 
increase of the apoptotic “pre-peak” in cell cycle analysis (Figures III-10). These 
results appear contradictory but might be explained as follows: The lack of an 
apoptotic “pre-peak” indicates the lack of small DNA fragments. However, the 
presence of a sub-diploid peak (sub G2/M, larger DNA fragments) is a second 
indicator of apoptosis (Darzynkiewicz et al 2001). Cell cycle analysis of BPH-1 cells 
after treatment with Me180 revealed a shift from G1 to S phase (Figure III-10). It was 
not possible to distinguish a clear “sub-diploid” G2/M peak, but we suggest that the 
enhanced DNA fragmentation, measured by DNA fragmentation assay, is due to 
larger DNA fragments found in the enhanced S phase. 
In PC-3 cells, in accordance with the minor cell growth inhibition, no apoptotic or 
cytotoxic effects could be assessed after the treatment with Me180. Cell cycle 
analysis revealed a slight dose-dependent but non significant decrease of the 
percentage of cells in G1 phase with a shift to S phase. However, this effects could 
not be explained by an apoptotic effect due to the lack of an increase of DNA 
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fragmentation and in the partial reversion with the pan-caspase inhibitor co-
treatment, indicating that the PC-3 cells are almost insensitive to SRE treatment 
(Figures III-13 and III-14). 
SRE exhibited a dose-dependent apoptotic effect in LNCaP cells, and, surprisingly, 
also in BPH-1 cells, whereas PC-3 cells were insensitive. Therefore, the extract 
possibly exerts these effects to cell lines at target sites present in both cell lines such 
as p53 which is lacking in PC-3 cells. p53 was reported to mediate G1 arrest, but has 
also been implicated in G2/M phase checkpoint (Levine 1997). However, cell cycle 
analysis of SRE treated BPH-1 and LNCaP cells did not show any significant dose-
dependent changes in cell cycle distribution of these phases (Figures III-10 and III-
11). Furthermore, it remains to be seen why the apoptotic effect did not result in a 
more pronounced cell growth inhibition in BPH-1 cells. 
Our data at least partly confirm results from fluorescence microscopy studies by 
Iguchi et al (2001), that the treatment of SRE induced mixed (apoptotic and necrotic) 
cell death involving caspase activation. Additionally, in a first report by Bayne and co-
workers, morphological changes were also observed in a co-culture model of BPH 
(epithelial and fibroblast cells (10:1) of human BPH tissue), including the polarisation 
of the nuclei and condensation of chromatin following treatment with SRE (Bayne et 
al 1999). These data suggested an induction of apoptosis in both the epithelial and 
stromal cell of the prostate. Furthermore, an increase of the apoptotic indices of 
prostate epithelial cells and stromal cells in vitro was detected by the same authors 
(Bayne et al 2000). These effects were further confirmed in prostate tissues of BPH-
patients by Vacherot and co-workers showing that after three months of SRE-
treatment the imbalance in the apoptosis/proliferation ratio was only reversed in 
treated but not in the untreated patients (Vacherot et al 2000). Another recent study 
reported the shrinkage of the epithelial tissue in the transition zone of the gland after 
six months of SRE-treatment (Marks et al 2000). 
Taken together, all these data underline the possible reversion of the imbalance 
between proliferation and apoptosis in progressive prostatic diseases by SRE 
extracts. However, in clinical trials the size of enlarged prostates was only weakly 
reduced by SRE after treatment for six months (Carraro et al 1996) or twelve months 
(Debruyne et al 2002). Nevertheless, in both studies, a further time-dependent 
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enlargement was not observed, indicating that the extract could at least exhibit a 
preventive action of a further enlargement of the prostate.  
In addition, SRE has so far rarely been investigated on prostate carcinoma specific 
models. Interestingly, Ishii and co-workers reported that the invasive activity of PC-3 
cells into Matrigel was effectively suppressed by low doses of 10µg/ml of a SRE (Ishii 
et al 2001). They further showed that the purified urokinase-type plasminogen 
activator (uPA) activity was inhibited by SRE in a dose-dependent manner, 
suggesting that the suppression of PC-3 cell invasion by the extract is based on an 
inhibition of the uPA activity which is necessary for tumour cell invasion. SER was 
therefore proposed as a possible useful agent for the therapeutic treatment of 
prostate cancer. Moreover, it was suggested in a further study on prostate cancer 
cells (Goldmann et al 2001) that reduced cellular growth after SRE treatment may be 
related to decreased expression of COX-2 and may further be due to down-regulation 
in the expression of Bcl-2. Since increased COX-2 expression is associated with an 
increased development of prostate cancer, SRE was further proposed as a possible 
preventive prostate cancer treatment (Goldmann et al 2001).  
4.2.3 Anti-inflammatory activity of Serenoa repens extracts 
Frequently BPH is associated with a chronic inflammation that results from infiltration 
of inflammatory cells into the prostate and this inflammation is one of the aetiological 
factors involved in the development of BPH (Theyer et al 1992). Production of 
prostaglandins such as prostaglandin E2 (PGE2) and leukotrienes (leukotriene B4, 
LTB4) are potent inflammatory mediators and may contribute to the development of 
the disease. It was shown in a contemporaneous diploma thesis by Hubacher, that 
Me180 inhibited the activity of recombinant COX-1 and COX-2, as well as the activity 
of 5-LOX in differentiated HL-60 cells, with IC50 values of 6µg/ml, 30µg/ml and 
12µg/ml, respectively (Hubacher 2002). These results suggest that by inhibition of 
these enzymes the production of these inflammatory mediators is reduced after 
Me180 treatment. Our findings that Me180 inhibits COX-1, COX-2 and 5-LOX activity 
are consistent with previously reported investigations. Breu and co-workers showed a 
dual inhibitory activity of recombinant COX and LOX enzyme activity (Breu et al 
1992). Furthermore, Paubert-Braquet and co-workers showed that SRE significantly 
inhibited the production of several 5-lipoxygenase metabolites (5-HETE, 20-COOH 
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LTB4, LTB4 and 20-OH LTB4) at concentrations as low as 5 µg/ml in human 
polymorphonuclear neutrophils (Paubert-Braquet et al 1997). 
In this context several studies were conducted with patients treated with SRE. Helpap 
and co-workers found a significant reduction in periglandular stromal edema, 
intraglandular congestion and congestive prostatitis but no changes in the epithelium 
from patients treated for 12 weeks with SRE as compared to placebo (Helpap et al 
1995). In a very recent pilot study by Vela Navarrete and co-workers a 3-month 
treatment with the SRE produced a significant reduction of the cytokines IL-1β and 
TNF-α, concomitant with a reduction of prostatic interstitial B lymphocytes and a 
significant clinical improvement (Vela Navarrete et al 2003). The authors speculated 
that SRE modifies the inflammatory status of BPH tissue through this cytokine 
regulation. 
Beyond this positive effect in BPH, these anti-inflammatory effects are also important 
in the context of the cancer preventive effects by non-steroidal anti-inflammatory 
drugs (NSAIDs) (Steele et al 2003). It was shown that PGE2 is produced in greater 
amounts in BPH than the normal tissue from which they were derived (Chaudry et al 
1994). Moreover, several studies have also described increased COX-2 tissue 
expression in PCA (Steele et al 2003). As a group, non-steroidal anti-inflammatory 
drugs (NSAIDs) and particularly COX-2 inhibitors have been shown to have 
antiproliferative effects in BPH-1, LNCaP and PC-3 cells, by increasing the rate of 
apoptosis (Lim et al 1999; Hsu et al 2000; Andrews et al 2002a). Additionally, it was 
previously reported that inhibition of 5-lipoxygenase triggers massive apoptosis in 
both androgen-sensitive (LNCaP) and androgen-refractory (PC-3) human prostate 
cancer cells (Ghosh & Myers 1998). This leads to the assumption that the SRE by 
inhibiting COX-2 and 5-LOX activity can contribute to the apoptotic effects observed 
in LNCaP and BPH-1 cells in our study. However, further studies will be needed to 
clarify the involvement of these enzymes in cell growth inhibition by the extract. 
Taken together, these investigations show, that SRE may provide beneficial effects in 
concomitant inflammatory conditions in BPH but also act as a possible preventive 
agent against PCA. 
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4.2.4 Comparison of various Serenoa repens extracts with respect to cell 
growth inhibition in prostate cell lines 
It was further evaluated, if the ripeness condition and solvents used for extraction has 
an influence on the quality of the extracts with respect to their antiproliferative 
properties in the three prostate cell lines. No relevant differences were found among 
the extracts studied with respect to cell growth inhibitory effects (Figure III-8 and III-
9). IC50 of hexane extracts were found to be slightly lower (31µg/ml) than the ethanol 
extracts (35µ/ml), however these differences were statistically not significant 
(p>0.05). This lack of differences was in fact somewhat surprising. Extracts are 
mixtures of various constituents. Ripeness conditions and the solvent used for 
extraction may affect the final constituent composition. These parameters should 
therefore not be neglected when investigating plant extracts in in vitro models. Our 
results suggest that the active – cell growth inhibiting constituents must be present in 
all extracts in similar amounts, independent of ripeness condition whether with 
hexane or ethanol as solvents. However, so far, our extracts investigated were not 
studied analytically.  
Differences in cell growth inhibitory activities by different extracts could lead to further 
extract optimisations. Further investigations such as selective fractionation and tests 
with single compounds are needed to evaluate the responsible constituents and 
constituent groups involved in the observed actions, to allow a selection of the best 
(most effective and less toxic) extract for treatment. It was reported in previous 
studies that the anti-androgen (5α-reductase inhibitory activity (Weisser et al 1996; 
Raynaud et al 2002)) and anti-inflammatory (Breu et al 1992) effects were found in 
the lipophilic saponifiable subfraction consisting mainly of oleic acid (33%), lauric acid 
(24%), myristic acid (11%), and palmitic acid (9%) (Breu et al 1992). Moreover, 
myristoleic acid was identified as one of the active components of the extract, 
exhibiting a mixed apoptotic/necrotic action (Iguchi et al 2001).  
In our in vitro cell model system no relevant differences could be found regarding cell 
growth inhibitory activity. However, it is unknown, if ripeness condition or extract 
solvent may exert any influence on the activity of the extracts in other model systems 
(e.g. stroma cells) or in vivo. 
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4.2.5 In vitro results as indicators for activities in vivo 
In vitro studies, which represent antiproliferative effects following a constant drug 
exposure against rapidly growing cell lines as well as tests on recombinant enzymes, 
cannot be directly projected to effects in vivo. At present, the pharmacodynamic 
effects of our in vitro findings cannot be directly extrapolated to the clinical application 
since the concentration of biologically available SRE in the human prostate is 
unknown. However, they can indicate the possible mechanisms of action involved. 
Furthermore, as mentioned before, our data were confirmed by previously reported in 
vitro results from others using different SREs. The predicted physiological 
concentration of SRE, assuming distribution in total body fluid achievable using the 
recommended therapeutic dosage was reported to be 10-30µg/ml (Bayne et al 1999). 
It should be pointed out that the highest concentration of S.repens extract in our 
investigations was 100µg/ml. Due to solubility problems, the examination of higher 
concentrations was impossible. It was reported that using oral administration of 14C-
labeled oleic and lauric acids (two major components of SRE) in rats, the radioactivity 
selectively accumulated in the rat prostate gland (Chevalier et al 1997). In addition, 
when the effects of a SRE was investigated on human primary cultures of fibroblasts 
and epithelial cells from the prostate, epididymis, testes, kidney, skin and breast, a 
selectivity was found for prostate cells, indicating that the plant extract can be 
expected to be organ selective. In this study, the morphological changes in the 
prostate were accompanied by an increase in the apoptotic index in the prostate cells 
along with an inhibition of the activity of the nuclear membrane bound 5α- reductase 
isoenzymes. No such changes were observed in any of the other cells studied 
(Bayne et al 2000).  
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4.2.6 Conclusion on the effects by Serenoa repens extracts  
In conclusion, these results indicate that extracts of SRE may retard human prostate 
cell growth by multiple mechanisms, including hormone-dependent interaction, 
apoptosis, and inhibition of COX1, COX-2 and 5-LOX but also by a low cytotoxic 
action. These possible mechanisms may have beneficial effects on the one hand in 
symptomatic BPH and associated inflammation, and on the other hand, the observed 
apoptotic effect and the inhibition of COX-2 and 5-LOX may also contribute to a 
possible effect in prostate cancer prevention. 
In the present studies we found that the commercially available extract Me180 
exerted similar effects in vitro as other SRE previously investigated and that variation 
in ripeness conditions and the choice of solvents (hexane or ethanol) exert no crucial 
differences in potency on growth inhibitory activities. 
The exact mechanism of SRE in prostatic epithelial cell proliferation, however, 
remains elusive and needs to be further investigated, by e.g. fractionating the 
extracts to isolate active constituents. Since SRE is a more potent inhibitor of the 
growth of androgen-responsive prostate cells such as LNCaP, further studies should 
be performed to establish whether the action observed is related to androgen and 
estrogen receptor expression or to the apoptotic and inflammatory enzyme inhibiting 
effects observed.  
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4.3 In vitro investigations with extracts of Vitex agnus-castus 
4.3.1 Vitex agnus-castus –induced cell growth inhibition in prostate cell 
lines 
The present study provides a new insight into the mechanism of action of Vitex 
agnus-castus extracts. VACF are described to have a beneficial effect on disorders 
related to hyperprolactinaemia such as cycle disorders, luteal phase defect, 
mastodynia and premenstrual syndrome (Wuttke et al 2003). Recently, a VACF was 
shown to exhibit anti-tumour activities in different human cancer cell lines (Ohyama et 
al 2003), but its effects on human prostate epithelial cells has so far not been 
investigated.  
The proliferation of all three prostate cell lines was effectively inhibited in a dose- and 
time-dependent manner with IC50 values below 10µg/ml for Vitex agnus-castus fruit 
extract (VACF) and ~ 20µg/ml for Vitex agnus-castus leaf extract (VACL), 
respectively. All three cell lines were affected by the treatment in a comparable 
manner, without showing any cell specificity (Figure III-16). 
These findings prompted us to further investigate the mechanisms of action of these 
extracts at the cellular level. In contrast to cell proliferation, cell cycle analysis 
revealed a cell line specific alteration in the progression of cell growth. In all three cell 
lines, VACF treatment showed a dose-dependent, statistically significant increase of 
the apoptotic “pre-peak” (Figures III-18-20). Moreover, VACF-treated BPH-1 cells 
exhibited a significant dose-dependent G2/M arrest associated with a decrease of 
cells in G0/G1 phase (Figure III-18). It remains to be determined whether the ability of 
VACF to arrest cells in the G2/M phase is modulated by cyclin dependent activities, 
such as by cdc2-cyclin B kinase. The G2/M DNA damage checkpoint prevents cells 
from entering mitosis if the genome is damaged and the cdc2-cyclin B kinase is 
pivotal in regulating this transition (Ohi & Gould 1999). Beyond the apoptotic “pre-
peak”, cell cycle analysis of VACF treated LNCaP cells did not display any further 
significant cell cycle arrest (Figure III-19). In PC-3 cells the dose-dependent and 
statistically significant (p<0.01) increase of cells in S phase may be a second 
evidence of an increase of apoptotic bodies, since the presence of a sub diploid peak 
(sub G2/M) is a second hallmark of apoptosis (Darzynkiewicz et al 2001). 
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Cell cycle analysis did partially reveal a significant dose-dependent shift in cell cycle 
distribution. However, the mixture of compounds in extracts may have several 
different mechanisms, leading to complex changes in cell cycle distribution. Extract 
fractionations and the investigation of single compounds may lead to a better 
understanding of the mechanisms involved. Of particular relevance are the molecular 
mechanisms of cell cycle regulation involving cyclins, and cyclin dependent kinases 
linked to specific cell cycle phases, such as CDK4/6-cyclin D and CDK2-cyclin E 
controlling the G1/S phase checkpoint (Boonstra 2003) and cdc2-cyclin B kinase 
controlling G2/M phase checkpoint (Ohi & Gould 1999). 
The dose-dependent increase of sub G0/G1 (apoptotic) peak in all three cell lines 
suggested that part of the cells were undergoing apoptosis. This observed induction 
of apoptosis was confirmed by a dose-dependent enhancement of DNA 
fragmentation in the cytoplasm of cells after treatment with the extract (Figure III-23, 
III-24). Moreover, this interpretation was supported by the partial reversion of the 
growth-inhibitory effects in presence of a pan-caspase-inhibitor (Z-VAD-fmk) clearly 
indicating that caspases must be involved in the underlying mechanism (Figures III-
21, III-22). Taken together, these results suggest that the cell death induced by VACF 
and VACL proceeds, at least partly, via an apoptotic mechanism. However, the 
increased lactate dehydrogenase (LDH) activity in supernatants of VACF-treated 
cells, measured as a marker of cell necrosis, indicates additional cytotoxic effects 
with increasing doses of VACF and VACL (Figures III-23, III-24). 
It was previously reported that a Vitex agnus-castus fruit extract exhibits growth 
inhibitory activity in several cell lines (Ohyama et al 2003). The authors suggested 
that the cytotoxic activity may be attributed to the growth activity of the respective 
cells and that the cytotoxicity depended on the phase of cells in the cell cycle. This 
interpretation can not be confirmed by our investigations. Firstly, although our three 
investigated cell lines exhibited different cell growth rates, the VACF-induced cell 
growth inhibition was comparable in all three cell lines with IC50 values of 7, 8, and 7 
ug/ml, respectively (Figure III-16). Secondly, in our test system, cells of all three cell 
lines passed at least one cell cycle during the investigated treatment time of 48h. 
Therefore, the cell growth inhibitory activity cannot only depend on the phase of cells 
in the cell cycle. Moreover, if the chosen treatment time is too short for an entire cell 
cycle passage, such an effect can only be recorded and assessed in synchronized 
cells. Without prior synchronisation, results from a mixed cell population can lead to 
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misinterpretation. However, in agreement with the investigations by Ohyama and co 
workers we found that VACF induces cell growth inhibition partially by an apoptotic 
pathway and that caspases are involved. 
Our studies further revealed that Vitex agnus-castus LEAF extract exhibited weaker 
growth inhibitory effects than the FRUIT extract. It was shown by Huber (2002) that 
except for a higher quantity of hydrophobic flavonoids in leaves, the thin layer 
chromatographic fingerprints of Vitex agnus-castus fruit and leaf extracts of the same 
plant were very similar. Therefore, leaf extracts were investigated in order to test its 
suitability as an alternative raw material, since leaf extracts would have the 
advantage that the material could be harvested from plants growing in Switzerland, in 
contrast to fruits that are only found in higher amounts in Mediterranean regions. 
Moreover, further investigations with single compounds should be performed to 
examine which agents are responsible for the growth inhibitory activity. Two single 
compounds, rotundifuran, a labdane diterpene, and luteolin, a flavonoid present in 
Vitex agnus-castus extracts were reported to induce apoptotic effects in HL-60 cells 
(Ko et al 2001, 2002). A third agent, agnuside (an iridoid glycoside), showed 
preferential inhibition of COX-2, while having only small inhibitory effects on COX-1 
(Suksamrarn et al 2002). The cell growth inhibitory activities of VACF against 
prostate cell lines may be attributed to these compounds. Further investigations with 
extract fractionations and single compounds are needed to find the active 
components.  
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4.3.2 Potential beneficial effects of Vitex agnus-castus in prostate 
diseases 
VACF are described to have a beneficial effect on disorders related to 
hyperprolactinaemia such as cycle disorders, luteal phase defect, mastodynia and 
premenstrual syndrome (Wuttke et al 2003). The rationale for the investigations of 
VACF in our prostate screening model system was fourfold: 
• VACF induced cell growth inhibition in several human cell lines 
• Inhibition of binding to dopamine D2 and D3 receptors and inhibition of 
prolactin secretion  
• COX-1, COX-2 and 5-LOX inhibitory action in vitro 
• Estrogen receptor β selectivity action in vitro 
Our investigations revealed several potential uses of VAC in prostate diseases.  
Both BPH and PCA are typical slowly progressing diseases. Rates of PCA cellular 
proliferation of 3.0% and below are typical (Cher et al 1995), making this one of the 
slowest growing malignancies known. Indeed, this low growth rate of PCA may be 
responsible, at least in part, for the weak efficacy of cytotoxic agents, which interfere 
with DNA synthesis. Chemotherapeutic drugs currently available in clinical use 
preferentially inhibit the proliferation of cancer cells (Tang & Porter 1997). Thus, it 
can be expected, that patients with slow-growing prostate cancer cells will not 
respond to most of antiproliferative chemotherapeutics. Therefore, extracts that do 
not affect cancer cell proliferation or cell cycle progression because of their 
apoptosis-inducing effects may have beneficial effects in this indication.  
By demonstrating that Vitex agnus-castus induces cell growth arrest and apoptosis in 
PCA cells apparently through different mechanisms of action, Vitex agnus-castus 
appears to be a potential anti-prostate-cancer agent. Additionally, the complex 
mixture of phytotherapeutics, composed of different compounds may exhibit several 
pharmacological properties, accounting for their potential multiple mechanisms of 
action. Moreover, these multiple actions may possibly prevent the development of 
drug resistant tumours.  
Our in vitro experiments displayed new, interesting activities; it is however too early 
to extrapolate directly to clinical applications. Further investigations are needed to 
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gain further insights into the molecular mechanisms of cell death involved and to 
evaluate the potential effects on normal prostate cells. VACF was shown to be safe in 
various clinical studies, leading to the conclusion that the cytotoxicity cannot be very 
prominent. To our knowledge, the extracts were so far never clinically investigated in 
men. The interesting activity profile of VACF in our in vitro system points to potential 
new therapeutic targets also in men.  
Role of prolactin in the control of prostate growth: 
The mechanism of action in diseases related to hyperprolactinemia was mainly 
explained by the prolactin (PRL) lowering effect via a dopaminergic action 
(Schellenberg 2001; Wuttke et al 2003). PRL is widely expressed in different tissues, 
and it is one of several polypeptide factors known to exert trophic effects on the 
prostate. In males it is known to influence reproductive functions and it is well-
established that PRL stimulates the proliferation and differentiation of prostate cells 
(Reiter et al 1999). PRL, alone or synergistically with androgens, plays 
physiologically significant roles in the normal prostate (Reiter 1999). Moreover, it was 
shown that PRL acts as a direct growth and differentiation factor for human prostate, 
as indicated by changes in DNA synthesis and epithelial morphology of organ 
cultures (Nevalainen et al 1997). In addition, it was demonstrated by the same 
authors that human and rat prostate cells synthesize PRL. Thus, this hormone may 
regulate prostate growth by an autocrine/ paracrine loop.  
However, the potential role of PRL in proliferating prostate dieases, BPH and PCA, 
are very conflicting and need to be further defined. Controversies exist concerning an 
increase of circulating PRL levels with age (Vekemans & Robyn 1975; Hammond et 
al 1977). Additionally, conflicting results have been reported, showing either an 
increase in PRL levels (Saroff et al 1980; Odoma et al 1985), or unchanged levels of 
this hormone in the case of BPH and PCA (Harper et al 1976; Hammond et al 1977; 
Lissoni et al 2000). These differences could be partially explained by the recent 
observation that PRL is produced in the prostate itself (Reiter et al 1999).  
Moreover, the expression of PRL receptors in the prostate cell lines used in our study 
was controversially discussed: It was reported by Untergasser and co-workers  that in 
contrast to BPH and PCA samples, the used prostate cell lines used in our model 
system (BPH-1, LNCaP, PC-3) do not express PRL receptors (Untergasser et al 
1999). In contrast, it was recently reported that PRL receptors were expressed in 
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LNCaP and PC-3 cells but despite this, PRL had no significant effect on proliferation 
(Ruffion et al 2003). 
Taken together, the potential role of PRL in prostate is not fully understood, but a 
proliferative activity seems to be assured. The PRL pathway has not yet been taken 
into consideration for prostate diseases and its role in development of BPH and PCA 
is still an issue that needs to be further addressed. Thus, a potential interference of 
PRL on proliferative effects of the prostate in BPH and PCA by Vitex agnus-castus 
extract has to be further investigated.  
COX-1, COX-2 and 5-LOX inhibiting action in vitro 
At the present time, the precise mechanisms by which VAC exerts its growth 
inhibitory, apoptotic, and cytotoxic effects are not known. It was shown in a recent 
diploma thesis by Hubacher that VACF inhibited COX-1 and COX-2 and 5-LOX by 
blocking the synthesis of eicosanoids such as prostaglandin E2 and leukotriene B4 
with IC50 values of 30, 40, and 35 µg/ml, respectively (Hubacher 2002). The 
eicosanoids are known to play a critical role in cancer cell biology. They facilitate 
cancer transformation by stimulation of cell growth, tumour progression and immune 
suppression (Pruthi et al 2003). Formation of eicosanoids have been implicated in the 
action of a number of cytokines, and growth factors e.g. epidermal growth factor, 
platelet derived growth factor, and bombesin. The specific eicosanoids responsible 
for mitogenesis of prostate cancer cells included prostaglandin E2 (PGE2) as well as 
several lipooxygenase products. In human prostate tissues, PGE2, is the only 
significant eicosanoid produced (Chaudry et al 1994). Previous studies by 
Tjandrawinata and co-workers demonstrated that dimethylPGE2 stimulates cell 
growth of PC-3 and LNCaP cells (Tjandrawinata et al 1997). In PC-3 cells COX-2 
mRNA level was increased by PGE2, while the NSAID flurbiprofen (5µM) inhibited the 
up-regulation of COX-2 mRNA expression as well as PGE2 mediated stimulation of 
PC-3 cell growth. Moreover, it was shown in a in vivo study (Gupta et al 2000) that 
COX-2 is over-expressed in prostate cancer. The authors demonstrated that COX-2 
mRNA in prostate cancer was 3.4-fold higher in the non-cancerous tissue and that 
COX-2 protein was over-expressed in 83% of the tumour samples. In addition, the 
selective inhibition of 5-lipoxygenase (5-LOX) by the lipooxygenase inhibitor MK886 
was shown to completely block 5-HETE production and to induce massive apoptosis 
in both LNCaP and PC-3 cells (Ghosh & Myers 1998). 
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Another possible mode of action is the ability of both COX enzymes to deplete the 
substrate arachidonic acid. COX over expression depletes cellular arachidonic acid 
levels and correspondingly free arachidonic acid substrate. The increased level of 
arachidonic acid could result in activation of sphingomyelinase, which can cause 
increased levels of ceramide, a compound that also can induce apoptosis (Chan et al 
1998). However, specific COX-1, COX-2 and 5-LOX protein level measurement or 
the measurement of ceramides are needed to determine if the cyclooxygenase or 
LOX pathway is responsible for the growth inhibitory and apoptosis inducing activity 
observed with the extract. 
Several COX-2 inhibitors were shown to have anti-tumour activities in prostate 
cancer (Chan et al 1998; Cao & Prescott 2002; Pruthi et al 2003). COX-2 is highly 
expressed in all three cell lines (Lim et al 1999; Hsu et al 2000). Therefore, the COX-
2 inhibition found with isolated enzymes could give an explanation for the observed 
apoptosis in prostatic cell lines in our test system. It remains to further investigate, if 
VAC exhibits any effect on COX-2 expression and/or PGE2 production at the cellular 
level. 
Estrogen β receptor selectivity action 
Previous studies reported of estrogenic effects of fruit and leaf extract with the leaf 
extract being more active than fruit extracts (Berger 1998). Investigations on estrogen 
receptor subtype -α and –β revealed VACF induced inhibition with selectivity to the 
subtype β (Jarry et al 2003). Estrogen receptor β (ER-β) is preferentially localized in 
the prostate epithelium (Chang & Prins 1999). ER-β knockout mice exhibit prostatic 
hyperplasia and this animal model favours an antiproliferative role of ER-β (Weihua 
et al 2002). In this regard it was proposed that ER-β is a potential target of 
therapeutical intervention in proliferative prostatic disease. ER-β were reported to be 
highly expressed in our three cell lines investigated (Lau 2000). Therefore, induction 
of cell growth inhibition through binding of VAC to ER-β would be a further possible 
mechanism and deserves to be further investigated.  
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4.3.3 Conclusion on the effects of Vitex agnus-castus in prostate cells 
In summary, these studies provide the first evidence that fruit and leaf extract of Vitex 
agnus-castus are effective inhibitors of the growth of human prostate cancer cells by 
inducing apoptosis, but also by inducing a low cytotoxic effect. Comparing the effects 
of VAC fruit with leaf extract, the fruit extract revealed to be two fold more potent than 
the leaf extract. The VAC-induced cell growth inhibition was not cell type specific and 
a mixed apoptotic/cytotoxic cell death must be involved in all three cell lines 
investigated. However, cell cycle analysis revealed the mechanism involved may vary 
among the cells indicating that possibly more than one compound might be 
responsible for the observed effects. Moreover, before studies on its possible role in 
clinical use will be performed, VAC effects in normal prostate cells have to be 
examined. 
To our knowledge, these preclinical investigations were the first to examine the 
possible impact of Vitex agnus-castus fruit and leaf extracts in proliferative prostatic 
diseases. Our results suggest that extracts of VAC by modulating cell cycle and 
apoptotic machinery as well by inhibiting inflammatory enzymes may possess a 
potential for development as an agent for prevention and/or therapy of benign and 
malign prostatic hyperplastic diseases. Moreover, further development could lead to 
an extract modification, producing special extracts with stronger apoptotic activities, 
but with weak or no cytotoxic activities. Detailed studies are also required to further 
clarify their mechanisms of action and to investigate their effects in vivo.  
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5 General conclusion and outlook 
Our in vitro studies revealed to be a representative model for future screening of 
extracts for the rational use of phytotherapeutic drugs in proliferative prostate 
diseases. The data documented that the extracts of the two plants chosen, differed 
widely in their ability to inhibit prostate cell growth and in the mechanisms involved. 
Agents that are capable of specifically inducing apoptosis of tumour cells are 
desirable in developing novel therapeutic and preventive approaches. However, their 
effects on normal prostate cells remain to be investigated.  
BPH and PCA are heterogeneous diseases. In the development of BPH, epithelial 
and stromal factors are involved. Thus, our observations should be confirmed, e.g. by 
a co-culture cell system investigating epithelial and stromal cell interactions, to better 
represent the situation of human BPH tissue. As the toxicity of both extracts has 
already been widely assessed in clinical trials (for VACF with other clinical 
applications), and estimated to be safe (Wilt et al 2002; Wuttke et al 2003), the 
accurate model systems are still tissue investigations of patients and healthy 
volunteers after treatment with the extracts. 
The Serenoa repens extract Me180 induced a cell-specific stronger effect in 
androgen-responsive LNCaP cells than in androgen-unresponsive BPH-1 and PC-3 
cells, indicating that a hormone-related mechanism may be involved. In LNCaP cells 
Me180 induced both apoptotic but also cytotoxic effects, whereas in BPH-1 cells, 
Me180 induced weak apoptosis without exhibiting cytotoxicity and PC-3 cells were 
insensitive to the treatment. It was previously shown that Me180 exerts an inhibitory 
activity on COX-1, COX-2 and 5-LOX enzymes (Hubacher 2002). Therefore, it 
remains to be investigated, if the inhibitory activities mainly observed in LNCaP cells 
are linked to an inhibitory activity towards these enzymes. This could be either tested 
by the measurement of the production of prostaglandins such as prostaglandin E2 
(PGE2) and leukotrienes (leukotriene B4, LTB4) produced by these cells or by 
quantification of the expression of COX-2 and 5-LOX in treated cells versus control 
cells. 
Moreover, since Me180 is a more potent inhibitor of the growth of androgen-
responsive prostate cells LNCaP, further studies should be performed to establish 
whether the action observed has an impact on androgen and estrogen receptor 
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expression and its correlation to the apoptotic and anti-inflammatory effects 
observed.  
It was further evaluated, if the ripeness condition and solvents used for extraction 
changed the activity of SRE on proliferation properties of the three cell lines. With 
respect to cell growth inhibitory effects, no relevant differences were found among 
the extracts studied. Further investigations such as selective fractionation and tests 
with single compounds will be needed to find the responsible constituents or 
constituent groups involved in the observed actions to allow a selection of the best 
(most effective and less toxic) extract for the treatment. 
When comparing SRE and VAC, the latter was the more potent inducer of cell growth 
inhibition (Figure III-25). In addition, no cell specificity was shown in growth inhibitory 
effects of VAC. Comparing the effects of VAC fruit with leaf extract, the fruit extract 
revealed to be two fold more potent than the leaf extract. Exposure of BPH-1, 
LNCaP, and PC-3 to VAC induced characteristic features of apoptosis, including an 
increase of DNA fragmentation confirmed by a G1 “pre-peak” in cell cycle analysis, 
and the involvement of caspases action as cell growth inhibition was partly reversed 
by a pan-caspase inhibitor, but VAC also exhibited a low cytotoxic effect. However, 
first of all, its effect on normal prostate cells has to be investigated, since an effect on 
normal cell growth would not always be a desirable effect. Moreover, the described in 
vitro effects of VAC have to be addressed by means of additional cellular and 
molecular studies:  
The interference with the apoptotic machinery needs to be further elucidated. We 
have evidence to expect, that caspase-induction must be involved. The pan-caspase 
inhibitor Z-VAD-fmk does not distinguish among the numerous caspases involved. 
Therefore, specific caspase inhibitors could trace the exact pathway of cell death 
involved. Cell cycle analysis did partially reveal significant dose-dependent 
interference with the cell cycle distribution. Extract fractionations and the investigation 
of single compounds could lead to clearer results and to a simplification of the 
interpretation. Of particular relevance are the molecular mechanisms of cell cycle 
regulation involving various mitogen activated kinases, cyclins, and cyclin dependent 
kinases linked to the specific cell cycle phases. Additionally, more detailed studies to 
explore the genetic and signal transduction pathways should be addressed. BPH 
epithelial cells overexpress bcl-2, an antiapoptosis protein that could be involved in 
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the decrease of apoptosis in human BPH (Kyprianou et al 1996; Colombel et al 
1998). Furthermore, the involvement of COX and LOX enzymes and their association 
with cell growth inhibitory activities need to be investigated in more detail. This is an 
area worth additional investigations to further elucidate the mechanism of action of 
VAC in the human prostate gland. 
Consistent with previous reports of SRE, and shown for the first time with VAC, the 
exhibited cell growth inhibition in human prostate epithelial cells is preferentially due 
to apoptosis, although a low cytotoxic effect was also detected in both extracts. Our 
investigations underline the possible reversion of the imbalance between proliferation 
and apoptosis in progressive prostatic diseases by both extracts, however, by 
different mechanisms.  
The call for the development of more effective, more selective, and less toxic agents 
in age-related proliferative prostate diseases has become more urgent with the 
increasing age of the male population. One approach is the rational targeting of 
processes unique to BPH and PCA, respectively. Both diseases are uniquely 
recognised as multifactorial and slow-developing processes. Because of its high 
incidence and its long latency period, BPH and PCA are ideal targets for 
chemoprevention and therapy by phytotherapeuticals. Moreover, epidemiological 
studies show considerable geographical variation in the age-adjusted incidence of 
BPH and PCA (Moller-Jensen et al 1990). While some dietary constituents are 
implicated in cancer and BPH promotion, increasing evidence suggests that certain 
plant derived nutrients can suppress tumour development (Griffiths et al 1999). 
Therefore, phytotherapeuticals may supply further interesting means for preventive 
and therapeutic medication.  
Further studies have to assess if the in vitro results have any clinical relevance in 
vivo. The safety of both extracts was investigated in a few clinical trials, although for 
VACF in another clinical application, and they considered to be safe (Wilt et al 2002; 
Wuttke et al 2003). A reliable assessment of efficacy can only be stated by a placebo 
or at least reference controlled clinical trial, since only randomised controlled trials 
can provide sufficient evidence for effectiveness. Thus, only a rational phytotherapy 
based on this knowledge, can be considered as adequate for prevention or treatment 
in proliferative prostate diseases. 
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A controlled, double blind, randomised, parallel-group pilot study  
to compare safety, tolerability and therapeutical effects  
of a Serenoa repens extract Me180 versus tamsulosin  
in patients with obstructive benign prostatic hyperplasia 
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1 Introduction and aim of the pilot study 
Several plant extracts are widely used for the treatment of symptomatic benign 
prostatic hyperplasia (BPH) (Table II-1). Despite their traditional popularity, the role of 
phytotherapeutic agents for this treatment is continuously debated. Clinical studies 
have mainly assessed the effectiveness of Serenoa repens extracts (SRE). In a 
recent meta-analysis of controlled trials Wilt and co-workers noted that the effect of 
SRE significantly exceeded that of placebo with regard to overall urinary symptoms, 
nocturia and the maximal urinary flow rate (Wilt et al 2002a). However, in most of 
these trials, a number of shortcomings were identified, including a lack of rigid 
inclusion and/or exclusion criteria defining the patient population, short duration of 
the study, failure to administer a validated symptom questionnaire and including too 
few subjects. There is a lack of studies planned and conducted under strict 
methodology. In many studies, no placebo effect was noted, raising additional 
concern since placebo mediated improvement was noted in virtually all clinical trials 
of BPH pharmaceuticals. Moreover, conclusions of meta-analysis that include 
products from different plants undergoing different extraction procedures may be 
misleading. 
Two large, randomized, double blind studies have shown a Serenoa repens hexane 
extract (Permixon®) to be as effective as the uro-selective α-adrenergic blocker, 
tamsulosin, and the 5α-reductase inhibitor, finasteride, in achieving subjective and 
objective improvements of symptomatic BPH (Carraro et al 1996; Debruyne et al 
2002). Thus, the available data may suggest but do not clearly establish the efficacy 
and safety of the SRE for symptomatic BPH. 
Moreover, the most widely studied form of SRE is Permixon®, which uses the solvent 
hexane, other formulations have used ethanol, and liquid carbon dioxide as solvent. 
In contrast to the well studied Permixon®, our study medication consists of the 
hydroethanolic (96%) Serenoa repens extract Me180 (SabCaps®). SabCaps® is 
registered by the Swissmedic (No. 54823) and sold as over-the-counter in 
Switzerland since 2001, without any previous conducted clinical studies. Direct 
comparison between different products is impossible because of the different 
extraction procedures used by the different manufacturers, the variations of the raw 
plant material used and the fact that the potentially active component(s) of the final 
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product and its (their) mechanism(s) of action are still under investigation. Thus, one 
product might show clinical efficacy while another might not. Therefore, the results of 
basic research and clinical trails cannot be transferred from one manufacturer’s 
product to another, and each manufacturer's preparation must be evaluated 
separately, using the gold standard of placebo-controlled studies or at least 
reference-controlled studies according to accepted guidelines. 
A major problem associated specifically with the objective evaluation of new 
therapies for BPH is the lack of consensus over the definition of BPH. This 
controversy is related principally to the terminology and how these terms are 
interpreted with resultant consequences for both the diagnosis of patients and the 
subsequent evaluation and follow up. The use of a definition narrows the concept of 
BPH by delineating a 'cleaner' patient population. This would have an impact on 
clinical management and yield more trustworthy research results. Unfortunately, most 
studies on incidence and prevalence of BPH do not encompass the same type of 
patients, because the definition of BPH is often lacking or is based on symptoms, or 
prostatic volume, or obstruction in isolation (Hald et al 1998). Therefore, we decided 
to narrow the patient collective to patients with obstructive BPH. 
The selective α1A-blocker, tamsulosin, can be considered as the first-line treatment 
option for symptomatic BPH because it provides effective relief of bothersome lower 
urinary tract symptoms (LUTS) with excellent tolerability (Schulman 2003). Due to the 
lack of any clinical investigations with the Serenoa repens extract Me180, the present 
pilot study was performed to systematically assess the therapeutical effects, safety 
and tolerability of the Serenoa repens extract Me180 versus tamsulosin as an active 
control in patients with obstructive BPH treated for 26 weeks. Primary and secondary 
outcome criteria were assessed according to the recommendations of the 4th 
International consensus committee on BPH (Roehrborn 1998).  
The aim of this pilot study is the systematical assessment of therapeutical effects, 
safety and tolerability of a 26 week-treatment with Serenoa repens fruit-extract 
Me180 (320mg/d) (SabCaps®) compared to tamsulosin (0.4mg/d) (Pradif®) in patients 
with obstructive BPH. The outcome of the present study was intended to form the 
basis for a subsequent, extended study with more patients to assess the efficacy of 
the extract over a longer treatment period.  
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2 Synopsis 
Objectives: Assessment of the efficacy, safety and tolerability of a Serenoa repens 
fruit-extract Me180 (320mg/d) versus tamsulosin (0.4mg/d) as an active 
control for patients with obstructive BPH 
Study design: Pilot study: prospective, randomised, double-blind, tamsulosin-
controlled,  parallel-group comparison over 26 weeks 
Types of participants: 19 patients with obstructive benign prostatic hyperplasia   
Inclusion criteria: • Age: ≥ 45 years ≤90 years • International Prostate Symptom Score IPSS > 6  
• Averaged peak urinary flow rate Qmax < 10ml/s for a voided volume of at 
least 150ml assessed twice at two different days, if averaged Qmax 10-
15ml/s obstruction has to be ascertained by pressure-flow study 
• Postvoid residual urine volume ≤200ml 
• Serum prostate-specific antigen (PSA)   
         <10ng/ml for prostates ≤ 60ml 
         <15ng/ml for prostates > 60ml 
         > 3ng/ml biopsy for exclusion of prostate cancer 
• Participants were required to declare their informed consent to participate in 
writing. 
• No indications for any acute medical treatment or for operative intervention.
Exclusion criteria • Co-medication that might interfere with study medication, including hormone preparation, cimetidine, cyclosporine A, anticoagulants, diuretics, 
calcium channel blockers, antidepressants and neuroleptics, 
anticholinergics, sympathomimetics, parasympatholytics, 5α-reductase 
inhibitors, or any other phytotherapeuticals intended for BPH-treatment. If 
such drugs had been used in the past 3 months, patients had to be 
excluded from the study. 
• Diabetes 
• Cardiovascular disorders  
• Hypertension 
• Orthostatic hypotension 
• Lower urinary tract infection  
• Retention of urine, hydronephrosis, renal insufficiency 
• Previous urological surgery (including the prostate, bladder and urethra) 
• Prostate cancer 
• marked disorders of other organ systems including renal or hepatic 
insufficiency  
• known pathological laboratory values (blood: abnormal ASAT, ALAT, 
alkaline phosphatase, creatinine > 150µmol/l;  
urine: leucocyte count and urine protein > 30mg/dl )  
• Senile dementia 
• Alcohol or drug abuse 
• Known history of drug hypersensitivity 
• Physical findings suggesting surgery in near future 
• Participation in another trial within the past 3 months. 
• Diseases affecting absorption such as crohn’s disease and celiac disease 
Study medication: Serenoa repens fruit extract Me180 (320mg hydroethanolic extract 
(96%),SabCaps®) or matching tamsulosin HCl (Pradif®) 400µg one 
capsule daily 
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Treatment duration: 26 weeks 
Outcome measures: Primary outcome measures 
• Peak urinary flow rate 
• I-PSS (Internationale Prostate Symptom Score)  
with quality-of-life index QoL 
Secondary outcome measures  
• Mean urinary flow rate 
• Residual urine volume 
• Prostate size 
• IIEF (Internationale Index of Erectile Function) 
Safety assessment: • Adverse effects • pulse and blood pressure (after sitting 5’ and subsequently standing up) 
and routine laboratory tests were assessed (serum values of alkaline 
phosphatase, aspartate aminotransferase ASAT, alanine aminotransferase 
ALAT, haemoglobin, creatinine, and prostate specific antigen (PSA) and 
urinalysis for leukocyte count and urine protein) 
Settings: Department of Urology, University Hospital, in Basel and Liestal, Switzerland. 
Visits pretrial selection, controls at weeks 0, 2, 8, 16, 26 
 
Table IV- 1 Monitoring schedule: 
week -1 0 2 4 6 8 10 12 14 16 18 20 22 24 26
visit no. I II III   IV    V     VI 
 selection 
begin 
control 1 
  control 2 
   control 3 
    term
ination 
treatment           _____________________________________________________ 
blood pressure and pulse x  x   x    x     x 
blood and urine withdrawal x              x 
IPSS, quality-of-life index x  x   x    x     x 
peak urinary flow rates x x x   x    x     x 
mean urinary flow rates x  x   x    x     x 
postvoid residual urine x  x   x    x     x 
IIEF x     x    x     x 
prostatic volume x              x 
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3 Patients and Methods 
3.1 Design 
This prospective, double-blind, randomised, active-controlled, parallel-group, pilot 
study was conducted at the Department of Urology, University Hospital, in Basel and 
Liestal, Switzerland. The pilot study was a 26 week, two-arm comparison, to 
systematically assess the therapeutical effects, safety and tolerability of the Serenoa 
repens extract Me180 (SabCaps®) versus tamsulosin (Pradif®) as an active control in 
patients with obstructive BPH treated for 26 weeks. Figure IV-1 shows the study 
design. 
 
              Serenoa repens extract Me180       35* 10** (0)*** 
              1x1 capsule Sabcaps® (320 mg extract) 
 
               tamsulosin                                      35*  9** (1)*** 
 
                1x1 capsule Pradif® (0.4mg)                  
    ↑            ↑      ↑             ↑                        ↑                        ↑                    
              -2           0     2            8                     16                    26 weeks  
                 * scheduled patients 
             ** randomised patients 
              *** withdrawals  
 
 
Figure IV- 1 Study design  
According to the calculations (3.8.1 required sample size) 70 patients were 
scheduled to be included in the pilot study, 35 for each treatment group. Patient 
recruitment was stopped prematurely, thus, just 19 patients with obstructive BPH 
were included in the double-blind phase of the study, of which 10 received 320mg 
Serenoa repens extract Me180 and 9 received 0.4mg tamsulosin once daily in the 
morning. The main part of the trial encompassed 26 weeks of randomised treatment 
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during which there were four further visits, after 2,8,16 and 26 weeks. Patients were 
randomised at start of treatment (week 0) into two study groups. 
3.2 Study population and selection of patients 
3.2.1 Inclusion and exclusion criteria 
Men, aged 45 to 90 years, were included in the trial if they had moderate BPH 
according to their International Prostate Symptom Score (I-PSS) (> 6 points) and an 
averaged peak urinary flow (Qmax) of < 10ml/s for a voided volume of 150ml 
measured at visit -2 and visit week 0. If Qmax was 10-15ml/s obstructive BPH had to 
be ascertained by pressure-flow study. Other inclusion criteria were a residual urine 
volume of ≤ 200ml, prostate specific antigen (PSA) < 10ng/ml for prostate ≤ 60ml, 
<15ng/ml for prostate> 60ml and no indications for any acute medical treatment nor 
for operative intervention. Participants were required to declare their informed 
consent to participate in writing. 
Exclusion criteria were concomitant medication likely to interfere with study 
medication, including hormone preparation, cimetidine, cyclosporine A, 
anticoagulants, diuretics, calcium channel blockers, antidepressants and 
neuroleptics, anticholinergics, sympathomimetics, parasympatolytics, 5α-reductase 
inhibitors, or any other phytotherapeuticals intended for BPH-treatment. If such drugs 
had been used in the past 3 months, patients had to be excluded from the study. 
Furthermore, patients with any of the following disorders were also excluded: 
presence of urinary tract infections, diabetes, cardiovascular disorders, hypertension, 
orthostatic hypotension, retention of urine, hydronephrosis, renal insufficiency, 
previous urological surgery (including the prostate, bladder and urethra), prostate 
cancer, severe organic diseases, marked disorders of other organ systems including 
renal or hepatic insufficiency, senile dementia, alcohol or drug abuse, known history 
of drug hypersensitivity, physical findings suggesting surgery in near future, diseases 
affecting absorption such as crohn’s disease and celiac disease, or participation in 
another trial within the past 3 months. Patients who fulfilled one of these exclusion 
criteria were not allowed to participate in the study. 
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3.3 Recruitment and patient selection 
Patients were recruited by several local newspapers of Basel and environments. 
Participants were screened for eligibility by telephone interview, and at the first visit, 
and they were randomised at the second one. Men who had severe symptoms like 
increased frequency of urination, hesitancy and poor stream, were invited to the first 
visit. They were required to be aged between 45 and 90 years and to have no items 
mentioned under exclusion criteria (3.2.1 Inclusion and exclusion criteria). At the first 
visit, patients with obstructive BPH were enrolled into the study (Figure IV-2). 
 
Figure IV- 2 Pilot study profile 
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3.4 Examination procedures 
The 4th International Consensus on BPH recommended a duration of at least 12 
months for clinical trials to document the efficacy for BPH treatment. We decided to 
conduct the first pilot study with a duration of 6 months. The study consisted of six 
hospital visits. The main part of the trial encompassed 26 weeks of randomised 
treatment during which there were 4 further visits, at week 2,8,16 and 26. Subjective 
and objective outcome assessments were carried out according to the monitoring 
schedule outlined in Table IV-1. The time flow of the visits was adhered to with 
accepted deviations of ±1 week. Because of circadian changes of uroflowmetry 
(Golomb et al 1992) and postvoid residual urine volume (Griffith et al 1996) all 
assessments were carried out in the morning. 
At visit I (pre-trial assessment), medical history was taken to identify other causes of 
voiding dysfunction, symptoms were evaluated using the International Prostate 
Symptom Score (IPSS), and quality-of-life (QOL), peak (Qmax) and mean (Qave) 
urinary flow rate, postvoid residual urine, prostate volume, pulse and blood pressure 
(BP), after sitting 5’ and subsequently standing up, and routine laboratory tests were 
assessed. Patients who fulfilled the inclusion criteria were invited for visit II, if they 
wished to participate. 
Biopsy of the prostate was proposed to patients with elevated PSA values (>3ng/ml) 
according to the reference ranges used locally. If the biopsies were negative for 
carcinoma, the patient was invited for the second visit. 
At visit II, Qmax was assessed and averaged with Qmax of visit I giving the baseline 
Qmax. Patients with baseline Qmax < 10ml/s were included, if averaged Qmax 10-
15ml/s, the obstruction had to be ascertained by pressure-flow study. 
Visits III,IV,V and VI were scheduled 2,8,16,and 26 weeks later. At each visit, the 
patients were asked to fill out the IPSS questionnaire and objective measurements 
peak (Qmax) and average (Qave) urinary flow rates, the residual urine volume, systolic 
and diastolic blood pressure and pulse rate were assessed. At visits IV, V and VI 
patients were asked to fill out the IIEF questionnaire. Patients were interviewed 
regarding concomitant medication and occurrence of adverse events. Information of 
adverse events was collected based on a standardized questionnaire according to 
good clinical practice guidelines, which included type of adverse events, beginning 
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and duration, intensity, frequency, necessity for adverse event treatment, assumed 
relationship with study medication, severity and outcome. At visit VI (study 
termination), additionally, prostate volume was assessed and physicians and patients 
were asked a global subjective question to estimate the efficacy of the treatment on a 
five-stage scale and physicians were asked a second question concerning the 
tolerability. 
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3.5 Outcome and efficacy parameters 
The efficacy of the two study treatments was assessed according to the 
recommendations of 4th International Consultation on BPH (1997) (Roehrborn 1998). 
3.5.1 International Prostate Symptom Score (IPSS) 
The most widely used symptom score is the American Urological Association 
Symptom Score (AUA-SS) and with the addition of a single disease specific question 
on quality-of-life (added by the WHO) becomes the International Prostate Symptom 
Score IPSS (Barry et al 1992) (Table IV-2). Unlike previously published symptom 
scores, this index has been designed for self-administration in a uniform manner. A 
validated German version of the IPSS was filled out by the patients. 
Table IV- 2 International Prostate Symptom Score IPSS made up of the American Urological 
Association Symptom Score (Barry et al 1992) and a single question to assess quality-of-life 
added by WHO. 
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The IPSS comprises a set of seven questions on urinary function, covering 
frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete 
emptying and urgency. Each question is measured on a 5-point scale, resulting in a 
total score of 35 points. ‘Obstructive’ symptoms are assessed by questions 1, 3, 5 
and 6 (total 20 points), while ‘irritative symptoms’ are assessed by questions 2, 4, 
and 7 (total 15 points). 
In recognition of the importance of the disease specific quality-of-life, and the degree 
to which it is affected by the symptoms, a single quality-of-life question was added to 
the symptom score (Table IV-2). This answer is rated on a 0-6 point scale, where the 
highest score corresponded to the worst perception.  
3.5.2 Urinary flow rate 
Urinary flow rate recording is a non-invasive technique to assess the strength of the 
urinary stream using an uroflowmeter.  
The peak and average urine flow rates are those rates most usefully. 
Peak urinary flow rate:  Qmax, greatest flow per unit of time 
Average flow rate:    Qave, the voided volume divided by the flow time  
Presently, the only available direct method to assess the presence or absence of 
obstruction is a pressure-flow study. Urine flow studies are limited by their failure to 
identify detrusor underactivity as a cause of low flow rates and by their failure to 
indicate obstruction in those patients who have normal flow rates but ‚supranormal‘ 
detrusor voiding pressures. However, this non-invasive method has gained wide-
spread use to assess obstruction. It was shown that 90% of patients with peak flow 
rate of less than 10ml/s have bladder outlet obstruction (BOO) while this percentage 
decreased to 67% in those with a Qmax of 10-15ml/s. The specificity will depend on 
the patient group, but two series correlated well. The following data for 3 bands or 
Qmax gives the percentages of patients who will be obstructed (Abrams 1998). 
Qmax < 10ml/s   90% BOO 
Qmax 10-14ml/s   67% BOO 
Qmax > 15ml/s    30% BOO 
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As urinary flow rates are dependent on voided volume, a voided volume of > 150ml is 
required for an accurate reading (Haylen et al 1989). Controversy exists regarding 
the reproducibility of this parameter in the same individual on repeated 
measurements (Golomb et al 1992). A single flow rate does not give adequate 
information, except when it is clearly normal (e.g. Q max >25ml/s) and has a bell-
shaped course over time. Therefore, patients were only included with an averaged 
peak flow rate of < 10ml/s measured on two different days (Abrams 1998). In patients 
with Qmax 10-15ml/s obstruction had to be ascertained by pressure - flow study. 
3.5.3 Postvoid residual urine volume 
The amount of urine left in the bladder after urination was measured by 
transabdominal ultrasonography. Healthy volunteers have been found to have less 
than 12ml of residual urine (Roehrborn 1998). Thus, the presence of residual urine 
constitutes an abnormal finding, although it is certainly not specific for the diagnosis 
of BPH. While originally designed with a minimum of 30ml < R < 200ml, during the 
study, this criterion needed to be adjusted to R< 200ml because of the loss of 
patients. 
3.5.4 Prostate size 
It is a well established fact that prostate size correlates only moderately with patients’ 
symptoms (Roehrborn 1998). However, prostatic enlargement is one of the three 
aspects determining the picture of clinical BPH (Figure II-3). Therefore, prostatic size 
was assessed as a secondary outcome by transabdominal ultrasonography at 
baseline, and after 26 weeks of treatment. 
3.5.5 International Index of Erectile Function IIEF 
Diseases of the prostate may interfere with sexual function and treatment of prostatic 
diseases may exhibit an impact on sexuality (Burger et al 1999). To assess the effect 
of the treatments on sexual function the International Index of Erectile Function (IIEF) 
was completed. IIEF is a 15-item, self-administered questionnaire scale developed 
for the assessment of sexual function (Rosen et al 1997). Five factors or response 
domains were identified: erectile function, orgasmic function, sexual desire, 
intercourse satisfaction, and overall satisfaction.  
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3.5.6 Urodynamic pressure-flow studies 
Pressure flow studies are invasive studies that simultaneously measure urinary flow 
rates, bladder pressure, and abdominal pressure. To avoid the discomfort and 
potential complications, obstructive BPH was only diagnosed by pressure flow 
studies, in patients with flow rates between 10-15ml/s. 
3.5.7 Global subjective assessment of the treatment outcome and its 
tolerability 
Additionally, a global subjective assessment of the efficacy was added by an overall 
question to patients and physicians. The five-stage answer scheme ranges from 
”very good” to ”none”. 
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3.6 Safety assessment and documentation of adverse effects 
The safety of the study medication was evaluated by laboratory monitoring at 
baseline and endpoint of serum values of alkaline phosphatase, aspartate 
aminotransferase ASAT, alanine aminotransferase ALAT, haemoglobin, creatinine, 
and prostate specific antigen (PSA) and urinalysis for leukocyte count and urine 
protein. All the analyses were performed at the laboratory of the University Hospital 
in Basel. 
At every visit pulse and blood pressure were assessed after sitting 5’ and standing 
up. 
In every consultation the participants were asked if they had noticed any adverse 
effect and mentioned effects were documented based on a standardized 
questionnaire according to good clinical practice guidelines, which included type of 
adverse events, beginning and duration, intensity, frequency, necessity for adverse 
events treatment, assumed relationship with study medication, severity and outcome. 
After completing the therapy, physicians were asked a global subjective question to 
estimate the tolerability of the treatment on a five-stage scale, ranging from “very 
good” to “very poor”. 
If the physicians estimated the tolerability with “moderate”, “poor” or “very poor” they 
were asked to further explain. 
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3.7 Study medication 
Study medication consisted of either Serenoa repens fruit extract Me180 320mg/day 
(SabCaps®, 96% ethanol m/m, extract ratio 9-11:1) or the reference preparation of 
tamsulosin 0.4mg/day (Pradif®). Both drugs are commercially available and admitted 
by the Swissmedic, SabCaps® no. 54823 and Pradif® no. 53471. The first group 
received 320mg of Serenoa repens fruit extract Me180 (SabCaps®) per day and the 
second group received 0.4mg tamsulosin (Pradif®) per day, both in the morning. The 
used dosages of both regimens were based on the recommendations of the 
suppliers. Treatment was given for a total of 26 weeks. 
3.7.1 Blinding 
The drugs were blinded with special gelatine capsules for double-blind clinical trials 
DBcaps® supplied by Capsugel AG, Bornem, Belgium, and blinding of medication 
was conducted by Fisher Clinical Services, Pharmaceutical Packaging, Horsham, 
England, and blind-packaging by Fisher Clinical Services, Pharmaceutical 
Packaging, Allschwil, Switzerland. We used a single product lot throughout the study, 
and preparations were matching for appearance, size, colour, taste, and smell.  
3.7.2 Randomisation 
The patients were allocated symmetrically to the two treatment groups according to a 
randomisation schedule created by the statistician with random block sizes of four. 
The patient numbers were assigned to the patients chronologically in ascending 
order. Randomisation codes were concealed in sealed envelopes and opened only 
after the last man had completed treatment. 
3.7.3 Compliance 
Patients were informed at first and at all following visits about the importance of the 
conformable intake of the study medication. Patient compliance was estimated from 
capsule counts at each visit. Average compliance, assessed by counting the 
remaining capsules at each visit, was 98% for all men during the trial. No subject had 
a compliance of less than 93%. 
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3.8 Co-medication 
During the study, every co-medication which is not itemised under exclusion criteria 
was allowed. However, all co-medication had to be registered on a special form. 
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3.9 Biometrical planning and analysis 
3.9.1 Required sample sizes 
Based on results of conducted trails (Wilt et al 1998; Wilt et al 2002b) the following 
assumption was made: the mean difference of improvement for the peak urinary flow 
rate between Serenoa repens extract and tamsulosin is δ=0.88 (detectable treatment 
difference), for the improvement the pooled standard deviation is σ=1.17 (compare 
with (Carraro et al 1996)). Based on these specifications, the significance level 
α=0.05, the power 1-β=0.80 and the power determination by means of t-test the 
required sample sizes are 28 patients by treatment group (calculated with software 
Sample Power (Version 1.2), SPSS inc., 1997). Taking into consideration a dropout 
rate of 25% 35 patients should be included in each treatment group. 
3.9.2 Statistical methods 
The statistical evaluation was done based on the “Per-Protocol (PP)” principle. The 
two-sided alternative hypothesis was stated. The paired differences “under treatment 
minus before treatment” were the basic data to compare the two treatment efficacies. 
The parameters were described with usual statistical methods in an overall analysis 
according to the PP principle. 
• t-test for comparing the means of two independent samples under parametric 
normality condition. 
• Paired t-test for comparing the means of two paired samples under parametric 
normality condition. 
• Kruskal-Wallis test for comparing the means of two independent samples 
under non-parametric condition. 
• Wilcoxon test for comparing the means of two paired samples under non-
parametric condition. 
• Chi square test for analyzing contingency tables 
• Fisher’s exact test for analyzing contingency tables 
The significance level α=0.05 is used in statistical test applications. The two-sided 
probability p is determined according to the stated two-sided alternative hypothesis. 
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The probability p can shortly be interpreted as follows: 
 p > 0.10  :  no statistical significance 
0.05 <  p ≤ 0.10  :  tendency of statistical significance 
0.01 < p ≤ 0.05  :  slight statistical significance 
0.001 < p ≤ 0.01  :  statistical significance 
 p ≤ 0.001:  high statistical significance 
The statistical software tools, Microsoft EXCEL, Version 7.0 (1997) and SAS/STAT 
Version V8.02. (1999) were mainly used to describe and evaluate data collected in 
the present pilot study Serenoa repens extract versus tamsulosin. 
3.9.3 Data recording and statistical evaluation 
Data were acquired once on a paper version. In addition, an electronic case report 
form (eCRF) developed by pnn, pharma nation network AG, Zürich, was included to 
test electronic data entry. All data were analysed by Consult AG, Dr. U. Kreuter, 
Bern- Liebefeld. 
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3.10 Ethical and legal considerations 
The study preparation, execution, and analysis were performed according to current 
European Union and International Conference on Harmonisation guidelines on Good 
Clinical Practice and the Declaration of Helsinki with revision of Edinburgh, Scotland, 
October 2000, and the regulations of Swissmedic (Reglement über die Heilmittel im 
klinischen Versuch).  
The study was approved by the ethics committee of Basel and notified to 
Swissmedic.  
Written informed consent was obtained from all participating patients before 
treatment. 
Personal data obtained during the study are protected and were not given to any 
unauthorised person. 
Participations were insured by the ‘Probandenversicherung des Kantons Basel-
Stadt’. 
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4 RESULTS 
4.1 Patients distribution  
Between August 2002 and March 2003, 420 men living in Basel and region answered 
to the 6 advertisements placed in several local newspapers. Participants were 
screened for eligibility by a telephone interview, and 108 patients were invited for the 
first visit (Figure IV-3). 312 patients were excluded due to exclusion criteria, 
particularly because of medication possibly interfering with the study medication 
(Table VI-3). Of the 108 men invited to attend the initial visit for history and diagnosis 
of obstructive BPH, 19 were eligible to be randomised, 10 to the Serenoa repens 
Me180 arm and 9 to the tamsulosin arm (Figure IV-3). Of these, 10 of the Me180 and 
8 patients of the tamsulosin group completed the study. Only 1 patient of the 
tamsulosin group discontinued the study because of continuous dizziness. 
 
Figure IV- 3 Trial diagram showing the distribution of participants at each stage. 
The patient recruitment was stopped because of a high dropout rate at the telephone 
interview (74%) (Table IV-3), but also at the first visit (82%) (Table IV-4), so that only 
4.5% of interested participants were finally included and randomised in the pilot 
study. 
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Cardiovascular medication and pre-existing BPH treatment were the most frequent 
reasons why patients could not be included after the telephone interview (Table IV-
3).  
Table IV- 3 Excluded at the telephone interview 
Exclusion criteria at telephone interview No of patients 
in % 
within 
% 
overall 
interfering medication 205 65.7 48.8 
too young 20 6.4 4.8 
wished phytotherapeutic medication 6 1.9 1.4 
high franchise or HMO insurred 13 4.2 3.1 
no disorders 25 8.0 6.0 
unable to understand the significance of the trial 3 1.0 0.7 
miscellaneous 40 12.8 9.5 
Total initially excluded patients  312 100.0 74.3 
 
After the first visit, 89 patients were not eligible for the inclusion in the study, mainly 
because the flow rate was> 15ml/s or > 10ml/s and they were not willing to have a 
pressure-flow study done (Table IV-4). In 3 included patients obstructive BPH was 
assessed by pressure-flow study. 
Table IV- 4 Excluded at the first visit 
Exclusion criteria at the first visit No of patients in % within 
Peak urinary flow  43 39.8 
Residual urine volume 17 (3)* 15.7 
PCA 4 3.7 
Miscellaneous 15 13.9 
Total initially excluded patients  89 82.4 
*At the beginning of the pilot study, there was a minimum of 30ml residual urine 
volume required. These restrictions where eased after loss of patients. After protocol 
change there were 3 patients with R > 200ml, who needed to be treated beyond the 
study. 
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4.2 Baseline characteristics 
The randomised groups were similar in their baseline characteristics as shown in 
Table IV- 5. There were no significant differences in the characteristics (p>0.1). The 
mean age of patients in the Me180 group was 62.8 (50-74) years, while the mean 
age of the tamsulosin group was 61.4 (52-79) years.  
Table IV- 5: Baseline patient characteristics at selection visit 
Characteristics Me180 
(n=10) 
tamsulosin 
(n=8) 
 
No. randomised 10 9  
No. completing study 10 8  
 Me180 
(n=10) 
tamsulosin 
(n=8) 
p value 
Duration of symptoms 2.47 ± 1.23 2.61 ± 1.67 0.77 
Age (years) 62.8 ± 8.2 61.4 ± 9.1 0.73 
Body mass indexa 25.40 ± 2.5 25.42 ± 2.13 0.98 
IPSS (0-35 points) 16.9 ± 5.74 19.13 ± 6.27 0.48 
QoL (0-6 points) 2.1 ± 1.45 2.5 ± 1.6 0.55 
Peak urinary flow rate Qmax 9.17 ± 2.80 7.78 ± 2.34 0.35 
Mean urinary flow rate Qave 5.35 ± 2.09 4.59 ± 1.33 0.33 
Postvoid residual urine volume (ml) 58.9 ± 70.82 26.0 ± 17.20 0.42 
Prostate volume (ml) 45.9 ± 22.18 39.0 ± 14.66 0.72 
Serum PSA (ng/ml) 1.83 ± 1.53 1.16 ± 0.53 0.65 
a kg/m2  
Values are means ±SD 
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4.3 Treatment outcome 
Table IV-6 shows the evolution of IPSS, the quality-of-life index, the maximum and 
mean flow rates, the residual urinary volume and the prostate volume over the 26 
weeks treatment period. For these parameters, the effects in the two treatment 
groups were not significantly (p>0.1) different, meaning that the evolution was 
comparable in both groups. In detail, the single evolutions are shown in the following 
chapters. 
Table IV- 6: Study resultsa from baseline to endpoint 
Parameter 
 
Group 
 
n 
 
Baseline week 2 week 8 week 16 endpoint 
IPSS Me180 10 16.9 ± 5.7 16.1 ± 6.9 13.9 ± 6.7 13.6 ± 5.4 13.1 ± 7.6 
(points) tamsulosin 8 19.1 ± 6.2 16.6 ± 3.0 15.8 ± 2.3 14.0 ± 4.2 14.8 ± 4.8 
QoL Me180 10 2.1 ± 1.5 3.4 ± 1.6 2.4 ± 1.4 2.7 ± 1.3 2.0 ± 1.2 
(points) tamsulosin 8 2.5 ± 1.6 2.6 ± 1.2 2.4 ± 0.9 2.1 ± 1.1 2.0 ± 1.1 
Qmax Me180 10 9.2 ± 2.8 11.8 ± 5.5 12.4 ± 4.3 10.8 ± 5.4 10.1 ± 5.3 
(ml/s) tamsulosin 8 7.8 ± 2.3 9.9 ± 4.4 12.0 ± 5.5 10.8 ± 5.2 11.8 ± 8.8 
Qave Me180 10 5.4 ± 2.1 6.6 ± 3.5 6.4 ± 1.9 5.7 ± 2.4 5.0 ± .2 
(ml/s) tamsulosin 8 4.6 ± 1.3 5.0 ± 2.3 5.6 ± 2.0 5.7 ± 2 4.6 ± 1.2 
R Me180 10 58.9 ± 70.8 56.3 ± 53.0 54.8 ± 46.8 52.6 ± 58.8 53.2 ± 31.1
(ml) tamsulosin 8 26.0 ± 17.2 37.1 ± 43.5 57.1 ± 49.9 26.8 ± 25.9 43.4 ± 43.9
P Me180 10 45.9 ± 22.2 n.d. n.d. n.d. 47.5 ± 18.2
(ml) tamsulosin 8 39.0 ± 14.6 n.d. n.d. n.d. 38.7± 8.4 
a Data are presented as mean (± standard error (s.e.)) 
n.d. not determined 
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4.4 Primary outcome measures 
4.4.1 International Prostate Symptom Score (IPSS) 
After 26 weeks both treatments decreased the total IPSS in a similar pattern and to a 
similar extent with -3.8 points in the Me180 group and -4.38 points in the tamsulosin 
group. Comparing the means and means of paired differences “26 minus 0 weeks” 
no statistical significance was demonstrated between both treatment groups (p= 
0.48). Figure IV-4 shows the evolution of the total IPSS. 
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Figure IV- 4 Evolution of total IPSS means with 95% confidence intervals (CI) of Me180 and 
Tamsulosin treatment groups at five control time-points (weeks 0, 2, 8, 16, 26). 
At baseline, the score was slightly greater in the tamsulosin group but not statistically 
significant (p=0.48). At week 16, the decrease with respect to baseline in both 
treatment groups was statistically slightly significant (p = 0.03) for Me180 and with 
tendency of significance (p= 0.10) for the tamsulosin group. For both treatments, the 
mean percentage change from baseline to endpoint (26 weeks) was similar (22.5% 
for Me180 and 22.9% for tamsulosin).  
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Non significant differences were observed between the treatment groups at 26 weeks 
in terms of irritative symptoms (p=0.93) and obstructive symptoms (p=0.53) (Figure 
IV-5 and IV-6). However, within the treatment groups, Me180 showed a slight 
significance in the decrease in irritative symptoms (p=0.03) and a tendency to 
significance in the  decrease of obstructive symptoms in both treatment groups 
(p=0.07).  
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Figure IV- 5 Evolution of obstructive symptom score (IPSS 1,3,5,6) means with 95% CI of Me180 
and tamsulosin treatment groups at five control time-points (weeks 0, 2, 8, 16, 26). 
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Figure IV- 6 Evolution of irritative symptom score (IPSS 2,4,7) means with 95% CI of Me180 and 
tamsulosin treatment groups at five control time-points (weeks 0, 2, 8, 16, 26). 
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Furthermore, the analysis of each of the IPSS items showed no significant difference 
between the two preparations (Figure IV-7). Table IV-7 shows the evolution of the 
means over the 26 weeks with corresponding p values within the treatment groups 
and between the treatment groups. The strongest decrease of score was found for 
weak stream (IPSS-5), incomplete emptying (IPSS-1) and nocturia (IPSS-7). 
Table IV- 7 Means for individual IPSS questions (1-7) of treatment groups Me180 and 
tamsulosin in 5 controls (week 0,2,8, 18,26). 
      Weeks (Mean) p p 
 Group n 0 2 8 16 26 within  
IPSS-1 Me180 10 2,60 2,80 2,30 2,50 2,20 0.76 
incomplete 
emptying  tamsulosin 8 3,13 2,88 2,38 2,13 2,25 0.09 0.42 
IPSS-2 Me180 10 2,40 2,30 2,10 2,10 1,70 0.33 
frequency tamsulosin 8 2,75 2,88 2,63 2,50 2,63 0.78 0.93 
IPSS-3 Me180 10 2,00 1,90 1,80 1,50 1,60 0.24 
intermittency tamsulosin 8 2,63 2,00 2,38 2,00 2,25 0.39 0.53 
IPSS-4 Me180 10 2,40 2,30 1,90 1,70 1,90 0.09 
urgency tamsulosin 8 2,38 2,13 2,00 1,63 1,75 0.29 0.79 
IPSS-5 Me180 10 3,90 3,50 2,90 3,10 3,10 0.013 
weak stream tamsulosin 8 3,63 3,25 3,13 2,63 2,50 0.20 0.96 
IPSS-6 Me180 10 1,50 1,60 1,30 1,30 1,10 0.33 
straining tamsulosin 8 2,38 1,63 1,50 1,38 1,63 0.23 0.69 
IPSS-7 Me180 10 2,10 1,70 1,60 1,40 1,50 0.007 
nocturia tamsulosin 8 2,25 1,88 1,75 1,75 1,75 0.015 0.86 
IPSS Me180 10 16,90 16,10 13,90 13,60 13,10 0.03 
total tamsulosin 8 19,13 16,63 15,75 14,00 14,75 0.10 0.48 
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Figure IV- 7 Evolution of individual IPSS questions in both treatment groups with time. 
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Quality-of-life score 
No significant differences were found between the quality-of-life score of the two 
treatment groups comparing means of values and means of paired differences “26 
minus 0 weeks” with reached probability (p=0.62 based on Kruskal-Wallis test). The 
absolute value of the score slightly declined within the two treatment groups as 
shown in Figure IV-8 but did not reach statistical significance. 
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Figure IV- 8 Evolution of quality of life QoL means ± 95% CI for of treatment groups Me180 and 
tamsulosin at five control time-points (weeks 0, 2, 8, 16, 26).  
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4.4.2 Peak urinary flow rate (Qmax) 
The peak urinary flow rates for the first two visits were averaged to give the baseline 
rate. All peak urinary flow rate measures were for a minimum urine volume of 150ml. 
Again, concerning the peak urinary flow rates, no significant differences were found 
between the two treatment groups comparing means of values and means of paired 
differences “26 minus 0 weeks” with a reached probability of p =0.42 based on 
Kruskal-Wallis test . The evolution of Qmax plotted over time is shown in Figure IV-9. 
Within the two treatment groups up to week 8 a modest improvement with tendency 
to significance (p=0.056) was noticeable for Me180 and with slight significance 
(p=0.033) for the tamsulosin group. However, after week 8 this improvement was 
reversed in both treatment groups.  
Comparing the absolute differences from baseline to endpoint the tamsulosin group 
showed a stronger increase with 3.99ml/s (51%) whereas the Me180 group showed 
only 0.89ml/s (10%). However, these differences where not significant. 
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Figure IV- 9 Evolution of means ± 95% CI for peak urinary flow rates Qmax of treatment groups 
Me180 and Tamsulosin at the five control time-points (weeks 0, 2, 8, 16, 26) 
In Figure IV-10 and IV-11 the evolution of mean Qmax values over time of each patient 
is depicted. Values of visits at week 2, 8 and 16 are missing in one patient from the 
Me180 group. 
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Figure IV- 10 Evolution of peak urinary flow rate (Qmax) values over time (26 weeks) in single 
patients in the group Me180 (n=10 patients) 
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Figure IV- 11 Evolution of peak urinary flow rate (Qmax) values over time (26 weeks) in single 
patients in the group tamsulosin (n= 9 patients) 
CLINICAL INVESTIGATIONS 
137 
4.5 Secondary outcome measures of efficacy 
4.5.1 Mean urinary flow rate 
After six months of treatment, no significant differences were found between the two 
treatment groups comparing mean values of mean urinary flow rate Qave and means 
of paired differences “26 minus 0 weeks” with reached a probability p = 0.25 based 
on Kruskal-Wallis’ test (Figure IV- 12). 
Within the two treatment groups no significant mean differences were observed 
(p=0.68 for Me180 and p=0.12 for tamsulosin), however evolution of both treatment 
groups were similar to that of Qmax (Figure IV-9). 
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Figure IV- 12 Evolution of means ± 95% CI for mean urinary flow rates Qave of treatment 
groups Me180 and tamsulosin at the five control time-points (weeks 0, 2, 8, 16, 26) 
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4.5.2 Postvoid residual urine volume 
No significant changes were found between the two treatment groups comparing 
means of values and means of paired differences “26 minus 0 weeks” (p>0.33 based 
on Kruskal-Wallis’ test )(Figure IV- 13). 
In the tamsulosin group the mean was increasing up to week 8, but decreased again 
at week 16 and 26. Within the two treatment groups no significant mean modification 
was demonstrated (p=0.68 for the Me180 group, and p=0.10 due to the increase in 
the tamsulosin group, based on t-test). 
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Figure IV- 13 Evolution of means ± 95% CI for postvoid residual urine volume of treatment 
groups Me180 and tamsulosin at the five control time-points (weeks 0, 2, 8, 16, 26). 
In Figure IV-14 and IV-15 the evolution of postvoid residual urine volume values over 
time of the single patients are depicted. Values of visits at week 2, 8 and 16 are 
missing in one patient from the Me180 group. 
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Figure IV- 14 Evolution of residual urinary volume values over time (26 weeks) in patients of the 
group Me180 (n=10 patients) 
Evolution of residual urinary volume values over time in 
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Figure IV- 15 Evolution of residual urinary volume values over time (26 weeks) in patients of the 
tamsulosin group (n=8 patients) 
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4.5.3 Prostate volume 
The mean prostate volumes of both treatment groups at baseline and endpoint are 
shown in Table IV-6. No significant (p=0.59) differences were found between the two 
treatment groups comparing means of values and means of paired differences “26 
minus 0 weeks”. Within the two treatment groups no significant mean modifications 
could be observed, with p=0.72 in the Me180 group and p=0.77 in the tamsulosin 
group. 
4.5.4 International Index of Erectile Function (IIEF) 
The mean evolution in the tamsulosin treatment group is significantly higher than in 
the Me180 treatment group (p=0.02). Comparing means of paired differences “26 
minus 0 weeks” of the two treatment groups no significant differences were found 
(p>0.1). In none of the two treatment groups significant mean modifications could be 
observed: p= 0.10 within the Me180 group and p=0.19 within the tamsulosin group. 
However, absolute mean values decreased in both treatment groups. 
4.6 Overall question 
Additionally, the patient himself and the physicians were asked a global subjective 
question to determine the overall improvement (Table IV-8 and IV-9) and the 
tolerability (Table IV-10). There was no significant difference between the two 
treatment groups (p>0.1).  
Table IV- 8: Overall improvement assessed by physician: 
 Me180 Tamsulosin 
very good 1 (10.0%) 1 (12.5%) 
good 0 (0.0%) 0 (0.0%) 
moderate 2 (20.0%) 1 (12.5%) 
poor 3 (30.0%) 2 (25.0%) 
none 4 (40.0%) 4 (50.0%) 
total 10 (100%) 8 (100%) 
p=0.96 (Fisher’s Exact Test) 
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Table IV- 9: Overall improvement assessed by patient: 
 Me180 Tamsulosin 
very good 0 (00.0%) 1 (12.5%) 
good 3 (30.0%) 1 (12.5%) 
moderate 2 (20.0%) 3 (37.5%) 
poor 3 (30.0%) 1 (12.5%) 
none 2 (20.0%) 2 (25.0%) 
total 10 (100%) 8 (100%) 
p=0.73 (Fisher’s Exact Test) 
 
Table IV- 10: Overall tolerability assessed by physician: 
 Me180 Tamsulosin 
very good 8 (80.0%) 7 (77.8%) 
good 1 (10.0%) 1 (11.1%) 
moderate 1 (10.0%) 0 (0.0%) 
very poor 0 (00.0%) 1 (11.1%) 
total 10 (100%) 9 (100%) 
p=0.47 (Fisher’s Exact Test) 
 
In the tamsulosin group one patient withdrew from the study because of strong 
dizziness. His medication tolerability was estimated to be very poor. The patient 
exhibiting moderate tolerability out of the Me180 group reported repeated dizziness. 
The patient himself estimated the medication tolerability to be moderate. 
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4.7 Safety results 
4.7.1 Vital signs 
Treatment affected neither systolic (SBP) nor diastolic blood pressure (DBP) nor 
pulse rate. No significant changes were found in intra- and inter group comparison of 
the two treatment groups in pulse and blood pressure measurement after sitting 5’ 
and subsequently standing up (p > 0.10).(Table IV-11) 
Table IV- 11: Means for pulse systolic (SPB) and diastolic blood pressure (DBP) over time 
    Weeks (Mean ± SD) 
Parameter Group (n) 0 2 8 16 26 
Pulse Me180 (10) 76.8±10.2 74.9± 6.1 77.2±11.6 74.5±12.9 73.8±10.9 
(1/min) 
 tamsulosin (8) 71.9± 9.0 67.8± 6.0 71.8± 8.8 71.9± 9.0 70.8 ± 8.1 
SBP after Me180 (10) 135.3±13.9 138.1±14.2 138.0±13.5 134.6±12.9 130.9±12.4
sitting 5' 
(mmHg) tamsulosin (8) 136.4± 17.2 126.6± 15.3 134.0± 20.9 133.5± 10.3 128.4 ± 1.7
DBP after Me180 (10) 83.4± 10.2 83.4± 11.1 82.5± 6.6 87.7± 14.0 82.7 ± 7.9 
sitting 5' 
(mmHg) tamsulosin (8) 82.0± 11.4 82.5± 8.7 80.8± 9.9 81.0± 4.6 78.1 ± 5.1 
SBP after Me180 (10) 135.1± 13.2 134.4± 12.7 137.5± 13.9 139.4± 13.4 134.2± 10.6
standing 
(mmHg) tamsulosin (8) 135.9± 19.0 125.0± 12.4 140.0± 21.2 140.9 ± 6.9 130.6± 15.6
DBP after Me180 (10) 84.6± 9.9 82.2± 6.7 87.4± 9.6 88.8 ± 9.1 85.6 ± 7.1 
standing  
(mm Hg) tamsulosin (8) 87.9± 12.8 82.4± 10.1 85.5± 11.3 87.9 ± 10.0 82.8 ± 5.2 
 
CLINICAL INVESTIGATIONS 
143 
4.7.2 Laboratory parameters 
A panel of 6 standard blood tests (alkaline phosphatase, aspartate aminotransferase 
(ASAT), alanine aminotransferase (ALAT), haemoglobin, creatinine, and prostate 
specific antigen (PSA)) was assessed at baseline and endpoint (Table IV-12). Within 
the two individual treatment groups no significant changes were found between 
baseline and endpoint (p> 0.01). 
The baseline mean of alc. phosphatase in the Me180 group was significantly higher 
compared to the tamsulosin group (p=0.026). This might explain why, at the 
endpoint, the mean of the Me180 group decreased compared to baseline and within 
the tamsulosin group the mean increased from baseline to endpoint with a tendency 
to significance (p=0.07). However, between the two treatment groups no significant 
changes were found for the 6 laboratory parameters (p> 0.01). 
Table IV- 12 Means for laboratory parameters of treatment groups Me180 and Tamsulosin at 
controls 0 and 26 weeks as means of paired differences “26 minus 0 weeks” with reached 
probability p based on the Kruskal-Wallis test 
   weeks (means)  
Parameter Group n O 26 p 
Alc. phosphatase Me180 10 87,5 84,5 
(U/l) tamsulosin 8 60,9 66,1 0,07 
ASAT Me180 10 27,6 27,2 
(U/l) tamsulosin 8 24,8 25,9 0,35 
ALAT Me180 10 29,2 30,6 
(U/l) tamsulosin 8 27,5 29,3 0,86 
Creatinine Me180 10 79,2 79,2 
(umol/l) tamsulosin 8 78,0 81,3 0,37 
Hemoglobine Me180 10 15,44 15,18 
(mg/dl) tamsulosin 8 14,86 14,90 0,31 
PSA Me180 10 1,83 1,39 
(ng/ml) tamsulosin 8 1,16 0,99 0,65 
 
CLINICAL INVESTIGATIONS 
144 
4.7.3 Comorbidity and comedication 
At baseline 4 patients in the Me180 group and 2 patients in the tamsulosin group 
reported comorbidity and comedication accepted during the study treatment. (Table 
IV-13). 
Table IV- 13 Comorbidity and comedication at baseline 
 comorbidity 
 
comedication 
 
enhanced intra-ocular pressure Latanoprost (Xalatan®) once daily 
eczema and neurodermatitis 
cutaneous fluticasoni propionas (Cutivate crème) and 
Clobetasoli-proprionas (Dermovate Crème) 
previous arthritic pain 
Pitosan shell extract  
Ginkgo extract (Ginkgo vital) 
Me180 
group 
hepatitis C carrier since 30 years   
enhanced cholesterol level Atorvastatinum 10mg(Sortis®) once daily tamsulosin 
group previous polymyalgia Magnesii omeprazolum 20mg (Antra®) once daily 
   
In Table IV-14 comorbidity and comedication of patients are shown, of which a 
relationship with the active drug was excluded.  
Table IV- 14: Comorbidity and comedication during study 
 comorbidity 
 
comedication 
 
headache 
paracetamol 250mg , propyphenazoum 50mg
(Saridon®) each 2nd week against headache 
neurodermatitis, known 
triamcinolon 4mg (Kenacort®) reductive therapy 
scheme over one week 
cold 
Triofan® nose spray(xylometazolinum, carbocisteinum) 
for 3 days 
headache mefenacidum 500mg (Ponstan®) two times 
Me180 
group 
allergic rhinitis, known 
calf cramp, known 
mometasoni 50ug/d (Nasonex®) 
magnesium 300mg (Magnesium Diasporal ®) 
cold 
sore throat 
acidum salicylicum 500mg (Alca C®) 3 times taken  
amoxicilin 1000mg (Aciclav®) for 6 days 
Tamsulosin 
group 
headache mefenacidum 500mg (Ponstan®) 
 diarrhoea once in vacation 
sleeping trouble once in vacation  
charcoal tablet 1x  
zolpidem 10mg (Stilnox®) 1x 
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4.7.4 Adverse events and withdrawal from treatment 
Adverse effects, of which a relationship with the treatment could not be excluded, 
were reported in 3 out of the 10 patients in the Me180 group and in 4 out of the 8 
patients in the tamsulosin group (Table IV-15). Severity was mild to moderate for all 
events. There was no serious adverse effect reported. Only one patient in the 
tamsulosin group withdrew from the trial because of continuous strong dizziness, this 
patient already reported stomach problems in the first period (study begin to control 
1), in the second period (control 1- 2) he started to feel dizzy and stopped study 
participation in the third period (control 2-3). All other events resolved without 
treatment discontinuation.  
The most frequent adverse events in the tamsulosin group were ejaculation disorders 
(n=3). Other adverse events not resulting in withdrawal included occasional 
dizziness, and occasional headaches in the same patient, and reduced ejaculate 
volume, or absence of ejaculate volume.   
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Three patients in the Me180 group reported mild adverse effects with a possible 
association (Table IV-15). These were non-serious and additional medication or 
interruption of therapy was not required. Beyond the drop-out patient in the 
tamsulosin group there were three patients reporting mild to moderate adverse 
effects (Table IV-15): 
 
Table IV- 15 adverse effects of which a relation to active drug can not be excluded 
Treatment 
group 
Patient 
number 
Mentioned adverse effects by patients 
No.9 - throw ups after intake without breakfast, temporary 
No.15 - dizziness, a few times temporary, disappeared after contr. 3
Me180 
group 
No.17 - flatulence, temporary 
 
No.4 - decrease ejaculatory volume, mild but continuous, likely 
associated with study treatment 
No.5 - pyrosis at control 1, dizziness in the morning at control 2, 
discontinuation of the study because of continuous strong 
dizziness 
No.12 - repeatedly reported decrease ejaculatory volume, swollen 
eyes, reduced libido, which may have been associated with 
study treatment 
tamsulosin 
group 
No.13 - reduced ejaculatory volume, during one period, possibly 
associated with the study treatment 
 
Patients receiving tamsulosin experienced a statistically significant (p=0.013) higher 
occurrence of adverse events listed compared to Me180 group as shown in Table IV-
15. 
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5 Discussion 
In this second, clinical part, a controlled randomised double-blind pilot study was 
conducted to compare the therapeutical effects and safety of the over-the-counter 
Serenoa repens extract Me180 with tamsulosin, a selective α1A-blocker commonly 
used in patients with symptomatic obstructive BPH. As mentioned before, although 
this extract is already commercially available, it has not been investigated in patients 
with BPH so far. The outcome of the present pilot study is intended to form the basis 
for the design of an extended study with more patients, to assess the efficacy of the 
extract over a longer treatment period. 
This study was exploratory and with the included 19 patients not sufficiently powered 
to specifically test the efficacy of Serenoa repens extract Me180 compared to 
tamsulosin. Therefore, our results may only indicate a tendency for a non significant 
difference between the treatments over the 26 weeks. During the treatment period 
most of the participants had some improvements in their symptoms of BPH but there 
was no significant beneficial effect of both treatment groups over the 26-week 
treatment time. These effects were not as pronounced as reported in previous 
studies, particularly for the IPSS and peak urinary flow, which apparently improved 
with Serenoa repens extract (SRE) treatment and tamsulosin treatment, as assessed 
in two meta-analyses by the Cochrane Library (Wilt et al 2002a; Wilt et al 2003). 
Moreover, Debruyne and co-workers demonstrated that a Serenoa repens hexane 
extract (Permixon®) and tamsulosin are equivalent in the medical treatment of lower 
urinary tract symptoms in 542 men with BPH, during and up to 12 months of therapy 
(Debruyne et al 2002). 
Obviously, these findings provoke the question of why the investigated preparation 
failed to confirm results from this previous trial. Study medication capsules were 
returned and counted at every control and we consider that the compliance with over 
90% was good. Explanations for the lack of improvement could be that there were 
too few patients, or that the duration of 26 weeks was insufficient to detect any 
significant change.  
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5.1 Number of patients and recruitment 
As shown in Figure IV-1 we intended to include 70 patients in the pilot study. The 
patient recruitment was stopped because of a high dropout rate at the telephone 
interview (74%) but also at the first visit (82%), so that only 4.5% of interested 
participants were finally included and randomised in the treatment groups (Table IV-3 
and Table IV-4).  
The study was conducted according to the guidelines of 4th International Consultation 
on BPH (1997) (Roehrborn 1998), which established guidelines to standardise the 
trials and to allow a comparison of them. Strict inclusion and exclusion criteria were 
applied to form a homogeneous patient group, to ensure that the study population 
represented obstructive BPH, and to avoid interferences with other drugs.  
On one hand, without a solid definition of the diagnosis of BPH, it can be difficult to 
interpret the results of clinical trials for effectiveness; on the other hand applying to 
strict inclusion criteria, may lead to a high exclusion rate of patients, making it difficult 
to recruit enough patients for the study. Unexpectedly many men responded to our 
advertisements (420 patients to 6 advertisements). This might be because many men 
have not sought medical advice, accepting LUTS as part of ageing, but with 
increased publicity about men’s health and raised awareness of prostate cancer, 
more men are seeking help. Nevertheless, 205 patients (48.8%) were not invited 
after the telephone interview because of concomitant medication not accepted during 
the study treatment. A large proportion of men with LUTS have already 
cardiovascular, diabetic and/or prostatic medication being exclusion criteria in the 
present pilot study. This may possibly be due to the extended health care system in 
Switzerland. Another explanation for the problems in patient recruitment is that 
participants were recruited in the region of Basel, in a region with a high density of 
medical doctors (357 medical doctors per 100 000 inhabitants in Basel – City 
compared to 137 per 100 000 inhabitants practising in Central Switzerland 
(Bundesamt für Statistik 2001)). It remains an open question, if more patients could 
be invited for the first visit in other regions with less medical doctors. However, one 
has to consider that the selected co-medication inclusion and exclusion criteria are 
according to the recommendations of the Consultation on BPH (1997), but also to the 
supplier recommendation mainly of importance in the case of tamsulosin.  
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5.2 Impact of the treatment on symptoms and quality-of-life 
The establishment of symptoms is only one facet of the response to treatment of 
obstructive BPH, although an extremely important one from the patient’s perspective.  
During the treatment time, most of the participants had some improvement in their 
symptoms of BPH but there was no significant beneficial effect of both treatments 
during 26 weeks. The lack of a significant improvement within the treatment groups, 
particularly for the tamsulosin group was somewhat surprising. Up to week 16, a 
slight significant improvement was shown in the Me180 group and an improvement in 
the tamsulosin group with a tendency to significance. However, compared to 
literature, the decline from baseline in the absolute mean value of the total IPSS is 
poor.  
Most of the tamsulosin studies used a different symptom score making a percentage 
comparison difficult. However, many studies reported an improvement of the IPSS 
even after a short time of treatment with tamsulosin (Michel et al 2001; Wilt et al 
2003). For the Serenoa repens hexane extract, Permixon®, a IPSS reduction of 37% 
after 26 weeks was reported (Carraro et al 1996). In a further trial with Permixon® 
and tamsulosin, a somewhat smaller IPSS reduction was seen with 26.7% and 27.5 
respectively, after 12 months. However maximum improvement of symptom score 
was already achieved after 3 months in both treatment groups (Debruyne et al 2002). 
These improvements in symptom score are greater with respect to reduction than our 
observed 22.5% in the Me180 group. We suggest that the amount of 10 and 8 
patients, respectively, within in the two groups was not sufficient to show any 
significance. 
The initial tendency of improvement could be explained by the start motivation for the 
therapy of the patients. It has been shown in literature that during the placebo run-in-
period, the mean total IPSS decreased from a mean of 16.8 to 15.3 (Debruyne et al 
2002). There is considerable evidence to support the belief that a significant placebo 
effect is manifest in trials for treatments of BPH (Nickel 1998). It appears that simply 
having some medical attention and talking about their condition was therapeutic for 
these men. In further studies, this run-in-phase improvement has to be taken in 
account, by inclusion of a placebo-run-in- phase. 
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In other recent trials by Willets and co workers with a CO2 Serenoa repens extract, 
no significant improvement over 12 weeks and in comparison to placebo treatment 
was reported (Willetts et al 2003). The lack of improvement was explained by a 
relative low mean baseline IPSS 14.1 for SRE and 17.9 for placebo. It has been 
previously established, that the magnitude of IPSS changes during medical therapy, 
is related to the baseline score: the higher the initial score, the greater the decrease 
(Denis et al 1998). In the present study, however, the mean baseline of 16.9 in the 
Me180 group and 19.1 in the tamsulosin group was comparable to earlier reports of 
trials investigating SRE’s: 15.3 (Debruyne et al 2002) , 15.7 (Carraro et al 1996), 17.4 
(Marks et al 2000) and 17.7 for tamsulosin (Michel et al 2001). 
LUTS can be divided into obstructive and irritative symptoms. The former occur 
during the bladder emptying phase and include hesitancy, decreased stream, feeling 
of incomplete emptying, straining to void, intermittency, postvoid dribbling, and 
urinary retention. The latter occur during the storing phase and include daytime 
frequency, nocturia, urgency, and urge incontinence. 
Non significant differences were observed between the two treatment groups at 26 
weeks in terms of irritative symptoms (p=0.93) and obstructive symptoms (p=0.53) 
(Figure IV-5 and IV-6). However, within the treatment groups, the Me180 group 
showed a slight significance of decrease in irritative symptoms (p=0.03) and a 
tendency to significance for a decrease of obstructive symptoms in both treatment 
groups (0.07). 
Although obstructive (voiding) symptoms are most prevalent, irritative (storage) 
symptoms are considered to be the most bothersome for the patient, interfering to 
great extent with activities of daily life, and having therefore a considerable negative 
impact on quality-of-life (Djavan 2003). They may cause social embarrassment or 
social isolation because the patient may no longer undertake long journeys or 
activities, where poor access to lavatories may be a problem. The improvement 
particularly of irritative symptoms may therefore have a beneficial effect on quality-of-
life for these patients. However, no significant changes were assessed during the 26 
week treatment time in any of the two treatments. The initial worsening at week 2 in 
the Me180 group cannot be explained. In the tamsulosin group QoL remained on the 
same level over the treatment time. 
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Mortality from benign prostatic enlargement is very rare and other sequelae such as 
acute urinary retention, severe urinary tract infection and acute renal failure are 
increasingly rare (MacDonald & McNicholas 2003). The main focus for the vast 
majority of men is the effect of the drug treatment on symptoms and on their quality-
of-life. Since the impact of LUTS on the patient’s quality-of-life is highly variable and 
not directly related to any measurable physiological factors, the patient’s perception 
of the severity of the condition, as well as the degree to which it interferes with his 
lifestyle or causes embarrassment, should be the primary consideration in choosing 
therapy. 
5.3 Urinary flow rate, residual urine and prostate volume 
While the improvement of the symptoms are clearly most important to patients, 
indirect benefits such as changes in urinary flow rate, postvoid residual urine volume, 
and prostate size are useful for comparing different treatment modalities. 
5.3.1 Urinary flow rate 
Concerning peak urinary flow rates, no significant differences were found between 
the two treatment groups (Figure IV-9). Within the two treatment groups up to week 8 
a modest improvement with tendency to significance was noticeable, however, after 
week 8 this improvement was reversed in both groups.  
This initial improvement could be explained by a learning effect. It is to consider that 
patients may improve their performance from measurement to measurement. 
Moreover, controversy exists regarding the reproducibility of this parameter in the 
same individual on repeated measurements. Golomb and co workers  studied the 
variability and circadian changes in 32 men with BPH by repeated home flow rate 
recording (total number of recordings 476, average per subject 15) (Golomb et al 
1992). In 87.5% of patients the peak flow rate varied by at least one standard 
deviation, and in 47% by two. To prevent the influence of diurnal and other variations, 
all visits were performed in the morning and the first two Qmax were averaged for the 
definition of obstructive BPH (Abrams 1998). However, for the execution of the study, 
it was not possible to perform all flow studies in by double measurements.  
There are some more aspects of flow rate recording which are of immediate 
relevance for the outcome reporting of BPH treatment: The peak flow rate was based 
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on a minimum voided volume of 150ml to ensure that no patient was included in 
whom the low peak flow was the result of an inadequate voided volume. However, 
during the trial this minimum volume of 150ml turned out to be a problem for many 
patients leading them to excessive drinking and subsequently to potentially artificial 
values. 
A meta-analysis of tamsulosin showed that the mean change from baseline in peak 
urine flow of 1.1 ml/sec (95% CI = 0.59, 1.51) for 0.4 mg (Wilt et al 2003). In a larger 
comparative trial of Debruyne et al (2002) the increase in Qmax was similar in both 
treatment groups with 1.8ml/s for Permixon® and 1.9ml/s tamsulosin. Interestingly 
these small increases led to significant improvement of LUTS. 
5.3.2 Residual urine volume 
Concerning postvoid residual urine volume, no significant changes were found within 
and between the treatment groups during the study. However, the evolution in Figure 
IV-13 shows that the tamsulosin group showed much lower residuals at baseline than 
the Me180. As mentioned earlier, because of the lack of enough eligible patients, the 
design was adjusted from 30ml<R<200ml to R< 200ml. This might have led to a loss 
of homogeneity in the patient collective. 
The evolution of mean values shows a strong variability within the tamsulosin group 
(Figure IV-13). However, values of single patients (Figure IV-14 und IV-15) show 
strong variability in both treatment groups. This variability has been investigated 
earlier by Griffiths and co workers showing large within-patient variability because of 
large systematic variations with time of the day, with greatest volumes in the early 
morning (Griffiths et al 1996). To take circadian changes in account, in the present 
study all visits were performed in the morning. 
5.3.3 Prostate Size 
It is well established that the prostate size correlates only moderately with patients 
symptoms, perception of bother, or other commonly used parameters. There is only a 
poor correlation between the total symptom score and prostate volume (Barry et al 
1993; Bosch et al 1995), and it was concluded by Barry et al. that the prostatic 
enlargement is not the critical factor in the production of either symptoms or 
physiological outlet obstruction. In some patients a relatively small degree of 
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strategically located hyperplasia in the periurethral area might cause considerable 
physiological obstruction, while in other individuals considerable hyperplasia can 
occur without producing obstruction (Barry et al 1993). Therefore, the measurement 
of the prostate size is only of secondary importance. 
The mean prostate volume of both treatment groups at baseline and endpoint 
showed no statistically significant differences whether between the groups or within 
the groups. This is in accordance with previous results of other tamsulosin- and SRE- 
studies where only weak modulations of prostate volumes were found (Debruyne et 
al 2002; Wilt et al 2002a; Wilt et al 2003). 
5.4 Treatment effects on sexuality 
There was a significant difference in IIEF at baseline between the two treatment 
groups, however no change in the IIEF was observed within the groups during the 
26-week treatment time. This is consistent with previous studies where the effect on 
libido and sexuality was compared in SRE and placebo treatment groups (Reece 
Smith et al 1986; Willetts et al 2003). To our knowledge, the IIEF questionnaire was 
so far not investigated in tamsulosin studies, however, there is agreement within the 
studies that tamsulosin exhibits an ejaculatory dysfunction (retrograde ejaculation) 
without affecting libido. 
The IIEF as a questionnaire turned out not to be an ideal tool to test the effect on 
libido induced by the treatment. Most of the patients were not very interested in filling 
in these answers, particularly when they were not sexually active. Patients are 
seeking help because of their symptoms associated with BPH. The IIEF was found to 
be too extensive for the identification of treatment induced effects on sexuality. 
Generally, and mainly towards the end of the trial, it was noted that the patients felt 
less inclined to spend time completing the questionnaires accurately. The value of 
this questionnaire is limited by the sole focus on current sexual functioning, the 
superficial assessment of non-erectile components of sexual response like 
ejaculation and the limited assessment of the partner’s relationship. Nevertheless, 
treatment effects on sexuality remains an interesting fact. In a larger trial, it should be 
possible to measure only those patients who are sexually active.  
In the present pilot study 3 out of 8 patients in the tamsulosin group reported a 
reduced ejaculatory volume, whereas no patient of the Me180 group reported such 
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an effect. Ejaculation disorders have been reported to occur in patients treated with 
tamsulosin (Lepor 1998; Schulman 2001; Debruyne et al 2002). It is probably related 
to the mode of action of α1-adrenoceptor antagonists (Schulman 2003).  
5.5 Tolerability, adverse effects and safety  
In general the treatment was well tolerated. Moderate tolerability was reported for 
only one patient in the Me180 group because of occasional dizziness, and in the 
tamsulosin group one patient withdrew from the study because of continuous strong 
dizziness in the morning. For this patient the tolerability was reported to be very poor.  
The overall incidence of adverse events was higher in the tamsulosin group, with a 
slight significance compared to the Me180 group. Reduced ejaculatory volume was 
the most frequently reported event. As mentioned above, this is a known adverse 
effect of tamsulosin. This effect is usually not affecting patients’ quality-of-life and is 
therefore well accepted by the patients when having a positive therapeutic effect. 
Concerning Me180-induced adverse effects, one patient reported throw ups after 
medication intake and another patient reported flatulence. However, both adverse 
effects occurred only at initiation of therapy. Other Me180 extracts were reported to 
cause mild gastrointestinal disturbances (Wilt et al 2002a).  
The safety data published previously for other SRE’s and for tamsulosin were 
confirmed (Wilt et al 2002a; Wilt et al 2003). In our pilot study, treatment with either 
Me180 or tamsulosin had no effect on serum PSA levels, consistent with earlier 
results with other SRE preparations and tamsulosin. This is in contrast to 5α-
reductase inhibitors, such as finasteride and dutasteride (Andriole & Kirby 2003), 
which in addition to their 5α-reductase enzyme-inhibitory activities, alter the level of 
PSA expression by inhibiting the complex formed between androgen receptors and 
the steroid receptor binding consensus, a functional androgen-responsive element in 
the promoter region of the PSA gene (Wang et al 1997). 
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5.6 Data recording 
During the pilot study, a new electronic case report form (eCRF), developed by pnn, 
pharma nation network AG, Zurich, was tested. Data were therefore not only 
recorded on conventional CRF (hard copy paper version) but also on electronic CRF. 
The layout of the eCRF was arranged according to the finished paper version. 
Otherwise, a more user-friendly design could have been chosen, appropriate to 
requirements of electronic acquisition such as less scrolling between templates that 
have to be filled in. Nevertheless, the eCRF revealed to be a convenient method for 
data recording. The advantages of the eCRF would be particularly notable in large 
multicenter trials: Data would be entered directly after the visits, and therefore, the 
conventional, doubled data entry after study termination could be omitted. Data 
analysis after study termination is thereby considerably simplified. For example, at 
each time point during the study in-between-evaluations are possible. Data entries 
from various study centres can be reviewed from anywhere. In addition, the actual 
status of the trial may be accessed and be clearly determined at any time point via a 
“status function”. 
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6 Limitations of the study protocol 
The present study aimed to assess a significant improvement of the symptoms after 
26 weeks, and to investigate the safety and tolerability of Serenoa repens fruit-extract 
Me180 (320mg/d) versus tamsulosin (0.4mg/d) as an active control for patients with 
obstructive benign prostatic hyperplasia. The efficacy of this Serenoa repens extract 
Me180 can only be assessed by a larger and extended study, powered to assess at 
least equivalence versus a reference-control or even superiority over placebo. 
This present study was conducted as a two-arm, parallel-group, and active-controlled 
pilot study. No placebo arm was included, since it was not stated mandatory in the 
ICH guidelines. Nevertheless, the lack of a placebo arm, ultimately limits the possible 
judgement of efficacy of the drugs under study and the trial cannot be put into context 
with any other trials. Since only the equivalence of Serenoa repens extract Me180 
versus reference should be assessed, it is therefore recommendable to additionally 
include a third placebo-arm. 
We decided to conduct the first pilot study with a duration of 6 months. To document 
the efficacy, the 4th International Consensus on BPH recommended a duration of at 
least 12 months for clinical trials. Summarized data from several studies indicate that 
spontaneous improvement of symptoms may occur within 3-6 months, while in most 
cases deterioration takes a longer period of time (Schulze et al 1992). Therefore, it 
would be appropriate to prolong the treatment time to 12 months.  
In the present study, we found an initial decrease of the symptom score with a 
tendency to significance. This confirms, the study of Debruyne and coworkers  the 4 
week placebo run-in-phase showed a significant decrease in the IPSS. Therefore, 
such a run-in-phase needs to be conducted with all treatment parameters (Debruyne 
et al 2002). 
We had to stop our trial prematurely because of difficulties in patient recruitment. 
Most of the patients did not fulfil all inclusion criteria at the telephone interview 
because of concomitant medication which possibly could have could interfere with 
the study medication. However, one has to consider that extracts of Serenoa repens 
are usually given to a patient population which is taking these drugs anyway. A 
combination of phytotherapeutics with other medication may have possible 
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interactions, and this fact should be considered before treatment. However, this can 
only be judged when it is evaluated in clinical studies. It would therefore be a 
possible inclusion in order to reach this group of patients.  
The IIEF revealed to be a too extensive questionnaire to assess associated changes 
in sexual function by the study medication, especially for patients not being sexually 
active. In a larger trial it should be possible to measure only those patients who are 
sexually active.  
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7 Comparison of the pilot study with previous Serenoa 
trials 
Earlier reports have suggested a beneficial effect of SRE preparations mainly of one 
Serenoa hexane extract (Permixon®) (Champault et al 1984; Descotes et al 1995; 
Carraro et al 1996; Braeckman 1997; Debruyne et al 2002). The lack of a significant 
improvement of symptoms score and Qmax is consistent with earlier placebo-
controlled studies by Reece Smith and co workers and Willets and co workers 
(Reece Smith et al 1986, Willetts et al 2003). In one study with 45 patients with LUTS 
suggestive of BPH being treated for 12 weeks, the α1-adrenoceptor inhibitor prazosin 
was significantly more efficacious than a SRE (Adriazola Semino 1992). Another 
study with 63 patients being treated for 3 weeks found that the α1-adrenoceptor 
antagonist alfuzosin reduced irritative and obstructive symptoms in the Boyarski 
score to a greater extent than SRE (Grasso et al 1995). Moreover, in an open-label 
study of 50 patients treated with SRE for 6 months, despite an improvement of 
symptoms, no significant improvement was noted in any urodynamic parameter: 
peak urinary flow rate, postvoid residual urine volume, detrusor pressure at peak 
flow, or Abrams-Griffiths number (Gerber et al 1998). However, all these trials were 
also of short duration and with a small number of patients, limiting the conclusion of 
these trials. 
Combination therapy, SRE plus tamsulosin, did not provide an additional clinical 
benefit expected in individual patients submitted to the therapy (Glemain et al 2002). 
Neither did combinations of 5α-reductase inhibitor plus α-blockers provide any 
additional benefits (Lepor et al 1996; Debruyne et al 1998). This may be due to the 
magnitude of clinical benefit expected in individual patients.  
The tolerability and safety of tamsulosin and various SRE’s were reported to be good 
in all studies investigating one of these products. The only adverse event that 
occurred with a higher incidence with tamsulosin than with SRE was abnormal 
ejaculation (Schulman 2003), which is in accordance to the present pilot study. 
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8 Conclusion 
Taking into account the limitations of the small sample size, our pilot study showed 
no significant differences between the two treatment groups Serenoa repens extract 
Me180 and tamsulosin, in 19 patients over 26 weeks. Within the treatment group, 
there was a moderate improvement of symptoms and Qmax in particular up to week 8 
of the study. Thus, the clinical significance of these small degrees of statistically 
significant improvements remains uncertain. Confirming previous studies 
investigating several SRE’s, the investigated extract was well tolerated and 
investigated laboratory values remained unchanged, leading us to assume that the 
treatment was safe. 
Our study lacks sufficient numbers of participants for assessment of efficacy. In 
favour of the present results are the rigid inclusion and exclusion criteria, clearly 
defining the patient population. The study used blinding, an active control and 
randomisation, had a high compliance and a low withdrawal rate. The dosage of both 
regimens was according to the recommendations of the suppliers. In the present pilot 
study, the protocol was evaluated and several of its limitations were found and 
suggestions for improvement stated. On the basis of the present data, the first study 
available for Me180, an enlarged study with a larger sample size and longer duration 
can be designed. Only by such a follow-up study it can be evidenced if the Serenoa 
repens extract Me180 is a reasonable alternative medical therapy for men with 
obstructive BPH. 
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